Feed:All articles

{"articlesQuery":{"articles":[{"title":"Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study","pmid":"28533265","statusUsableDate":"2019-09-12","abbreviation":"3C","published":"2017-05-22","timestamp":"2019-09-12T17:46:55Z","briefDesignDescription":"Antibiotic strategies in lower respiratory tract infections","fulltexturl":"https://www.bmj.com/content/357/bmj.j2148.long","subspecialties":"Infectious Disease;Pulmonology","pdfurl":"https://www.bmj.com/content/bmj/357/bmj.j2148.full.pdf","expansion":"Cough Complication Cohort","pageid":2956,"citation":"Little P, et al. \"Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study\". The British Medical Journal. 2017. 357:j2148.","pageName":"3C","diseases":"Pneumonia","briefResultsDescription":"Similar outcomes in upfront, delayed, and no antibiotic strategies","trainingLevel":"Resident"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500964","briefDesignDescription":"Central line complications by insertion site","subspecialties":"Critical Care;Infectious Disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1500964","abbreviation":"3SITES","timestamp":"2017-12-03T22:32:58Z","published":"2015-09-24","title":"Intravascular Complications of Central Venous Catheterization by Insertion Site","pmid":"26398070","statusUsableDate":"2015-11-01","trainingLevel":"Student","pageName":"3SITES","briefResultsDescription":"Subclavian lines yield fewer CRBSIs and DVTs compared to IJ/femoral lines","diseases":"Critical Illness;Catheter-Related Bloodstream Infection","citation":"Parienti JJ, et al. \"Intravascular Complications of Central Venous Catheterization by Insertion Site\". The New England Journal of Medicine. 2015. 373(13):1220-1229.","pageid":2479,"expansion":""},{"title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","statusUsableDate":"2013-08-01","pmid":"7968073","abbreviation":"4S","published":"1994-11-19","timestamp":"2017-12-14T19:22:25Z","briefDesignDescription":"Simvastatin in stable CAD","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract","subspecialties":"Cardiology","pdfurl":"","expansion":"Scandinavian Simvastatin Survival Study","pageid":1587,"citation":"Pedersen TR, et al. \"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\". The Lancet. 1994. 344(8934):1383-1389.","pageName":"4S","diseases":"Hyperlipidemia;Coronary Artery Disease","briefResultsDescription":"Simvastatin reduces all mortality in stable CAD","trainingLevel":"Student"},{"diseases":"Hypotension","briefResultsDescription":"No difference in mortality between groups","pageName":"65 Trial","trainingLevel":"resident","expansion":"","pageid":4436,"citation":"Lamontagne F, et al. \"Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension; A Randomized Clinical Trial\". JAMA. 2020. 323(10):938-949.","fulltexturl":"https://doi.org/10.1001/jama.2020.0930","subspecialties":"Critical Care;Neurology;Geriatrics","briefDesignDescription":"MAP 60-65 vs. usual care in vasodilatory hypotension in ICU","pdfurl":"","statusUsableDate":"2021-08-19","pmid":"32049269","title":"Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension; A Randomized Clinical Trial","published":"2020-02-12","timestamp":"2021-08-21T01:56:39Z","abbreviation":"65 Trial"},{"diseases":"Heart Failure","briefResultsDescription":"Improved survival among black patients with HF","pageName":"A-HeFT","trainingLevel":"Student","expansion":"African-American Heart Failure Trial","pageid":41,"citation":"Taylor AL, et al. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". The New England Journal of Medicine. 2004. 351(20):2049-2057.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa042934","subspecialties":"Cardiology","briefDesignDescription":"ISDN/hydralazine for black patients with HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934","pmid":"15533851","statusUsableDate":"2012-03-01","title":"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure","published":"2004-11-11","timestamp":"2019-02-22T06:12:34Z","abbreviation":"A-HeFT"},{"subspecialties":"Nephrology","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/195530","briefDesignDescription":"BP management for CKD in African Americans","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/195530/joc20772.pdf","statusUsableDate":"2019-08-29","pmid":"12435255","title":"Intensive blood-pressure control in hypertensive chronic kidney disease","timestamp":"2019-10-29T18:24:45Z","published":"2002-11-20","abbreviation":"AASK","briefResultsDescription":"Intensive BP control didn't prevent progression of kidney disease but ACE-inhibitors did","diseases":"Chronic Kidney Disease;Hypertension","pageName":"AASK","trainingLevel":"Intern","expansion":"African American Study of Kidney Disease and Hypertension","citation":"Wright JT Jr., et al. \"Intensive blood-pressure control in hypertensive chronic kidney disease\". JAMA. 2002. 288(19):2421-2431.","pageid":2666},{"expansion":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device","pageid":2829,"citation":"Di Biase et al. \"Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device\". Circulation. 2016. 133(17):1637-1634.","diseases":"Atrial Fibrillation;Heart Failure","briefResultsDescription":"AF ablation superior to amiodarone in HFrEF with LVEF ≤40%","pageName":"AATAC","trainingLevel":"Resident","pmid":"27029350","statusUsableDate":"2016-09-01","title":"Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device","published":"2016-04-26","timestamp":"2017-12-03T22:33:01Z","abbreviation":"AATAC","fulltexturl":"http://circ.ahajournals.org/content/early/2016/03/30/CIRCULATIONAHA.115.019406","subspecialties":"Cardiology","briefDesignDescription":"AF ablation vs. amiodarone in HFrEF with LVEF ≤40%","pdfurl":null},{"statusUsableDate":"2025-05-29","pmid":"7723155","title":"Endarterectomy for Asymptomatic Carotid Artery Stenosis","published":"1995-05-10","timestamp":"2025-05-29T18:18:33Z","abbreviation":"ACAS","fulltexturl":"https://jamanetwork.com/journals/jama/article-abstract/388335","subspecialties":"Surgery;Neurology;Cardiology","briefDesignDescription":"CEA vs. medical therapy in asymptomatic carotid stenosis","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/388335/jama_273_18_035.pdf","expansion":"Asymptomatic Carotid Artery Stenosis Trial","pageid":4279,"citation":"Micheal Walker, et al. \"Endarterectomy for Asymptomatic Carotid Artery Stenosis\". Journal of the American Medical Association. 1995. 273(18):1421-1428.","diseases":"Carotid Stenosis;Stroke;Transient Ischemic Attack","briefResultsDescription":"CEA reduced stroke/death rate compared to medical management","pageName":"ACAS","trainingLevel":"Student"},{"title":"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients","statusUsableDate":"2013-06-01","pmid":"19052124","abbreviation":"ACCOMPLISH","timestamp":"2018-01-11T18:23:02Z","published":"2008-12-04","briefDesignDescription":"Benazepril/amlodipine vs. benazepril/HCTZ in HTN","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0806182","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182","expansion":"Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension","citation":"Jamerson K, et al. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". The New England Journal of Medicine. 2008. 359(23):2417-2428.","pageid":1448,"pageName":"ACCOMPLISH","briefResultsDescription":"Benazepril/amlodipine is associated with fewer CV events","diseases":"Hypertension","trainingLevel":"Resident"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743","subspecialties":"Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802743","briefDesignDescription":"Intensive glycemic therapy in T2DM","timestamp":"2019-12-18T14:23:33Z","published":"2008-06-12","abbreviation":"ACCORD","pmid":"18539917","statusUsableDate":"2012-03-01","title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","trainingLevel":"Intern","briefResultsDescription":"Increased mortality and no cardiovascular benefit with intensive glycemic control","diseases":"Diabetes Mellitus","pageName":"ACCORD","citation":"Gerstein HC, et al. \"Effects of Intensive Glucose Lowering in Type 2 Diabetes\". The New England Journal of Medicine. 2008. 358(24):2545-59.","pageid":105,"expansion":"Action to Control Cardiovascular Risk in Diabetes"},{"citation":"ACCORD Study Group. \"Effects of intensive blood-pressure control in type 2 diabetes mellitus\". The New England Journal of Medicine. 2010. 362(17):1575-1585.","pageid":1760,"expansion":"ACCORD Study Group","trainingLevel":"Student","briefResultsDescription":"Intensive BP control doesn't reduce CV events in T2DM","diseases":"Diabetes Mellitus;Hypertension","pageName":"ACCORD BP","timestamp":"2024-12-12T20:32:12Z","published":"2010-03-14","abbreviation":"ACCORD BP","pmid":"20228401","statusUsableDate":"2014-08-01","title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001286","subspecialties":"Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001286","briefDesignDescription":"Intensive BP control in T2DM"},{"pmid":"20228404","statusUsableDate":"2018-01-17","title":"Effects of combination lipid therapy in type 2 diabetes mellitus","timestamp":"2018-01-31T01:55:15Z","published":"2010-04-29","abbreviation":"ACCORD Lipid","subspecialties":"Cardiology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001282","briefDesignDescription":"Fibrate add-on to statins in T2DM","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001282","expansion":"Action to Control Cardiovascular Risk in Diabetes-Lipid","citation":"ACCORD Study Group. \"Effects of combination lipid therapy in type 2 diabetes mellitus\". The New England Journal of Medicine. 2010. 362(17):1563-1574.","pageid":3520,"briefResultsDescription":"Fenofibrates don't reduce CVD among adults with T2DM on statins","diseases":"Diabetes Mellitus;Coronary Artery Disease;Stroke","pageName":"ACCORD Lipid","trainingLevel":"Student"},{"pdfurl":null,"briefDesignDescription":"Empiric cefepime vs. pip-tazo for infection","subspecialties":"Infectious Disease;Critical Care;Emergency Medicine","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/2810592","abbreviation":"ACORN","timestamp":"2024-03-28T17:22:37Z","published":"2023-10-14","title":"Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection","pmid":"37837651","statusUsableDate":"2024-02-22","trainingLevel":"Resident","pageName":"ACORN","briefResultsDescription":"Similar rates of AKI; cefepime causes more CNS toxicity","diseases":"Infection","citation":"Qian E, et al. \"Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection\". JAMA. 2023. 330(16):1557-1567.","pageid":5478,"expansion":"Antibiotic Choice on Renal Outcomes"},{"pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/645514/joc15004_569_575.pdf","briefDesignDescription":"ALND in SLND-positive breast cancer","subspecialties":"Oncology;Surgery","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/645514","abbreviation":"ACOSOG Z0011","timestamp":"2018-09-06T17:17:42Z","published":"2011-02-09","title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","pmid":"21304082","statusUsableDate":"2018-09-06","trainingLevel":"Fellow","pageName":"ACOSOG Z0011","briefResultsDescription":"ALND no better than monitoring in SLNB-positive disease","diseases":"Breast Cancer","citation":"Giuliano AE, et al. \"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial\". The Journal of the American Medical Association. 2011. 305(6):569-575.","pageid":3545,"expansion":"The American College of Surgeons Oncology Group (ACOSOG) Z0011"},{"fulltexturl":"http://circ.ahajournals.org/cgi/pmidlookup?view","subspecialties":"Nephrology;Cardiology","briefDesignDescription":"Acetylcysteine with IV contrast","pdfurl":"http://circ.ahajournals.org/content/124/11/1250.full.pdf","statusUsableDate":"2015-08-01","pmid":"21859972","title":"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography","published":"2011-06-28","timestamp":"2017-12-03T22:33:07Z","abbreviation":"ACT","diseases":"Acute Kidney Injury;Acute Coronary Syndrome","briefResultsDescription":"Acetylcysteine doesn't prevent contrast-induced acute kidney injury","pageName":"ACT","trainingLevel":"Intern","expansion":"Acetylcysteine for Contrast-Induced Nephropathy Trial","pageid":2425,"citation":"ACT Investigators. \"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography\". Circulation. 2011. 124:1250-1259."},{"pageid":2721,"citation":"Rosenfield K, et al. \"Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis\". The New England Journal of Medicine. 2016. 374(11):1011-20.","expansion":"Stent versus endarterectomy for asymptomatic carotid stenosis","trainingLevel":"Resident","pageName":"ACT I","diseases":"Carotid Stenosis","briefResultsDescription":"Carotid stenting noninferior to endarterectomy in asymptomatic carotid stenosis","abbreviation":"ACT I","published":"2016-02-17","timestamp":"2023-02-03T04:55:43Z","title":"Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis","statusUsableDate":"2023-02-01","pmid":"26886419","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1515706","briefDesignDescription":"Carotid stenting vs. endarterectomy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1515706","subspecialties":"Cardiology"},{"statusUsableDate":"2012-04-01","pmid":"19336502","title":"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation","timestamp":"2017-12-03T22:33:09Z","published":"2009-05-14","abbreviation":"ACTIVE A","subspecialties":"Cardiology;Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0901301","briefDesignDescription":"ASA/clopidogrel vs. ASA in AF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0901301","expansion":"Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events","citation":"Connolly SJ, et al. \"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation\". The New England Journal of Medicine. 2009. 360(20):2066-78.","pageid":360,"briefResultsDescription":"ASA/clopidogrel ↓ composite of stroke, non-CNS embolism, MI, or CV death and ↑ bleeding","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","pageName":"ACTIVE A","trainingLevel":"Resident"},{"pageid":1438,"citation":"Connolly SJ, et al. \"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.\". The Lancet. 2006. 367(9526):1903-12.","expansion":"Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events","trainingLevel":"Intern","pageName":"ACTIVE W","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","briefResultsDescription":"Warfarin is superior to ASA/clopidogrel for stroke prevention in AF","abbreviation":"ACTIVE W","published":"2006-06-10","timestamp":"2017-12-03T22:33:10Z","title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.","statusUsableDate":"2013-05-01","pmid":"16765759","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606688454.pdf","briefDesignDescription":"ASA/clopidogrel vs. warfarin in AF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68845-4","subspecialties":"Cardiology;Neurology"},{"trainingLevel":"Student","pageName":"ACTT-1","briefResultsDescription":"Remdesivir modestly shortens time to recovery mostly in severe disease","diseases":"Covid-19","citation":"Beigel JH, et al. \"Remdesivir for the Treatment of Covid-19 - Preliminary Report\". The New England Journal of Medicine. 2020. 1-12.","pageid":4238,"expansion":"Adaptive Covid-19 Treatment Trial","pdfurl":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/pdf/NEJMoa2007764.pdf","briefDesignDescription":"Remdesivir vs. placebo in Covid-19","subspecialties":"Infectious Disease","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2007764","abbreviation":"ACTT-1","timestamp":"2020-07-02T17:55:05Z","published":"2020-05-22","title":"Remdesivir for the Treatment of Covid-19 - Preliminary Report","pmid":"32445440","statusUsableDate":"2020-06-30"},{"trainingLevel":"resident","briefResultsDescription":"Cisatracurium improves 90-day survival and increases ventilator-free days","diseases":"Acute Respiratory Distress Syndrome","pageName":"ACURASYS","citation":"Papazian L, et al. \"Neuromuscular blockers in early acute respiratory distress syndrome\". The New England Journal of Medicine. 2010. 363(12):1107-1116.","pageid":1119,"expansion":"ARDS et Curarisation Systematique","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005372","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005372","briefDesignDescription":"Cisatracurium in ARDS","timestamp":"2019-06-05T22:43:36Z","published":"2010-09-16","abbreviation":"ACURASYS","pmid":"20843245","statusUsableDate":"2013-06-01","title":"Neuromuscular blockers in early acute respiratory distress syndrome"},{"briefDesignDescription":"Age-adjusted D-dimer for PE","subspecialties":"Hematology;Emergency Medicine","fulltexturl":"http://bit.ly/1QgJ5k1","pdfurl":"http://bit.ly/1HTY4kQ","title":"Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study","pmid":"24643601","statusUsableDate":"2015-05-01","abbreviation":"ADJUST-PE","timestamp":"2021-12-19T22:24:03Z","published":"2014-03-19","pageName":"ADJUST-PE","briefResultsDescription":"Age-adjusted D-dimer (age × 10 in patients >50) rules out PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","trainingLevel":"Resident","expansion":"Age aDJUSTed D-Dimer to rule out PE","citation":"Righini M, et al. \"Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study\". JAMA. 2014. 311(11):1117-1124.","pageid":2367},{"statusUsableDate":"2018-02-08","pmid":"29347874","title":"Adjunctive glucocorticoid therapy in patients with septic shock","timestamp":"2018-02-08T17:58:17Z","published":"2018-01-19","abbreviation":"ADRENAL","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1705835","briefDesignDescription":"Hydrocortisone in septic shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1705835","expansion":"Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock","citation":"Venkatesh B, et al. \"Adjunctive glucocorticoid therapy in patients with septic shock\". New England Journal of Medicine. 2018. Epub 2018-01-19:1-12.","pageid":3528,"briefResultsDescription":"Hydrocortisone provides no benefit in 90-day mortality","diseases":"Sepsis;Shock","pageName":"ADRENAL","trainingLevel":"Resident"},{"abbreviation":"ADVANCE","published":"2008-06-06","timestamp":"2014-09-19T13:02:39Z","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","pmid":"18539916","statusUsableDate":"2012-03-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802987","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802987","subspecialties":"Endocrinology","pageid":248,"citation":"Patel A, et al. \"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes\". The New England Journal of Medicine. 2008. 358(24):2560-2572.","expansion":"Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation","trainingLevel":"Intern","pageName":"ADVANCE","diseases":"Diabetes Mellitus","briefResultsDescription":"Intensive therapy reduces microvascular complications"},{"pageName":"ADVOR","briefResultsDescription":"Acetazolamide improves diuresis in acute HF","diseases":"Heart Failure","trainingLevel":"Student","expansion":"Acetazolamide in Decompensated Heart Failure With Volume OveRload","citation":"Mullens W, et al. \"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload\". NEJM. 2022. Epub 2022-08-27:1-11.","pageid":4655,"briefDesignDescription":"Acetazolamide vs. placebo in acute HF","subspecialties":"Cardiology;Emergency Medicine;Critical Care","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2203094","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2203094","title":"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload","pmid":"36027559","statusUsableDate":"2022-09-15","abbreviation":"ADVOR","timestamp":"2022-12-20T15:19:03Z","published":"2022-08-27"},{"expansion":"Atrial Fibrillation and Congestive Heart Failure","citation":"Roy D, et al. \"Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure\". The New England Journal of Medicine. 2008. 358(25):2667-2677.","pageid":2800,"briefResultsDescription":"Rhythm control does not reduce CV mortality in AF with HF","diseases":"Heart Failure","pageName":"AF-CHF","trainingLevel":"Resident","pmid":"18565859","statusUsableDate":"2018-12-07","title":"Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure","timestamp":"2018-12-21T13:20:11Z","published":"2008-06-19","abbreviation":"AF-CHF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0708789","briefDesignDescription":"Rhythm control for AF in HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0708789"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021328","briefDesignDescription":"Rate vs. rhythm control in AF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021328","abbreviation":"AFFIRM","timestamp":"2025-05-15T20:16:04Z","published":"2002-11-05","title":"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation","statusUsableDate":"2012-03-01","pmid":"12466506","trainingLevel":"Student","pageName":"AFFIRM","briefResultsDescription":"No mortality difference, trend towards harm with rhythm control","diseases":"Atrial Fibrillation","citation":"Wyse DG, et al. \"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation\". The New England Journal of Medicine. 2002. 347(23):1825-1833.","pageid":87,"expansion":"Atrial Fibrillation Follow-up Investigation of Rhythm Management"},{"trainingLevel":"Student","pageName":"Age Trial","briefResultsDescription":"Mammograms don't reduce breast cancer mortality in age 40-49 year old women","diseases":"Breast Cancer","citation":"Moss SM, et al. \"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial\". The Lancet. 2006. 368(9552):2053-2060.","pageid":2307,"expansion":"","pdfurl":"","briefDesignDescription":"Mammograms for 40-49 year old women","subspecialties":"Oncology;Preventive Medicine","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69834-6","abbreviation":"Age Trial","timestamp":"2017-12-03T22:33:43Z","published":"2006-12-09","title":"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial","statusUsableDate":"2015-01-01","pmid":"17161727"},{"fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2211868","subspecialties":"Critical Care","briefDesignDescription":"Haloperidol for ICU delirium","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2211868","pmid":"36286254","statusUsableDate":"2022-11-02","title":"Haloperidol for the Treatment of Delirium in ICU Patients","published":"2022-10-26","timestamp":"2023-01-15T01:17:39Z","abbreviation":"AID-ICU","diseases":"Delirium","briefResultsDescription":"Haloperidol does not improve days alive out of hospital","pageName":"AID-ICU","trainingLevel":"resident","expansion":"Agents Intervening against Delirium in the Intensive Care Unit","pageid":5131,"citation":"Andersen-Ranberg NC, et al. \"Haloperidol for the Treatment of Delirium in ICU Patients\". The New England Journal of Medicine. 2022. Online ahead of print(2022-10-26):1-11."},{"pmid":"28402237","statusUsableDate":"2017-06-01","title":"Bioresorbable scaffolds versus metallic stents in routine PCI","published":"2017-06-14","timestamp":"2017-12-03T22:33:14Z","abbreviation":"AIDA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1614954","subspecialties":"Cardiology","briefDesignDescription":"Scaffold vs. stent in PCI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614954","expansion":"Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial","pageid":2940,"citation":"Wykrzykowska JJ et al. \"Bioresorbable scaffolds versus metallic stents in routine PCI\". The New England Journal of Medicine. 2017. 376(24):2319-2328.","diseases":"Coronary Artery Disease","briefResultsDescription":"Scaffold inferior to stent in PCI","pageName":"AIDA","trainingLevel":"Resident"},{"pmid":"29710295","statusUsableDate":"2024-10-24","title":"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial","published":"2018-03-01","timestamp":"2024-10-17T19:52:36Z","abbreviation":"AIDA-WP2","fulltexturl":"https://jamanetwork.com/journals/jama/article-abstract/2679131","subspecialties":"Infectious Disease;Emergency Medicine","briefDesignDescription":"Nitrofurantoin vs. fosfomycin in UTI","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/2679131/jama_huttner_2018_oi_180034.pdf","expansion":"","pageid":3640,"citation":"Huttner A, et al. \"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial\". JAMA. 2018. 319(17):1781-1789.","diseases":"Urinary Tract Infection","briefResultsDescription":"Nitrofurantoin improved outcomes uncomplicated UTI","pageName":"AIDA-WP2","trainingLevel":"Medical Student"},{"pmid":"27825009","statusUsableDate":"2016-12-01","title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence","published":"2016-11-08","timestamp":"2018-10-16T05:18:00Z","abbreviation":"AIRTRIP","fulltexturl":"http://jamanetwork.com/journals/jama/article-abstract/2579869","subspecialties":"Cardiology","briefDesignDescription":"Anakinra in colchicine-resistant pericarditis","pdfurl":null,"expansion":"AnakInRa for Treatment of Recurrent Idiopathic Pericarditis","pageid":2865,"citation":"Brucato A, et al. \"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence\". Journal of the American Medical Association. 2016. 316(18):1906-1912.","diseases":"Pericarditis","briefResultsDescription":"Anakinra superior to placebo in colchicine resistant, steroid-dependent pericarditis","pageName":"AIRTRIP","trainingLevel":"Resident"},{"expansion":"Artificial Kidney Initiation in Kidney Injury","pageid":2937,"citation":"Gaudry S, et al. \"Initiation strategies for renal-replacement therapy in the intensive care unit\". The New England Journal of Medicine. 2016. 375(2):122-133.","pageName":"AKIKI","diseases":"Acute Kidney Injury","briefResultsDescription":"No mortality difference between early or delayed RRT in ICU patients with AKI","trainingLevel":"Resident","title":"Initiation strategies for renal-replacement therapy in the intensive care unit","statusUsableDate":"2017-08-01","pmid":"27181456","abbreviation":"AKIKI","published":"2016-07-14","timestamp":"2019-03-27T18:29:53Z","briefDesignDescription":"Early vs. late RRT in severe AKI in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1603017","subspecialties":"Critical Care;Nephrology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603017"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305727","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305727","subspecialties":"Critical Care","briefDesignDescription":"Daily albumin in severe sepsis","published":"2014-03-18","timestamp":"2018-07-03T03:04:07Z","abbreviation":"ALBIOS","statusUsableDate":"2014-03-01","pmid":"24635772","title":"Albumin replacement in patients with severe sepsis or septic shock","trainingLevel":"resident","diseases":"Sepsis","briefResultsDescription":"Daily albumin with no mortality benefit at 28 days","pageName":"ALBIOS","pageid":1781,"citation":"Caironi P, et al. \"Albumin replacement in patients with severe sepsis or septic shock\". The New England Journal of Medicine. 2014. 370(15):1412-1421.","expansion":"Albumin Italian Outcome Sepsis"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199908053410603","briefDesignDescription":"Albumin for SBP in cirrhosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199908053410603","subspecialties":"Gastroenterology;Infectious Disease","abbreviation":"","published":"1999-08-05","timestamp":"2017-12-03T22:33:45Z","title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","pmid":"10432325","statusUsableDate":"2017-09-01","trainingLevel":"Intern","pageName":"Albumin for SBP","diseases":"Spontaneous Bacterial Peritonitis;Cirrhosis","briefResultsDescription":"Albumin reduces AKI and mortality in SBP in cirrhosis","pageid":2501,"citation":"Sort P, et al. \"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis\". The New England Journal of Medicine. 1999. 341(6):403-409.","expansion":""},{"pageid":171,"citation":"Wright JT, et al. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". Journal of the American Medical Association. 2002. 288(23):2981-2997.","expansion":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","trainingLevel":"Student","pageName":"ALLHAT","diseases":"Hypertension","briefResultsDescription":"Chlorthalidone performs similarly to lisinopril and amlodipine","abbreviation":"ALLHAT","published":"2002-12-18","timestamp":"2018-09-14T00:37:12Z","title":"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic","pmid":"12479763","statusUsableDate":"2012-03-01","pdfurl":null,"briefDesignDescription":"Chlorthalidone in HTN","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/vol/288/pg/2981","subspecialties":"Nephrology;Cardiology"},{"pmid":"28531241","statusUsableDate":"2020-11-20","title":"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial","published":"2017-07-01","timestamp":"2020-11-11T16:18:38Z","abbreviation":"ALLHAT-LLT","fulltexturl":"http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2628971","subspecialties":"Cardiology","briefDesignDescription":"Pravastatin vs usual care for ASCVD primary prevention","pdfurl":"http://www.natap.org/2017/HIV/jamainternal_Han_2017_oi_170031.pdf","expansion":"","pageid":2949,"citation":"Han BH, et al. \"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial\". JAMA Internal Medicine. 2017. 177(7):955-965.","diseases":"Coronary Artery Disease","briefResultsDescription":"Pravastatin does not decrease mortality","pageName":"ALLHAT-LLT Elderly","trainingLevel":"Intern"},{"subspecialties":"Nephrology;Rheumatology","fulltexturl":"http://jasn.asnjournals.org/content/20/5/1103.long","briefDesignDescription":"MMF vs. CTX in lupus nephritis","pdfurl":"http://jasn.asnjournals.org/content/20/5/1103.full.pdf","statusUsableDate":"2017-11-01","pmid":"19369404","title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.","timestamp":"2018-02-04T17:46:37Z","published":"2009-05-01","abbreviation":"ALMS","briefResultsDescription":"MMF similar to cyclophosphamide in lupus nephritis","diseases":"Lupus Nephritis;Lupus","pageName":"ALMS","trainingLevel":"Resident","expansion":"Aspreva Lupus Management Study","citation":"Appel GB, et al. \"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.\". Journal of American Society of Nephrology. 2009. 20(5):1103–1112.","pageid":2655},{"pageName":"AMAZES","diseases":"Asthma","briefResultsDescription":"Athithromycin reduced rate of exacerbations and improved QOL","trainingLevel":"Resident","expansion":"Azithromycin on Asthma Exacerbations and Quality of Life in Adults With Persistent Uncontrolled Asthma","pageid":3615,"citation":"Gibson PG, et al. \"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial\". Lancet. 2017. 390(10095):659-668.","briefDesignDescription":"Azithromycin in chronic asthma","fulltexturl":"https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)31281-3","subspecialties":"Pulmonology","pdfurl":"","title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial","pmid":"28687413","statusUsableDate":"2020-06-29","abbreviation":"AMAZES","published":"2017-08-12","timestamp":"2020-07-02T15:32:34Z"},{"abbreviation":"AMBITION","published":"2015-08-27","timestamp":"2025-06-19T18:32:30Z","title":"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension","statusUsableDate":"2025-02-26","pmid":"26308684","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1413687","briefDesignDescription":"Combination of ambrisentan & tadalafil vs monotherapy in PAH","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1413687","subspecialties":"Pulmonology","pageid":4410,"citation":"Galiè N, et al. \"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension\". The New England Journal of Medicine. 2015. 373(9):834-44.","expansion":"Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension","trainingLevel":"Resident","pageName":"AMBITION","diseases":"Pulmonary Hypertension","briefResultsDescription":"Ambrisentan & tadalafil combination therapy resulted in fewer clinical failures than monotherapy"},{"pmid":"23808982","statusUsableDate":"2013-08-01","title":"Oral apixaban for the treatment of acute venous thromboembolism","timestamp":"2023-06-22T19:17:55Z","published":"2013-07-01","abbreviation":"AMPLIFY","subspecialties":"Hematology;Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302507","briefDesignDescription":"Apixaban vs. warfarin in VTE","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302507","expansion":"Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy","citation":"Agnelli G, et al. \"Oral apixaban for the treatment of acute venous thromboembolism\". The New England Journal of Medicine. 2013. 369(9):799-808.","pageid":1609,"briefResultsDescription":"Apixaban noninferior to warfarin for VTE recurrence; less bleeding","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","pageName":"AMPLIFY","trainingLevel":"Intern"},{"pageName":"AMPLIFY-EXT","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","briefResultsDescription":"Apixaban reduces recurrent VTE","trainingLevel":"Resident","expansion":"Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment","pageid":1245,"citation":"Agnelli G, et al. \"Apixaban for extended treatment of venous thromboembolism\". The New England Journal of Medicine. 2013. 368(8):699-708.","briefDesignDescription":"Apixaban after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1207541","subspecialties":"Hematology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1207541","title":"Apixaban for extended treatment of venous thromboembolism","pmid":"23216615","statusUsableDate":"2013-05-01","abbreviation":"AMPLIFY-EXT","published":"2013-02-21","timestamp":"2023-04-19T12:49:42Z"},{"trainingLevel":"Resident","diseases":"Sepsis;Shock","briefResultsDescription":"Corticosteroids reduce mortality in septic shock with adrenal insufficiency","pageName":"Annane Trial","pageid":939,"citation":"Annane D, et al. \"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock\". Journal of the American Medical Association. 2002. 288(7):862-871.","expansion":"","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4844/JCE10061.pdf","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","subspecialties":"Critical Care","briefDesignDescription":"Corticosteroids in septic shock","published":"2002-08-21","timestamp":"2020-03-17T17:50:15Z","abbreviation":"Ger-Inf-05","pmid":"12186604","statusUsableDate":"2013-02-01","title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock"},{"pageName":"ANNEXA","briefResultsDescription":"Andexanet reverses Xa inhibitors","diseases":"Hemorrhage","trainingLevel":"Resident","expansion":"Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors","citation":"Siegal DM, et al. \"Andexanet alfa for the reversal of factor Xa inhibitor activity\". The New England Journal of Medicine. 2015. 373(25):2413-2424.","pageid":2502,"briefDesignDescription":"Andexanet for reversing Xa inhibitors","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1510991","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510991","title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","pmid":"26559317","statusUsableDate":"2017-03-01","abbreviation":"ANNEXA","timestamp":"2018-07-11T03:22:16Z","published":"2015-12-17"},{"trainingLevel":"Resident","briefResultsDescription":"Andexanet alfa achieved hemostasis in 80%","diseases":"Hemorrhage","pageName":"ANNEXA-4","citation":"Connolly SJ, et al. \"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors\". The New England Journal of Medicine. 2016. 375(12):1131-1141.","pageid":3641,"expansion":"Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607887","subspecialties":"Hematology;Emergency Medicine;Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1607887","briefDesignDescription":"Andexanet alfa for factor Xa inhibitor reversal","timestamp":"2019-03-07T17:07:14Z","published":"2016-09-22","abbreviation":"ANNEXA-4","pmid":"27573206","statusUsableDate":"2019-02-07","title":"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors"},{"expansion":"","pageid":2649,"citation":"Molina JM, et al. \"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection\". The New England Journal of Medicine. 2015. 373(23):2237-2246.","pageName":"ANRS IPERGAY","diseases":"HIV","briefResultsDescription":"Pre-exposure prophylaxis reduces HIV transmission in high-risk men","trainingLevel":"Student","title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","pmid":"26624850","statusUsableDate":"2015-12-01","abbreviation":"ANRS IPERGAY","published":"2015-12-03","timestamp":"2017-12-03T22:33:27Z","briefDesignDescription":"Pre-exposure prophylaxis in high-risk men","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1506273","subspecialties":"Infectious Disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506273"},{"abbreviation":"","published":"2006-10-01","timestamp":"2016-04-01T23:26:41Z","title":"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage","pmid":"17030175","statusUsableDate":"2012-03-01","pdfurl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/pdf","briefDesignDescription":"Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext","subspecialties":"Gastroenterology;Infectious Disease","pageid":82,"citation":"Fernández J, et al. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". Gastroenterology. 2006. 131(4):1049-56.","expansion":"","trainingLevel":"Intern","pageName":"Antibiotics in Cirrhosis with Hemorrhage","diseases":"Cirrhosis;Gastrointestinal Hemorrhage","briefResultsDescription":"Ceftriaxone reduces the incidence of bacterial infection"},{"pageid":4441,"citation":"Lewis G, et al. \"Maintenance or discontinuation of antidepressants in primary care\". The New England Journal of Medicine. 2021. 385(14):1257-1267.","expansion":"Antidepressants to Prevent Relapse in Depression","trainingLevel":"student","pageName":"ANTLER","diseases":"Depression","briefResultsDescription":"Maintenance of antidepressants associated with less depression relapse","abbreviation":"ANTLER","published":"2021-09-30","timestamp":"2021-10-08T13:12:27Z","title":"Maintenance or discontinuation of antidepressants in primary care","statusUsableDate":"2021-09-30","pmid":"34587384","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2106356","briefDesignDescription":"Maintenance vs. discontinuation of antidepressants","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2106356","subspecialties":"Psychiatry"},{"citation":"Cohen AT, et al. \"Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients\". The New England Journal of Medicine. 2016. 375(6):534-44.","pageid":3713,"expansion":"Acutely Medically Ill VTE Prevention with Extended Duration Betrixaban","trainingLevel":"resident","briefResultsDescription":"Betrixaban did not meet its primary endpoint","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","pageName":"APEX","timestamp":"2018-11-15T17:21:28Z","published":"2017-08-27","abbreviation":"APEX","statusUsableDate":"2018-11-15","pmid":"27232649","title":"Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1601747","subspecialties":"Hematology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1601747","briefDesignDescription":"Betrixaban for extended VTE prophylaxis"},{"subspecialties":"Surgery;Infectious Disease","fulltexturl":"https://jamanetwork.com/journals/jama/article-abstract/2703354","briefDesignDescription":"Antibiotics vs. surgery for acute appendicitis","pdfurl":null,"statusUsableDate":"2018-07-26","pmid":"26080338","title":"Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial","timestamp":"2019-01-03T23:02:05Z","published":"2015-06-16","abbreviation":"AAPAC","briefResultsDescription":"Antibiotics not non-inferior to surgeyr","diseases":"Appendicitis","pageName":"APPAC","trainingLevel":"Resident","expansion":"Appendicitis Acuta","citation":"Salminen P, et al. \"Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial\". JAMA. 2018. 320(12):1259-1265.","pageid":3539},{"trainingLevel":"Resident","pageName":"APROCCHSS","briefResultsDescription":"Hydrocortisone plus fludrocortisone improved survival in septic shock","diseases":"Sepsis","citation":"Annane D, et al. \"Hydrocortisone plus Fludrocortisone for Adults with Septic Shock\". The New England Journal of Medicine. 2018. 378(9):809-818.","pageid":3551,"expansion":"Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1705716","briefDesignDescription":"Steroids in septic shock","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1705716","abbreviation":"APROCCHSS","timestamp":"2021-04-08T18:21:59Z","published":"2018-03-01","title":"Hydrocortisone plus Fludrocortisone for Adults with Septic Shock","pmid":"29490185","statusUsableDate":"2021-03-30"},{"expansion":"Acute Respiratory Distress Syndrome Network","citation":"Brower RG, et al. \"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome\". The New England Journal of Medicine. 2000. 342(18):1301-1308.","pageid":114,"briefResultsDescription":"Mortality benefit and more ventilator-free days with lung-protective strategy","diseases":"Acute Respiratory Distress Syndrome","pageName":"ARDSNet","trainingLevel":"Intern","pmid":"10793162","statusUsableDate":"2012-03-01","title":"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome","timestamp":"2021-02-23T14:31:34Z","published":"2000-05-04","abbreviation":"ARDSNet","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005043421801","briefDesignDescription":"Low vs. traditional volumes in ARDS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005043421801"},{"statusUsableDate":"2025-06-05","pmid":"19064828","title":"Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy","published":"2008-12-08","timestamp":"2025-06-05T17:23:41Z","abbreviation":"ARIC","fulltexturl":"http://archinte.jamanetwork.com/article.aspx?articleid","subspecialties":"Endocrinology","briefDesignDescription":"HbA1c and CKD risk in DM","pdfurl":"http://archinte.jamanetwork.com/article.aspx?articleid","expansion":"Atherosclerosis Risk in Communities","pageid":2701,"citation":"Bash LD, et al. \"Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy\". Archives of Internal Medicine. 2008. 168(22):2440-2447.","diseases":"Diabetes Mellitus;Diabetic Nephropathy","briefResultsDescription":"Elevated HbA1c increases risk of CKD","pageName":"ARIC A1c and CKD","trainingLevel":"Fellow"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1404380","subspecialties":"Critical Care","briefDesignDescription":"EGDT vs. usual care in sepsis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404380","pmid":"25272316","statusUsableDate":"2014-11-01","title":"Goal-directed resuscitation for patients with early septic shock","published":"2014-10-16","timestamp":"2017-12-03T22:33:28Z","abbreviation":"ARISE","diseases":"Sepsis","briefResultsDescription":"EGDT doesn't reduce mortality in sepsis","pageName":"ARISE","trainingLevel":"Intern","expansion":"Australasian Resuscitation in Sepsis Evaluation","pageid":2216,"citation":"ARISE and ANZICS writers. \"Goal-directed resuscitation for patients with early septic shock\". The New England Journal of Medicine. 2014. 371(16):1496-1506."},{"expansion":"Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation","pageid":1497,"citation":"Granger CB, et al. \"Apixaban versus warfarin in patients with atrial fibrillation\". The New England Journal of Medicine. 2011. 365(11):981-982.","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","briefResultsDescription":"Apixaban better for CVA prevention in AF","pageName":"ARISTOTLE","trainingLevel":"Intern","pmid":"21870978","statusUsableDate":"2013-06-01","title":"Apixaban versus warfarin in patients with atrial fibrillation","published":"2011-09-15","timestamp":"2018-03-29T18:55:04Z","abbreviation":"ARISTOTLE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1107039","subspecialties":"Cardiology;Neurology","briefDesignDescription":"Apixaban vs. warfarin in AF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107039"},{"expansion":"Adjunctive rifampicin for Staphylococcus Aureus Bacteraemia","citation":"Thwaites GE, et al. \"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial\". The Lancet. 2017. 391(10121):668-678.","pageid":3569,"pageName":"ARREST","briefResultsDescription":"Adjunctive rifampin does not reduce mortality in S. aureus bacteremia","diseases":"Bacteremia","trainingLevel":"Resident","title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","pmid":"29249276","statusUsableDate":"2019-07-31","abbreviation":"ARREST","timestamp":"2019-08-02T19:20:32Z","published":"2017-12-14","briefDesignDescription":"Rifampin in S. aureus bacteremia","subspecialties":"Infectious Disease","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32456-X/fulltext","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32456-X.pdf"},{"timestamp":"2019-10-17T17:40:06Z","published":"2019-01-31","abbreviation":"ART","statusUsableDate":"2019-02-02","pmid":"30699314","title":"Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1610021","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1610021","briefDesignDescription":"Bilateral vs. single IMA graft in multivessel CAD","citation":"Taggart DP, et al. \"Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years\". The New England Journal of Medicine. 2019. 380(5):437-446.","pageid":3756,"expansion":"Arterial Revascularization Trial","trainingLevel":"Resident","briefResultsDescription":"Single IMA grafting non-inferior to bilateral IMA grafting in multivessel CAD","diseases":"Coronary Artery Disease","pageName":"ART"},{"expansion":"Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation","pageid":5604,"citation":"Healey JS, et al. \"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation\". The New England Journal of Medicine. 2023. 390(2):107-117.","diseases":"Atrial Fibrillation","briefResultsDescription":"Apixaban reduced stroke, but increased major bleeding","pageName":"ARTESIA","trainingLevel":"Resident","pmid":"37952132","statusUsableDate":"2025-01-30","title":"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation","published":"2023-11-12","timestamp":"2025-01-30T19:13:30Z","abbreviation":"ARTESIA","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2310234","subspecialties":"Cardiology","briefDesignDescription":"Apixaban vs. aspirin in subclinical AF","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2310234"},{"abbreviation":"ASCEND","published":"2018-08-26","timestamp":"2019-09-03T18:02:52Z","title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","statusUsableDate":"2018-09-06","pmid":"30146931","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1804988","briefDesignDescription":"Aspirin for vascular disease prevention in DM","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1804988","subspecialties":"Cardiology","pageid":3698,"citation":"Bowman L, et al. \"Effects of aspirin for primary prevention in persons with diabetes mellitus\". The New England Journal of Medicine. 2018. epub 2018-08-26:1-11.","expansion":"A Study of Cardiovascular Events in Diabetes","trainingLevel":"Resident","pageName":"ASCEND (Aspirin)","diseases":"Diabetes","briefResultsDescription":"Aspirin reduces cardiovascular events but increases bleeding vs. placebo"},{"abbreviation":"ASCEND","published":"2014-05-29","timestamp":"2018-09-13T17:56:54Z","title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","statusUsableDate":"2014-07-01","pmid":"24836312","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402582","briefDesignDescription":"Pirfenidone in IPF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1402582","subspecialties":"Pulmonology","pageid":1825,"citation":"King TE, et al. \"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis\". The New England Journal of Medicine. 2014. 370(22):2083-2092.","expansion":"Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis","trainingLevel":"Fellow","pageName":"ASCEND (IPF)","diseases":"Pulmonary Fibrosis","briefResultsDescription":"Pirfenidone reduces progression of IPF"},{"pageName":"ASPEN","briefResultsDescription":"Similar efficacy, zanubrutinib perhaps less toxic","diseases":"Waldenström Macroglobulinemia;Lymphoma","trainingLevel":"Fellow","expansion":"","citation":"Tam C, et al. \"ASPEN\". Blood. 2020. 136(18):2038-2050.","pageid":4448,"briefDesignDescription":"Zanubrutinib vs. ibrutinib in WM","subspecialties":"Hematology;Oncology","fulltexturl":"https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs","pdfurl":"https://ashpublications.org/blood/article-pdf/136/18/2038/1779238/bloodbld2020006844.pdf","title":"ASPEN","statusUsableDate":"2021-11-30","pmid":"32731259","abbreviation":"ASPEN","timestamp":"2025-06-19T18:36:44Z","published":"2020-10-29"},{"briefResultsDescription":"ASA probably reduces recurrent VTE","diseases":"Venous Thromboembolism","pageName":"ASPIRE","trainingLevel":"Intern","expansion":"Aspirin to Prevent Recurrent Venous Thromboembolism","citation":"Brighton TA, et al. \"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism\". The New England Journal of Medicine. 2012. 367(21):1979-1987.","pageid":1241,"subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210384","briefDesignDescription":"Aspirin after VTE treatment","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210384","statusUsableDate":"2013-08-01","pmid":"23121403","title":"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism","timestamp":"2017-12-03T22:33:32Z","published":"2012-11-04","abbreviation":"ASPIRE"},{"briefDesignDescription":"Aspirin for ASCVD 1° prevention if age >70","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1800722","subspecialties":"Preventive Medicine;Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800722","title":"Effect of aspirin on disability-free survival in the healthy elderly","pmid":"30221596","statusUsableDate":"2019-05-23","abbreviation":"ASPREE","published":"2018-09-16","timestamp":"2025-05-22T17:33:23Z","pageName":"ASPREE","diseases":"Coronary Artery Disease","briefResultsDescription":"Aspirin without 1° prevention benefit in adults >70 years","trainingLevel":"Student","expansion":"Aspirin in Reducing Events in the Elderly","pageid":3709,"citation":"McNeil JJ, et al. \"Effect of aspirin on disability-free survival in the healthy elderly\". The New England Journal of Medicine. 2018. 379(16):1-10."},{"title":"Revascularization versus medical therapy for renal-artery stenosis","pmid":"19907042","statusUsableDate":"2013-09-01","abbreviation":"ASTRAL","published":"2009-11-12","timestamp":"2018-01-04T18:44:16Z","briefDesignDescription":"Revascularization in RAS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905368","subspecialties":"Nephrology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905368","expansion":"Angioplasty and Stenting for Renal Artery Lesions","pageid":1684,"citation":"Wheatley K, et al. \"Revascularization versus medical therapy for renal-artery stenosis\". The New England Journal of Medicine. 2009. 361(20):1953-1962.","pageName":"ASTRAL","diseases":"Renal Artery Stenosis;Hypertension","briefResultsDescription":"Revascularization no better than medical therapy alone in RAS","trainingLevel":"Resident"},{"citation":"Khanna A et al. \"Angiotensin II for the Treatment of Vasodilatory Shock\". New Engl J Med. 2017. 377:419-30.","pageid":2950,"expansion":"Angiotensin II for the Treatment of High-Output Shock","trainingLevel":"Resident","pageName":"ATHOS-3","briefResultsDescription":"Angiotensin II superior to placebo in vasodilatory shock","diseases":"Shock","abbreviation":"ATHOS-3","timestamp":"2019-09-11T15:27:57Z","published":"2017-08-03","title":"Angiotensin II for the Treatment of Vasodilatory Shock","pmid":"28528561","statusUsableDate":"2017-08-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1704154","briefDesignDescription":"Angiotensin II vs. placebo in vasodilatory shock","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1704154"},{"trainingLevel":"Fellow","diseases":"Breast Cancer","briefResultsDescription":"10 years of tamoxifen reduces recurrence and mortality","pageName":"ATLAS","pageid":1581,"citation":"Davies C, et al. \"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial\". The Lancet. 2013. 381(9869):805-16.","expansion":"Adjuvant Tamoxifen: Longer Against Shorter","pdfurl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/fulltext","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/","subspecialties":"Oncology","briefDesignDescription":"10y vs. 5y tamoxifen in breast cancer","published":"2013-03-09","timestamp":"2017-12-03T22:33:36Z","abbreviation":"ATLAS","pmid":"23219286","statusUsableDate":"2013-10-01","title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112277","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1112277","briefDesignDescription":"Rivaroxaban after ACS","timestamp":"2017-12-03T22:33:37Z","published":"2012-01-05","abbreviation":"ATLAS ACS 2-TIMI 51","pmid":"22077192","statusUsableDate":"2013-03-01","title":"Rivaroxaban in Patients with Recent Acute Coronary Syndrome","trainingLevel":"Resident","briefResultsDescription":"Rivaroxaban reduces cardiovascular death, MI, and stroke, but increases nonfatal bleeding","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","pageName":"ATLAS ACS-2, TIMI 51","citation":"Mega JL, et al. \"Rivaroxaban in Patients with Recent Acute Coronary Syndrome\". The New England Journal of Medicine. 2012. 366(1):9-19.","pageid":174,"expansion":"Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51"},{"trainingLevel":"Resident","briefResultsDescription":"Intensive RRT yields similar mortality as conventional RRT in critically ill patients with ATN","diseases":"Acute Kidney Injury;Critical Illness","pageName":"ATN","citation":"Palevsky PM, et al. \"Intensity of renal support in critically ill patients with acute kidney injury\". The New England Journal of Medicine. 2008. 359(1):7-20.","pageid":2339,"expansion":"Acute Renal Failure Trial Network Study","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802639","subspecialties":"Nephrology;Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802639","briefDesignDescription":"RRT intensity in ATN","timestamp":"2017-12-03T22:33:39Z","published":"2008-07-03","abbreviation":"ATN","statusUsableDate":"2015-03-01","pmid":"18492867","title":"Intensity of renal support in critically ill patients with acute kidney injury"},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805689","briefDesignDescription":"Tafamidis vs. placebo in amyloid cardiomyopathy","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1805689","abbreviation":"ATTR-ACT","timestamp":"2019-05-21T14:25:21Z","published":"2018-08-27","title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","statusUsableDate":"2018-09-05","pmid":"30145929","trainingLevel":"Resident","pageName":"ATTR-ACT","briefResultsDescription":"Tafamidis superior to placebo in amyloid cardiomyopathy","diseases":"Heart Failure","citation":"Maurer MS, et al. \"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy\". The New England Journal of Medicine. 2018. 379(11):1007-1016.","pageid":3696,"expansion":"The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial"},{"citation":"Vedantham S, et al. \"Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis\". The New England Journal of Medicine. 2017. 377(23):2240-2252.","pageid":3546,"expansion":"Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis","trainingLevel":"resident","briefResultsDescription":"No difference with intervention vs. anticoagulation","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Post-Thrombotic Syndrome","pageName":"ATTRACT","timestamp":"2019-07-17T05:12:53Z","published":"2017-12-07","abbreviation":"ATTRACT","statusUsableDate":"2018-07-19","pmid":"29211671","title":"Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1615066","subspecialties":"Hematology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1615066","briefDesignDescription":"Pharmacomechanical therapy vs. anticoagulation in DVT"},{"statusUsableDate":"2019-10-17","pmid":"30883055","title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","timestamp":"2025-05-22T17:32:42Z","published":"2019-04-18","abbreviation":"AUGUSTUS","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1817083","briefDesignDescription":"DOAC, VKA, antiplatelets after PCI with stent and AF","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817083","expansion":"An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention","citation":"Lopes RD, et al. \"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation\". The New England Journal of Medicine. 2019. 380(16):1509-1524.","pageid":3947,"briefResultsDescription":"Apixaban with lower bleeding","diseases":"Coronary Artery Disease;Atrial Fibrillation","pageName":"AUGUSTUS","trainingLevel":"Resident"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007432","briefDesignDescription":"Apixaban vs. ASA in AF","subspecialties":"Cardiology;Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007432","abbreviation":"AVERROES","timestamp":"2017-12-03T22:33:40Z","published":"2011-03-03","title":"Apixaban in patients with atrial fibrillation","pmid":"21309657","statusUsableDate":"2013-11-01","trainingLevel":"Intern","pageName":"AVERROES","briefResultsDescription":"Apixaban better than ASA without increased bleeding in AF","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","citation":"Connolly SJ, et al. \"Apixaban in patients with atrial fibrillation\". The New England Journal of Medicine. 2011. 364(9):806-817.","pageid":1718,"expansion":"Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment"},{"abbreviation":"AVERT","published":"2018-12-04","timestamp":"2019-02-05T14:44:30Z","title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","pmid":"30511879","statusUsableDate":"2019-01-31","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814468","briefDesignDescription":"Apixaban for VTE prevention in cancer","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1814468","subspecialties":"Hematology;Oncology","pageid":3752,"citation":"Carrier M, et al. \"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer\". The New England Journal of Medicine. 2018. E-pub 2018-12-04:1-8.","expansion":"Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients","trainingLevel":"Resident","pageName":"AVERT","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","briefResultsDescription":"Apixaban reduces risk of VTE, increases risk of bleeding"},{"expansion":"Comparing Oxygen with normal air in patients with ST-Segment Elevation Myocardial Infarction who are not hypoxic.","pageid":2930,"citation":"Stub D, et al. \"Air Versus Oxygen in ST-Segment Elevation Myocardial Infarction\". Circulation. 2015. 131(24):2143-2150.","pageName":"AVOID","diseases":"Myocardial Infarction","briefResultsDescription":"No benefit from in non-hypoxemic patients with STEMI","trainingLevel":"Intern","title":"Air Versus Oxygen in ST-Segment Elevation Myocardial Infarction","statusUsableDate":"2017-09-01","pmid":"26002889","abbreviation":"AVOID","published":"2015-05-22","timestamp":"2017-12-03T22:33:41Z","briefDesignDescription":"Supplemental oxygen in STEMI","fulltexturl":"http://circ.ahajournals.org/content/131/24/2143","subspecialties":"Cardiology","pdfurl":"http://circ.ahajournals.org/content/131/24/2143.full.pdf"},{"diseases":"HIV","briefResultsDescription":"Zidovudine reduces mortality in HIV/AIDS","pageName":"AZT Trial","trainingLevel":"Student","expansion":"","pageid":1775,"citation":"Fischl MA et al. \"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex\". The New England Journal of Medicine. 1987. 317(4):185-191.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198707233170401","subspecialties":"Infectious Disease","briefDesignDescription":"Zidovudine in HIV/AIDS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198707233170401","pmid":"3299089","statusUsableDate":"2014-01-01","title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex","published":"1987-07-23","timestamp":"2017-12-03T22:33:42Z","abbreviation":""},{"expansion":"Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode","pageid":4250,"citation":"Jondeau G, et al. \"B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode\". Eur Heart J. 2009. 30(18):2186-2192.","diseases":"Heart Failure","briefResultsDescription":"Beta-blocker withdrawal not needed in ADHF","pageName":"B-CONVINCED","trainingLevel":"Student","statusUsableDate":"2020-08-20","pmid":"19717851","title":"B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode","published":"2009-08-30","timestamp":"2020-08-20T18:18:36Z","abbreviation":"B-CONVINCED","fulltexturl":"https://doi.org/10.1093/eurheartj/ehp323","subspecialties":"Cardiology","briefDesignDescription":"Beta-blocker withdrawal in ADHF","pdfurl":""},{"trainingLevel":"Resident","briefResultsDescription":"CABG is superior to OMT in diabetics with CAD","diseases":"Coronary Artery Disease;Diabetes Mellitus","pageName":"BARI 2D","citation":"Frye RL, et al. \"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease\". The New England Journal of Medicine. 2009. 360(24):2503-2515.","pageid":1471,"expansion":"Bypass Angioplasty Revascularization Investigation 2 Diabetes","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805796","subspecialties":"Cardiology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805796","briefDesignDescription":"CABG/PCI vs. OMT in diabetes with CAD","timestamp":"2017-12-03T22:33:47Z","published":"2009-06-11","abbreviation":"BARI 2D","statusUsableDate":"2013-06-01","pmid":"19502645","title":"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease"},{"pageName":"BASALT","diseases":"Asthma","briefResultsDescription":"Symptom-, biomarker-, and physician-based treatments are similar","trainingLevel":"Resident","expansion":"Best Adjustment Strategy for Asthma in the Long Term","pageid":1864,"citation":"Calhoun WJ, et al. \"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial\". Journal of the American Medical Association. 2012. 308(10):987-997.","briefDesignDescription":"Symptom-based asthma therapy","fulltexturl":"http://bit.ly/1FNk0v0","subspecialties":"Pulmonology","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/24854/joc120069_987_997.pdf","title":"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial","pmid":"22968888","statusUsableDate":"2015-03-01","abbreviation":"BASALT","published":"2012-09-12","timestamp":"2017-12-03T22:33:48Z"},{"briefDesignDescription":"Tisa-cel vs. ASCT in R/R DLBCL","subspecialties":"Hematology;Oncology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2116596","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116596","title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","statusUsableDate":"2023-12-14","pmid":"34904798","abbreviation":"BELINDA","timestamp":"2023-12-15T03:08:03Z","published":"2022-02-17","pageName":"BELINDA","briefResultsDescription":"CART did not improve PFS compared to ASCT","diseases":"Lymphoma;Aggressive B-cell lymphoma","trainingLevel":"Fellow","expansion":"","citation":"Bishop MR, et al. \"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma\". The New England Journal of Medicine. 2022. 368(7):629-639.","pageid":4462},{"title":"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency","statusUsableDate":"2016-02-01","pmid":"16407508","abbreviation":"","published":"2006-01-12","timestamp":"2017-12-03T22:33:54Z","briefDesignDescription":"Benazepril in non-diabetic CKD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa053107","subspecialties":"Nephrology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa053107","expansion":"","pageid":2674,"citation":"Hou FF, et al. \"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency\". The New England Journal of Medicine. 2006. 354(2):131-140.","pageName":"Benazepril in Severe CKD","diseases":"Chronic Kidney Disease","briefResultsDescription":"Benazepril improves renal outcomes in non-diabetic CKD","trainingLevel":"Resident"},{"trainingLevel":"Resident","pageName":"BeSt","diseases":"Rheumatoid Arthritis","briefResultsDescription":"Combination therapy produces early functional improvement than DMARD alone","pageid":77,"citation":"Goekoop-Ruiterman YP, et al. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". Arthritis & Rheumatism. 2005. 52(11):3381-3390.","expansion":"Behandel-Strategeieën (\"treatment strategies\" in Dutch)","pdfurl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf","briefDesignDescription":"DMARD ± prednisone or infliximab in RA","fulltexturl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract","subspecialties":"Rheumatology","abbreviation":"BeSt","published":"2005-11-01","timestamp":"2022-04-17T20:47:43Z","title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis","statusUsableDate":"2012-03-01","pmid":"16258899"},{"trainingLevel":"Resident","briefResultsDescription":"PCI inferior to CABG for multivessel disease","diseases":"Coronary Artery Disease","pageName":"BEST","citation":"Reardon MJ, et al. \"Trial of everolimus-eluting stents or bypass surgery for coronary disease\". The New England Journal of Medicine. 2015. 372(13):1204-12.","pageid":2916,"expansion":"The Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1415447","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1415447","briefDesignDescription":"PCI vs. CABG for multivessel disease","timestamp":"2017-12-03T22:33:49Z","published":"2015-03-26","abbreviation":"BEST","statusUsableDate":"2017-05-01","pmid":"25774645","title":"Trial of everolimus-eluting stents or bypass surgery for coronary disease"},{"pageid":3721,"citation":"Jaber S, et al. \"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial\". The Lancet. 2018. 392(10141):31-40.","expansion":"Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill: A Multiple Center Randomized Clinical Trial","trainingLevel":"Resident","diseases":"Metabolic Acidosis;Critical Illness","briefResultsDescription":"No improvement in death with sodium bicarb in ICU patients","pageName":"BICAR-ICU","published":"2018-07-07","timestamp":"2019-03-05T05:23:16Z","abbreviation":"BICAR-ICU","statusUsableDate":"2019-02-28","pmid":"29910040","title":"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial","pdfurl":"","fulltexturl":"https://doi.org/10.1016/S0140-6736(18)31080-8","subspecialties":"Critical Care","briefDesignDescription":"Bicarbonate in severe metabolic acidosis"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210356","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210356","subspecialties":"Cardiology","briefDesignDescription":"RV pacing vs. BiV pacing in HF with AV block","published":"2013-04-25","timestamp":"2019-03-26T21:31:31Z","abbreviation":"BLOCK-HF","statusUsableDate":"2017-06-01","pmid":"23614585","title":"Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block","trainingLevel":"resident","diseases":"Atrioventricular Block","briefResultsDescription":"Biventricular pacing superior to right ventricular pacing in patients with CHF with AV block","pageName":"BLOCK-HF","pageid":2422,"citation":"Curtis A.B., et al. \"Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block\". The New England Journal of Medicine. 2013. 368(17):1585-1593.","expansion":"Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block"},{"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1717250","briefDesignDescription":"PharmD-guided BP reduction for Black men","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1717250","pmid":"29527973","statusUsableDate":"2018-04-05","title":"A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops","timestamp":"2025-07-28T00:00:39Z","published":"2018-04-05","abbreviation":"Blood-Pressure Reduction in Black Barbershops","briefResultsDescription":"Pharmacist-guided BP management improves","diseases":"Hypertension","pageName":"Blood Pressure Reduction in Black Barbershops","trainingLevel":"Resident","expansion":"Blood-Pressure Reduction in Black Barbershops","citation":"Victor RG, et al. \"A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops\". The New England Journal of Medicine. 2018. 378(14):1291-1301.","pageid":3578},{"expansion":"Blood Pressure Control Target in Diabetes","citation":"Bi Y, et al. \"Intensive blood-pressure control in patients with type 2 diabetes\". The New England Journal of Medicine. 2024. e-pub 2024-11-6:1-13.","pageid":5613,"briefResultsDescription":"Intensive BP control had fewer CVD events in DM","diseases":"Diabetes Mellitus;Hypertension","pageName":"BPROAD","trainingLevel":"student","statusUsableDate":"2024-11-30","pmid":"39555827","title":"Intensive blood-pressure control in patients with type 2 diabetes","timestamp":"2025-06-05T17:40:19Z","published":"2024-11-16","abbreviation":"BPROAD","subspecialties":"Cardiology;Endocrinology","fulltexturl":"","briefDesignDescription":"Intensive BP control in DM","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2412006"},{"title":"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation","pmid":"26095867","statusUsableDate":"2015-07-01","abbreviation":"BRIDGE","timestamp":"2018-01-17T21:45:20Z","published":"2015-06-22","briefDesignDescription":"LMWH bridging for surgery in AF","subspecialties":"Cardiology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501035","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035","expansion":"Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery","citation":"Douketis JD, et al. \"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation\". The New England Journal of Medicine. 2015. 373(9):823-33.","pageid":2402,"pageName":"BRIDGE","briefResultsDescription":"LMWH bridging didn't reduce VTE but increased bleeding","diseases":"Atrial Fibrillation;Stroke","trainingLevel":"Intern"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103782","subspecialties":"Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1103782","briefDesignDescription":"Vemurafenib in BRAF V600+ melanoma","timestamp":"2017-12-03T22:33:53Z","published":"2011-06-30","abbreviation":"BRIM-3","pmid":"21639808","statusUsableDate":"2015-07-01","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","trainingLevel":"Fellow","briefResultsDescription":"Vemurafenib improves survival in BRAF V600-mutated melanoma","diseases":"Melanoma","pageName":"BRIM-3","citation":"Chapman BP, et al. \"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation\". The New England Journal of Medicine. 2011. 364(26):2507-2516.","pageid":2391,"expansion":"BRAF Inhibitor in Melanoma 3"},{"pageName":"CABANA","briefResultsDescription":"Catheter ablation does not reduce cardiovascular events in patients with AF","diseases":"Atrial Fibrillation","trainingLevel":"Resident","expansion":"Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation","citation":"Packer DL, et al. \"Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation\". JAMA. 2019. 321(13):1261-1274.","pageid":3950,"briefDesignDescription":"Catheter ablation vs. anti-arrhythmic therapy in AF","subspecialties":"Cardiology","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/2728676","pdfurl":"","title":"Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation","statusUsableDate":"2019-04-11","pmid":"30874766","abbreviation":"CABANA","timestamp":"2019-04-11T17:25:17Z","published":"2019-04-11"},{"published":"2014-10-30","timestamp":"2024-08-29T19:09:38Z","abbreviation":"CALORIES","pmid":"25271389","statusUsableDate":"2024-08-28","title":"Trial of the route of early nutritional support in critically ill adults","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1409860","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1409860","subspecialties":"Critical Care","briefDesignDescription":"Early parenteral vs. enteral feeds in ICU","pageid":4141,"citation":"Harvey SE, et al. \"Trial of the route of early nutritional support in critically ill adults\". The New England Journal of Medicine. 2014. 371(18):1673-1684.","expansion":"","trainingLevel":"Resident","diseases":"Critical Illness","briefResultsDescription":"No difference between parenteral and enteral feeds in ICU","pageName":"CALORIES"},{"pdfurl":"http://ard.bmj.com/content/66/11/1443.full.pdf","briefDesignDescription":"Methotrexate strategies in RA","fulltexturl":"http://ard.bmj.com/content/66/11/1443.long","subspecialties":"Rheumatology","abbreviation":"CAMERA","published":"2007-11-01","timestamp":"2017-12-04T00:13:32Z","title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","statusUsableDate":"2017-11-30","pmid":"17519278","trainingLevel":"Fellow","pageName":"CAMERA","diseases":"Rheumatoid Arthritis","briefResultsDescription":"Intensive methotrexate dosing better than conventional","pageid":2859,"citation":"Verstappen SM, et al. \"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)\". Annals of the Rheumatic Diseases. 2007. 66(11):1443-1449.","expansion":"Computer Assisted Management in Early Rheumatoid Arthritis"},{"briefDesignDescription":"Light therapy vs. SSRI for SAD","fulltexturl":"http://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.5.805","subspecialties":"Psychiatry","pdfurl":"http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.5.805","title":"The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder","pmid":"16648320","statusUsableDate":"2015-04-01","abbreviation":"Can-SAD","published":"2006-05-01","timestamp":"2017-12-03T22:34:40Z","pageName":"Can-SAD","diseases":"Seasonal Affective Disorder;Depression","briefResultsDescription":"No difference between light therapy and SSRI in SAD","trainingLevel":"Intern","expansion":null,"pageid":2173,"citation":"Lam RW, et al. \"The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder\". The American Journal of Psychiatry. 2006. 165(5):805-812."},{"title":"The Canadian CT Head Rule for patients with minor head trauma","pmid":"11356436","statusUsableDate":"2012-03-01","abbreviation":"","published":"2001-05-05","timestamp":"2012-06-13T05:04:26Z","briefDesignDescription":"CT head rules for trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext","subspecialties":"Emergency Medicine;Neurology","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS014067360004561X.pdf","expansion":"","pageid":93,"citation":"Stiell IG, et al. \"The Canadian CT Head Rule for patients with minor head trauma\". The Lancet. 2001. 357(9266):1391-96.","pageName":"Canadian CT Head Rule","diseases":"Trauma","briefResultsDescription":"GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk","trainingLevel":"resident"},{"briefResultsDescription":"Canakinumab reduces cardiovascular events in patients with previous MI","diseases":"Coronary Artery Disease","pageName":"CANTOS","trainingLevel":"Resident","expansion":"Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)","citation":"Ridker PM, et al. \"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease\". The New England Journal of Medicine. 2017. 377(12):1119-1131.","pageid":2964,"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1707914","briefDesignDescription":"Canakinumab in patients with previous MI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707914","pmid":"28845751","statusUsableDate":"2017-10-01","title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","timestamp":"2018-11-12T16:15:18Z","published":"2017-08-27","abbreviation":"CANTOS"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611925","briefDesignDescription":"Canagliflozin for CV outcomes in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611925","subspecialties":"Endocrinology;Cardiology;Nephrology","abbreviation":"CANVAS","published":"2017-08-17","timestamp":"2022-10-13T17:45:18Z","title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","pmid":"28605608","statusUsableDate":"2017-08-01","trainingLevel":"intern","pageName":"CANVAS","diseases":"Diabetes Mellitus","briefResultsDescription":"Canagliflozin reduces CV events compared to placebo in patients with type 2 diabetes","pageid":2952,"citation":"Neal B, et al. \"Canagliflozin and cardiovascular and renal events in type 2 diabetes\". The New England Journal of Medicine. 2017. 377(7):644-657.","expansion":"Canagliflozin Cardiovascular Assessment Study"},{"pageid":2838,"citation":"Postma DF, et al. \"Antibiotic treatment strategies for community-acquired pneumonia in adults\". The New England Journal of Medicine. 2015. 372(14):1312-1323.","expansion":"Community-Acquired Pneumonia—Study on the Initial Treatment with Antibiotics of Lower Respiratory Tract Infections","trainingLevel":"Student","pageName":"CAP-START","diseases":"Pneumonia","briefResultsDescription":"Beta-lactam alone is noninferior to quinolone or beta-lactam+macrolide","abbreviation":"CAP-START","published":"2015-04-02","timestamp":"2018-03-08T18:31:23Z","title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","pmid":"25830421","statusUsableDate":"2018-03-08","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406330","briefDesignDescription":"Antibiotic strategies for PNA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1406330","subspecialties":"Infectious Disease"},{"abbreviation":"CAPE COD","timestamp":"2023-04-24T20:34:11Z","published":"2023-03-21","title":"Hydrocortisone in severe community-acquired pneumonia","statusUsableDate":"2023-04-06","pmid":"36942789","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2215145","briefDesignDescription":"Hydrocortisone in severe CAP","subspecialties":"Critical Care;Pulmonology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2215145","citation":"Dequin PF, et al. \"Hydrocortisone in severe community-acquired pneumonia\". The New England Journal of Medicine. 2023. Epub 2023-03-21:1-11.","pageid":5318,"expansion":"","trainingLevel":"student","pageName":"CAPE COD","briefResultsDescription":"Hydrocortisone lowers mortality in severe CAP","diseases":"Pneumonia"},{"trainingLevel":"resident","briefResultsDescription":"Improved mortality with carvedilol post-MI with LVEF ≤40%","diseases":"Acute Coronary Syndrome","pageName":"CAPRICORN","citation":"Dargie HJ, et al. \"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial\". The Lancet. 2001. 357(9266):1385-1390.","pageid":2944,"expansion":"Carvedilol Post-Infarct Survival Control in LV Dysfunction","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(00)04560-8.pdf","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04560-8","briefDesignDescription":"Carvedilol post-MI with HFrEF","timestamp":"2019-03-15T15:10:50Z","published":"2001-05-01","abbreviation":"CAPRICORN","statusUsableDate":"2019-03-07","pmid":"11356434","title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial"},{"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673696094573.pdf","briefDesignDescription":"Clopidogrel vs. aspirin in CV disease","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09457-3/fulltext","subspecialties":"Neurology;Cardiology","abbreviation":"CAPRIE","published":"1996-11-16","timestamp":"2023-03-30T18:14:36Z","title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events","statusUsableDate":"2012-03-01","pmid":"8918275","trainingLevel":"Intern","pageName":"CAPRIE","diseases":"Stroke;Transient Ischemic Attack;Coronary Artery Disease","briefResultsDescription":"Clopidogrel reduces risk of cardiovascular events","pageid":7,"citation":"Gent M, et al. \"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events\". The Lancet. 1996. 348(9038):1329-39.","expansion":"Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events"},{"citation":"Agnelli G, et al. \"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer\". The New England Journal of Medicine. 2020. 382:1599-607.","pageid":4265,"expansion":"","trainingLevel":"resident","pageName":"CARAVAGGIO","briefResultsDescription":"Apixaban is noninferior to dalteparin for cancer VTE","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","abbreviation":"CARVAGGIO","timestamp":"2020-11-05T18:09:03Z","published":"2020-03-29","title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","statusUsableDate":"2020-10-31","pmid":"32223112","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915103","briefDesignDescription":"Apixaban vs. dalteparin in cancer VTE","subspecialties":"Hematology;Oncology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1915103"},{"title":"Coronary-artery revascularization before elective major vascular surgery","pmid":"15625331","statusUsableDate":"2015-09-01","abbreviation":"CARP","published":"2004-12-30","timestamp":"2017-12-03T22:33:59Z","briefDesignDescription":"Preop coronary revascularization if stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa041905","subspecialties":"Cardiology;Preventive Medicine","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa041905","expansion":"","pageid":1332,"citation":"McFalls EO, et al. \"Coronary-artery revascularization before elective major vascular surgery\". The New England Journal of Medicine. 2004. 351(27):2795-2804.","pageName":"CARP","diseases":"Coronary Artery Disease;Cardiac Risk Assessment","briefResultsDescription":"Preop coronary revascularization doesn't reduce mortality","trainingLevel":"Resident"},{"trainingLevel":"Resident","briefResultsDescription":"Ultrafiltration worse then meds in acute HF","diseases":"Heart Failure","pageName":"CARRESS-HF","citation":"Bart BA, et al. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". The New England Journal of Medicine. 2012. 367(24):2296-2304.","pageid":1356,"expansion":"Cardiorenal Rescue Study in Acute Decompensated Heart Failure","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210357","briefDesignDescription":"Ultrafiltration in decompensated HF","timestamp":"2017-12-03T22:34:00Z","published":"2012-12-13","abbreviation":"CARRESS-HF","statusUsableDate":"2013-05-01","pmid":"23131078","title":"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome"},{"citation":"Khorana AA, et al. \"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer\". The New England Journal of Medicine. 2019. 380(8):720-8.","pageid":3945,"expansion":"Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer","trainingLevel":"Resident","briefResultsDescription":"Rivaroxaban did not reduce VTE","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","pageName":"CASSINI","timestamp":"2019-05-23T17:55:30Z","published":"2019-02-21","abbreviation":"CASSINI","statusUsableDate":"2019-03-07","pmid":"30786186","title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814630","subspecialties":"Hematology;Oncology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1814630","briefDesignDescription":"Rivaroxaban for VTE prevention in cancer"},{"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199103213241201","briefDesignDescription":"Antiarrhythmics post-MI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199103213241201","pmid":"1900101","statusUsableDate":"2012-12-01","title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","timestamp":"2017-12-03T22:34:01Z","published":"1991-03-21","abbreviation":"CAST I","briefResultsDescription":"Antiarrhythmics increase mortality","diseases":"Acute Coronary Syndrome;Myocardial Infarction","pageName":"CAST I","trainingLevel":"Resident","expansion":"Cardiac Arrhythmia Suppression Trial","citation":"Echt DS, et al. \"Mortality and morbidity in patients receiving encainide, flecainide, or placebo\". The New England Journal of Medicine. 1991. 324(12):781-788.","pageid":1110},{"trainingLevel":"Resident","pageName":"CASTLE-AF","briefResultsDescription":"Catheter ablation superior to standard therapy in AF and HF","diseases":"Atrial Fibrillation","citation":"Marrouche NF, et al. \"Catheter Ablation for Atrial Fibrillation with Heart Failure\". The New England Journal of Medicine. 2018. 378(5):417-27.","pageid":3533,"expansion":"Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707855","briefDesignDescription":"Catheter ablation vs. standard therapy in AF+HF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1707855","abbreviation":"CASTLE-AF","timestamp":"2018-08-10T15:33:15Z","published":"2018-02-01","title":"Catheter Ablation for Atrial Fibrillation with Heart Failure","statusUsableDate":"2018-02-08","pmid":"29385358"},{"abbreviation":"CATIE","published":"2005-09-22","timestamp":"2017-12-03T22:34:03Z","title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","statusUsableDate":"2012-06-01","pmid":"16172203","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa051688","briefDesignDescription":"Antipsychotics in schizophrenia","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa051688","subspecialties":"Psychiatry","pageid":419,"citation":"Lieberman JA, et al. \"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia\". The New England Journal of Medicine. 2005. 353(12):1209-23.","expansion":"Clinical Antipsychotic Trials of Intervention Effectiveness","trainingLevel":"Resident","pageName":"CATIE","diseases":"Schizophrenia","briefResultsDescription":"Olanzapine ↓discontinuations but ↑metabolic syndrome, and perphenazine ˜ atypicals"},{"trainingLevel":"Intern","pageName":"CATIE-AD","diseases":"Dementia;Alzheimer Disease;Psychosis","briefResultsDescription":"Antipsychotics no better than placebo","pageid":2724,"citation":"Schneider LS, et al. \"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease\". The New England Journal of Medicine. 2006. 355(15):1525-38.","expansion":"Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061240","briefDesignDescription":"Antipsychotics in dementia with psychosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061240","subspecialties":"Psychiatry","abbreviation":"CATIE-AD","published":"2006-10-12","timestamp":"2017-12-03T22:34:04Z","title":"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease","statusUsableDate":"2016-04-01","pmid":"17035647"},{"citation":"The CATT Research Group Writers. \"Ranibizumab and bevacizumab for neovascular age-related macular degeneration\". The New England Journal of Medicine. 2011. 364(20):1897-1908.","pageid":2250,"expansion":"Comparison of Age-Related Macular Degeneration Treatment Trails","trainingLevel":"Resident","briefResultsDescription":"Ranibizumab vs. bevacizumab similar even when comparing monthly vs. PRN scheduling","diseases":"Macular Degeneration","pageName":"CATT","timestamp":"2017-12-03T22:34:05Z","published":"2011-05-19","abbreviation":"CATT","statusUsableDate":"2014-10-01","pmid":"21526923","title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102673","subspecialties":"Ophthalmology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102673","briefDesignDescription":"Ranibizumab vs. bevacizumab for macular degeneration"},{"pageid":2935,"citation":"Bhatt DL, et al. \"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events\". The New England Journal of Medicine. 2013. 368(14):1303-1313.","expansion":"Cangrelor versus standard therapy to achieve optimal management of platelet inhibition","trainingLevel":"Fellow","pageName":"CHAMPION PHOENIX","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction","briefResultsDescription":"Cangrelor reduces rate of ischemic events during PCI","abbreviation":"CHAMPION PHOENIX","published":"2013-04-04","timestamp":"2025-07-25T00:26:24Z","title":"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events","statusUsableDate":"2017-06-01","pmid":"23473369","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300815","briefDesignDescription":"Cangrelor during urgent or elective PCI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300815","subspecialties":"Cardiology"},{"trainingLevel":"Resident","pageName":"CHANCE","diseases":"Stroke;Transient Ischemic Attack","briefResultsDescription":"ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA","pageid":1530,"citation":"Wang Y, et al. \"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack\". The New England Journal of Medicine. 2013. 369(1):11-19.","expansion":"Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215340","briefDesignDescription":"ASA/clopidogrel vs. ASA in TIA/stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215340","subspecialties":"Neurology","abbreviation":"CHANCE","published":"2013-07-04","timestamp":"2020-01-03T00:19:05Z","title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","statusUsableDate":"2013-07-01","pmid":"23803136"},{"expansion":null,"pageid":2126,"citation":"McMurray JJ, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial\". The Lancet. 2003. 362(9386):767-771.","pageName":"CHARM-Added","diseases":"Heart Failure","briefResultsDescription":"Adding ARB to ACE-I reduces CV events and HF hospitalizations","trainingLevel":"Intern","title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","pmid":"13678869","statusUsableDate":"2014-08-01","abbreviation":"Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added","published":"2003-09-06","timestamp":"2017-12-03T22:34:11Z","briefDesignDescription":"ARB plus ACE-I in HF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2914283-3/fulltext","subspecialties":"Cardiology","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603142833.pdf"},{"briefResultsDescription":"ARBs reduce CV mortality and HF hospitalization in HFrEF","diseases":"Heart Failure","pageName":"CHARM-Alternative","trainingLevel":"Intern","expansion":"","citation":"Granger CB, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial\". The Lancet. 2003. 362(9386):772-776.","pageid":2416,"subspecialties":"Cardiology","fulltexturl":"https://doi.org/10.1016/s0140-6736(03)14284-5","briefDesignDescription":"ARBs in HFrEF","pdfurl":"","statusUsableDate":"2023-03-29","pmid":"13678870","title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","timestamp":"2023-03-30T17:58:17Z","published":"2003-09-06","abbreviation":"CHARM-Alternative"},{"expansion":"Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved","pageid":2381,"citation":"Yusuf S, et al. \"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial\". The Lancet. 2003. 362(9386):777-781.","pageName":"CHARM-Preserved","diseases":"Heart Failure","briefResultsDescription":"Candesartan modestly reduces HF admissions but does not affect CV mortality","trainingLevel":"Intern","title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","statusUsableDate":"2015-06-01","pmid":"13678871","abbreviation":"CHARM-Preserved","published":"2003-09-06","timestamp":"2017-12-03T22:34:16Z","briefDesignDescription":"ARBs in HFpEF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14285-7/fulltext","subspecialties":"Cardiology","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14285-7.pdf"},{"abbreviation":"","published":"2012-06-28","timestamp":"2017-12-03T22:34:42Z","title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","pmid":"22658127","statusUsableDate":"2014-10-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690","briefDesignDescription":"Nivolumab in solid tumors","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200690","subspecialties":"Oncology","pageid":2220,"citation":"Topalian SL, et al. \"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer\". The New England Journal of Medicine. 2012. 366(26):2443-54.","expansion":"","trainingLevel":"Resident","pageName":"CheckMate-003","diseases":"Melanoma;Lung Cancer;Renal Cell Carcinoma","briefResultsDescription":"Nivolumab was well tolerated, yielded durable remissions in about 30% of patients"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400506","subspecialties":"Gynecology;Preventive Medicine;Obstetrics","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1400506","briefDesignDescription":"Free long-acting reversible contraception in teens","timestamp":"2017-12-03T22:34:18Z","published":"2014-10-02","abbreviation":"CHOICE","pmid":"25271604","statusUsableDate":"2014-10-01","title":"Provision of no-cost, long-acting contraception and teenage pregnancy","trainingLevel":"Student","briefResultsDescription":"LARC reduced pregnancy, live births, and abortions","diseases":"Unplanned Pregnancy","pageName":"CHOICE","citation":"Secura GM, et al. \"Provision of no-cost, long-acting contraception and teenage pregnancy\". The New England Journal of Medicine. 2014. 371(14):1316-1326.","pageid":2233,"expansion":"CHOICE is not an abbreviation per a communication with the research team"},{"citation":"Singh AK, et al. \"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease\". The New England Journal of Medicine. 2006. 355(20):2085-2098.","pageid":422,"expansion":"Correction of Hemoglobin and Outcomes in Renal Insufficiency","trainingLevel":"Resident","briefResultsDescription":"Increased morbidity/mortality with higher hgb targets","diseases":"Chronic Kidney Disease;Anemia","pageName":"CHOIR","timestamp":"2019-02-21T16:44:19Z","published":"2006-11-16","abbreviation":"CHOIR","pmid":"17108343","statusUsableDate":"2012-05-01","title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485","subspecialties":"Nephrology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa065485","briefDesignDescription":"EPO in CKD with anemia"},{"pmid":"10023943","statusUsableDate":"2023-01-30","title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","published":"1999-01-02","timestamp":"2023-02-02T19:39:17Z","abbreviation":"CIBIS-II","fulltexturl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673698111819","subspecialties":"Cardiology","briefDesignDescription":"Bisoprolol in HFrEF","pdfurl":"","expansion":"","pageid":2436,"citation":"CIBIS-II Writers. \"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial\". The Lancet. 1999. 353(9146):9-13.","diseases":"Heart Failure","briefResultsDescription":"Bisoprolol lowers mortality in HFrEF","pageName":"CIBIS-II","trainingLevel":"Student"},{"fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1809798","subspecialties":"Cardiology","briefDesignDescription":"Low-dose MTX for secondary prevention of CAD","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1809798","pmid":"30415610","statusUsableDate":"2018-11-14","title":"Low-dose methotrexate for the prevention of atherosclerotic events","published":"2018-11-10","timestamp":"2025-05-22T17:32:54Z","abbreviation":"CIRT","diseases":"Coronary Artery Disease","briefResultsDescription":"Low-dose methotrexate not superior to placebo for secondary prevention of CAD","pageName":"CIRT","trainingLevel":"Resident","expansion":"Cardiovascular Inflammation Reduction Trial","pageid":3739,"citation":"Ridker PM, et al. \"Low-dose methotrexate for the prevention of atherosclerotic events\". The New England Journal of Medicine. 2018. epub 2018-11-10:1-11."},{"trainingLevel":"Fellow","pageName":"CLOSURE I","briefResultsDescription":"PFO closure does not reduce recurrent stroke","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack","citation":"Furlan AJ, et al. \"Closure or medical therapy for cryptogenic stroke with patent foramen ovale\". The New England Journal of Medicine. 2012. 366(11):991-999.","pageid":1093,"expansion":"Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639","briefDesignDescription":"PFO closure in cryptogenic stroke","subspecialties":"Neurology;Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009639","abbreviation":"CLOSURE I","timestamp":"2017-12-03T22:34:21Z","published":"2012-03-15","title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","statusUsableDate":"2013-01-01","pmid":"22417252"},{"expansion":"Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism","citation":"Lee AY, et al. \"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer\". The New England Journal of Medicine. 2003. 349(2):146-53.","pageid":13,"briefResultsDescription":"LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","pageName":"CLOT","trainingLevel":"Intern","statusUsableDate":"2012-03-01","pmid":"12853587","title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","timestamp":"2018-04-14T12:16:19Z","published":"2003-07-10","abbreviation":"CLOT","subspecialties":"Hematology;Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa025313","briefDesignDescription":"LMWH vs. warfarin in cancer VTE","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa025313"},{"fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1806640","subspecialties":"Cardiology","briefDesignDescription":"Mitra Clip for HF-related MR","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806640","pmid":"30280640","statusUsableDate":"2018-12-19","title":"Transcatheter Mitral Valve Repair in Patients with Heart Failure","published":"2018-09-23","timestamp":"2021-04-29T17:37:05Z","abbreviation":"COAPT","diseases":"Mitral Regurgitation","briefResultsDescription":"Mitra Clip reduces HF hospitalization rate in HF-related MR","pageName":"COAPT","trainingLevel":"Resident","expansion":"Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation","pageid":3714,"citation":"Stone GW, et al. \"Transcatheter Mitral Valve Repair in Patients with Heart Failure\". The New England Journal of Medicine. 2018. 379:2307-2318."},{"trainingLevel":"Resident","pageName":"COGENT","diseases":"Coronary Artery Disease","briefResultsDescription":"PPIs reduce bleeding but do not increase CV events when given with clopidogrel","pageid":313,"citation":"Bhatt DL, et al. \"Clopidogrel with or without omeprazole in coronary artery disease\". The New England Journal of Medicine. 2010. 363(20):1909-17.","expansion":"Clopidogrel and the Optimization of Gastrointestinal Events Trial","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007964","briefDesignDescription":"PPI plus clopidogrel in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007964","subspecialties":"Cardiology","abbreviation":"COGENT","published":"2010-11-11","timestamp":"2017-12-03T22:34:23Z","title":"Clopidogrel with or without omeprazole in coronary artery disease","statusUsableDate":"2012-04-01","pmid":"20925534"},{"title":"Efficacy and safety of low-dose colchicine after myocardial infarction","statusUsableDate":"2019-11-24","pmid":"31733140","abbreviation":"COLCOT","published":"2019-11-16","timestamp":"2021-02-18T20:37:27Z","briefDesignDescription":"Colchicine vs. placebo in ACS","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1912388","subspecialties":"Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1912388","expansion":"Colchicine Cardiovascular Outcomes Trial","pageid":4145,"citation":"Tardif J, et al. \"Efficacy and safety of low-dose colchicine after myocardial infarction\". The New England Journal of Medicine. 2019. 381(26):2497-2505.","pageName":"COLCOT","diseases":"Acute Coronary Syndrome","briefResultsDescription":"Colchicine superior to placebo in ACS","trainingLevel":"Resident"},{"abbreviation":"COLONPREV","published":"2012-02-23","timestamp":"2021-09-16T13:55:19Z","title":"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening","pmid":"22356323","statusUsableDate":"2016-07-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1108895","briefDesignDescription":"FIT vs. colonoscopy for colon cancer screening","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1108895","subspecialties":"Preventive Medicine;Gastroenterology;Oncology","pageid":2393,"citation":"Quintero E, et al. \"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening\". The New England Journal of Medicine. 2012. 366(8):697-706.","expansion":null,"trainingLevel":"Resident","pageName":"COLONPREV","diseases":"Colorectal Cancer","briefResultsDescription":"FIT is noninferior to colonoscopy for detecting colon cancer"},{"subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext","briefDesignDescription":"Carvedilol vs. metoprolol in HFrEF","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf","statusUsableDate":"2012-03-01","pmid":"12853193","title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial","timestamp":"2015-08-24T04:36:50Z","published":"2003-07-05","abbreviation":"COMET","briefResultsDescription":"Carvedilol extends survival in HFrEF","diseases":"Heart Failure","pageName":"COMET","trainingLevel":"Resident","expansion":"Carvedilol Or Metoprolol European Trial","citation":"Poole-Wilson PA, et al. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". The Lancet. 2003. 362(9377):7-13.","pageid":121},{"citation":"Chen ZM, et al. \"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial\". The Lancet. 2005. 366(9497):1622-1632.","pageid":1451,"expansion":"ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study","trainingLevel":"Student","briefResultsDescription":"High-dose IV and PO metoprolol increases cardiogenic shock","diseases":"Acute Coronary Syndrome;Myocardial Infarction","pageName":"COMMIT","timestamp":"2018-03-08T18:56:18Z","published":"2005-11-05","abbreviation":"COMMIT/CCS-2","statusUsableDate":"2013-05-01","pmid":"16271643","title":"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673605676611.pdf","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67661-1/fulltext","briefDesignDescription":"Metoprolol in acute MI"},{"citation":"Smits PC, et al. \"Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction\". The New England Journal of Medicine. 2017. 376(13):1234-1244.","pageid":3543,"expansion":"","trainingLevel":"Resident","pageName":"Compare-Acute","briefResultsDescription":"FFR-guided complete revascularization superior to infarct-related artery only PCI","diseases":"Coronary Artery Disease","abbreviation":"Compare-Acute","timestamp":"2018-03-12T00:27:10Z","published":"2017-03-30","title":"Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction","statusUsableDate":"2018-03-11","pmid":"28745981","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMc1706275","briefDesignDescription":"Multivessel PCI vs. FFR-guided complete revascularization","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMc1706275"},{"trainingLevel":"Resident","briefResultsDescription":"Rivaroxaban + ASA superior to placebo + ASA for secondary prevention of CAD","diseases":"Coronary Artery Disease","pageName":"COMPASS","citation":"Eikelboom JW et al. \"Rivaroxaban with or without aspirin in stable cardiovascular disease\". The New England Journal of Medicine. 2017. 377(14):1319-1330.","pageid":2955,"expansion":"Cardiovascular Outcomes for People Using Anticoagulation Stratgies","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709118","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1709118","briefDesignDescription":"Rivaroxaban, ASA, or both in stable CAD","timestamp":"2024-08-27T16:42:59Z","published":"2017-08-27","abbreviation":"COMPASS","pmid":"28844192","statusUsableDate":"2017-09-01","title":"Rivaroxaban with or without aspirin in stable cardiovascular disease"},{"expansion":"Cooperative North Scandinavian Enalapril Survival Study","citation":"CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". The New England Journal of Medicine. 1987. 316(23):1429-35.","pageid":18,"briefResultsDescription":"Enalapril ↓mortality in NYHA class IV HFrEF","diseases":"Heart Failure","pageName":"CONSENSUS","trainingLevel":"Intern","statusUsableDate":"2012-03-01","pmid":"2883575","title":"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study","timestamp":"2021-02-20T21:38:07Z","published":"1987-06-04","abbreviation":"CONSENSUS","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198706043162301","briefDesignDescription":"Enalapril in severe HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301"},{"trainingLevel":"Intern","briefResultsDescription":"Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF","diseases":"Heart Failure","pageName":"COPERNICUS","citation":"Packer M, et al. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". Circulation. 2002. 106(17):2194-9.","pageid":42,"expansion":"Carvedilol Prospective Randomized Cumulative Survival","pdfurl":"http://circ.ahajournals.org/content/106/17/2194.full.pdf","subspecialties":"Cardiology","fulltexturl":"http://circ.ahajournals.org/content/106/17/2194.full","briefDesignDescription":"Carvedilol in HFrEF","timestamp":"2014-06-13T04:33:43Z","published":"2002-10-22","abbreviation":"COPERNICUS","pmid":"12390947","statusUsableDate":"2012-03-01","title":"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure"},{"trainingLevel":"Resident","diseases":"Heart Failure;Hyperlipidemia","briefResultsDescription":"Statins confer no survival benefit but may reduce hospitalizations in ischemic HFrEF","pageName":"CORONA","pageid":524,"citation":"Kjekshus J, et al. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". The New England Journal of Medicine. 2007. 357(22):2248-61.","expansion":"Controlled Rosuvastatin Multinational Trial in Heart Failure","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706201","subspecialties":"Cardiology","briefDesignDescription":"Rosuvastatin in ischemic HFrEF","published":"2007-11-29","timestamp":"2017-12-03T22:34:30Z","abbreviation":"CORONA","statusUsableDate":"2012-07-01","pmid":"17984166","title":"Rosuvastatin in Older Patients with Systolic Heart Failure"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa071366","subspecialties":"Critical Care;Endocrinology","briefDesignDescription":"Hydrocortisone in septic shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366","statusUsableDate":"2012-03-01","pmid":"18184957","title":"Hydrocortisone therapy for patients with septic shock","published":"2008-01-10","timestamp":"2018-03-03T22:13:51Z","abbreviation":"CORTICUS","diseases":"Sepsis;Shock","briefResultsDescription":"Improved survival of hydrocortisone in septic shock","pageName":"CORTICUS","trainingLevel":"Student","expansion":"Corticosteroid Therapy of Septic Shock","pageid":4,"citation":"Sprung CL, et al. \"Hydrocortisone therapy for patients with septic shock\". New England Journal of Medicine. 2008. 358(2):111-24."},{"title":"Optimal medical therapy with or without PCI for stable coronary disease","statusUsableDate":"2012-03-01","pmid":"17387127","abbreviation":"COURAGE","timestamp":"2017-12-14T14:38:53Z","published":"2007-04-12","briefDesignDescription":"PCI vs. medical therapy in CAD","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa070829","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa070829","expansion":"Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation","citation":"Boden WE, et al. \"Optimal medical therapy with or without PCI for stable coronary disease\". The New England Journal of Medicine. 2007. 356:1503-16.","pageid":21,"pageName":"COURAGE","briefResultsDescription":"No difference between PCI and OMT in stable CAD","diseases":"Coronary Artery Disease","trainingLevel":"Student"},{"expansion":"","pageid":2900,"citation":"Juthani-Mehta M, et al. \"Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial\". JAMA. 2016. 316(18):1879-1887.","pageName":"Cranberry for prevention of pyuria and bacteriuria","diseases":"Bacteriuria;Pyuria","briefResultsDescription":"Cranberry ineffective to prevent pyuria and bacteriuria","trainingLevel":"student","title":"Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial","pmid":"27787564","statusUsableDate":"2017-04-01","abbreviation":"","published":"2016-11-08","timestamp":"2017-12-03T22:34:43Z","briefDesignDescription":"Cranberry in for prevention of pyuria and bacteriuria","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.16141","subspecialties":"Infectious Disease;Geriatrics","pdfurl":""},{"briefDesignDescription":"Tranexamic acid in trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext","subspecialties":"Emergency Medicine;Surgery;Hematology","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf","title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage","pmid":"20554319","statusUsableDate":"2013-07-01","abbreviation":"CRASH-2","published":"2010-07-03","timestamp":"2022-12-01T18:56:37Z","pageName":"CRASH-2","diseases":"Trauma","briefResultsDescription":"Tranexamic acid reduces 4-week mortality","trainingLevel":"resident","expansion":"Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2","pageid":490,"citation":"Shakur H, et al. \"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage\". The Lancet. 2010. 376(9734):23-32."},{"fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1817226","subspecialties":"Hematology;Oncology","briefDesignDescription":"Ide-cel CART in myeloma","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817226","pmid":"31042825","statusUsableDate":"2022-06-16","title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","published":"2019-05-02","timestamp":"2022-06-17T05:34:20Z","abbreviation":"CRB-401","diseases":"Multiple Myeloma","briefResultsDescription":"CRS 76%, ORR 85%, PFS 11.8 months","pageName":"CRB-401","trainingLevel":"Fellow","expansion":"","pageid":4096,"citation":"Raje N, et al. \"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma\". The New England Journal of Medicine. 2019. 380(18):1726-1737."},{"abbreviation":"CREDENCE","timestamp":"2019-10-15T19:28:09Z","published":"2019-06-13","title":"Canagliflozin and renal outcomes in diabetic nephropathy","pmid":"30990260","statusUsableDate":"2019-07-31","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811744","briefDesignDescription":"Canagliflozin in diabetic nephropathy","subspecialties":"Endocrinology;Nephrology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1811744","citation":"Perkovic V, et al. \"Canagliflozin and renal outcomes in diabetic nephropathy\". The New England Journal of Medicine. 2019. 380(24):2295-2306.","pageid":4088,"expansion":"Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluation","trainingLevel":"Resident","pageName":"CREDENCE","briefResultsDescription":"Canagliflozin reduces renal and CVD endpoints vs. placebo","diseases":"Diabetes Mellitus;Diabetic Nephropathy"},{"trainingLevel":"Intern","pageName":"CREST","diseases":"Carotid Stenosis;Stroke;Transient Ischemic Attack","briefResultsDescription":"No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI","pageid":492,"citation":"Brott TG, et al. \"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis\". The New England Journal of Medicine. 2010. 363(1):11-23.","expansion":"Carotid Revascularization Endarterectomy vs. Stenting Trial","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0912321","briefDesignDescription":"Stenting vs. CEA in carotid stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0912321","subspecialties":"Surgery;Neurology;Cardiology","abbreviation":"CREST","published":"2010-07-01","timestamp":"2019-01-30T21:43:56Z","title":"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis","pmid":"20505173","statusUsableDate":"2012-03-01"},{"fulltexturl":"http://bit.ly/1kLbQWJ","subspecialties":"Critical Care","briefDesignDescription":"Colloids vs. crystalloids in shock","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/928522/joi130081.pdf","statusUsableDate":"2014-07-01","pmid":"24108515","title":"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock","published":"2013-11-06","timestamp":"2017-12-03T22:34:32Z","abbreviation":"CRISTAL","diseases":"Shock","briefResultsDescription":"Colloids no different from crystalloids in mortality","pageName":"CRISTAL","trainingLevel":"resident","expansion":"Colloids Versus Crystalloids for the Resuscitation of the Critically Ill","pageid":1768,"citation":"Annane D, et al. \"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock\". The Journal of the American Medical Association. 2013. 310(17):1809-1817."},{"diseases":"Diabetic Nephropathy;Diabetes Mellitus","briefResultsDescription":"Captopril reduces T1DM nephropathy progression","pageName":"CSG Captopril Trial","trainingLevel":"Student","expansion":"Collaborative Study Group Captopril Trial","pageid":1591,"citation":"Lewis EJ, et al. \"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\". The New England Journal of Medicine. 1993. 329(20):1456-1462.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199311113292004","subspecialties":"Nephrology;Endocrinology","briefDesignDescription":"Captopril in T1DM nephropathy","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199311113292004","pmid":"8413456","statusUsableDate":"2013-08-01","title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.","published":"1993-11-11","timestamp":"2021-04-22T22:10:39Z","abbreviation":"CSG Captopril Trial"},{"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1710261#t","briefDesignDescription":"Culprit-only vs. multivessel PCI in cardiogenic shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1710261#t","pmid":"29083953","statusUsableDate":"2017-11-01","title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","timestamp":"2018-08-28T15:50:00Z","published":"2017-10-30","abbreviation":"CULPRIT-SHOCK","briefResultsDescription":"Culprit-only PCI superior to multivessel PCI in cardiogenic shock","diseases":"Coronary Artery Disease","pageName":"CULPRIT-SHOCK","trainingLevel":"Resident","expansion":"Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock","citation":"Thiele H, et al. \"PCI strategies in patients with acute myocardial infarction and cardiogenic shock\". New England Journal of Medicine. 2017. epub 2017-10-30:1-13.","pageid":2977},{"abbreviation":"CURE","published":"2001-08-16","timestamp":"2017-12-03T22:34:36Z","title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","pmid":"11519503","statusUsableDate":"2012-12-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010746","briefDesignDescription":"Clopidogrel in UA/NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010746","subspecialties":"Cardiology","pageid":921,"citation":"Yusuf S, et al. \"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation\". The New England Journal of Medicine. 2001. 345(7):494-502.","expansion":"Clopidogrel in Unstable Angina to Prevent Recurrent Events","trainingLevel":"Resident","pageName":"CURE","diseases":"Acute Coronary Syndrome","briefResultsDescription":"Clopidogrel reduces CV events but increases bleeding in UA/NSTEMI"},{"briefDesignDescription":"Culprit lesion-only vs. complete revascularization","fulltexturl":"http://www.onlinejacc.org/content/65/10/963","subspecialties":"Cardiology","pdfurl":"http://www.onlinejacc.org/content/accj/65/10/963.full.pdf?download","title":"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease","statusUsableDate":"2017-02-01","pmid":"25766941","abbreviation":"CvLPRIT","published":"2015-03-17","timestamp":"2017-12-03T22:34:45Z","pageName":"CvLPRIT","diseases":"Coronary Artery Disease","briefResultsDescription":"Complete revascularization superior to culprit lesion-only revascularization","trainingLevel":"Resident","expansion":"Complete Versus Lesion-Only Primary PCI Trial","pageid":2880,"citation":"Gershlick et al. \"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease\". J Am Coll Cardiol. 2015. 65(10):963-72."},{"briefResultsDescription":"Pulse no worse than daily cyclophosphamide","diseases":"Vasculitis","pageName":"CYCLOPS","trainingLevel":"Fellow","expansion":null,"citation":"de Groot K, et al. \"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial\". Annals of Internal Medicine. 2009. 150(10):670-680.","pageid":2338,"subspecialties":"Rheumatology;Nephrology","fulltexturl":null,"briefDesignDescription":"Pulse cyclophosphamide for ANCA vasculitis","pdfurl":"http://annals.org/data/Journals/AIM/20182/0000605-200905190-00004.pdf","pmid":"19451574","statusUsableDate":"2015-03-01","title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","timestamp":"2017-12-03T22:34:37Z","published":"2009-05-19","abbreviation":"CYCLOPS"},{"trainingLevel":"Intern","diseases":"Tobacco Abuse","briefResultsDescription":"Cytisine superior to NRT for abstinence at 1 month","pageName":"Cytisine for Smoking Cessation","pageid":2319,"citation":"Walker N, et al. \"Cytisine versus nicotine for smoking cessation\". The New England Journal of Medicine. 2014. 371(25):2353-2362.","expansion":null,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407764","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1407764","subspecialties":"Pulmonology;Preventive Medicine","briefDesignDescription":"Cytisine vs. NRT for tobacco abuse","published":"2014-12-18","timestamp":"2018-01-13T01:32:16Z","abbreviation":null,"statusUsableDate":"2015-01-01","pmid":"25517706","title":"Cytisine versus nicotine for smoking cessation"},{"title":"Cardiovascular events and intensity of treatment in polycythemia vera","statusUsableDate":"2016-02-01","pmid":"23216616","abbreviation":"CYTO-PV","published":"2013-01-03","timestamp":"2017-12-03T22:34:39Z","briefDesignDescription":"Hematocrit thresholds in PV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208500","subspecialties":"Hematology;Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208500","expansion":"Cytoreductive Therapy in Polycythemia Vera","pageid":2709,"citation":"Marchioli R, et al. \"Cardiovascular events and intensity of treatment in polycythemia vera\". The New England Journal of Medicine. 2013. 368(1):22-33.","pageName":"CYTO-PV","diseases":"Polycythemia Vera;Myeloproliferative Neoplasms","briefResultsDescription":"Fewer vascular events with hematocrit <45% compared to 45-50%","trainingLevel":"Fellow"},{"pageid":1554,"citation":"Kress JP, et al. \"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation\". The New England Journal of Medicine. 2000. 342(20):1471-1477.","expansion":"","trainingLevel":"Intern","diseases":"Respiratory Failure","briefResultsDescription":"Sedation holidays reduce intubated, ICU, hospital days","pageName":"Daily ICU Sedation Holidays","published":"2000-05-18","timestamp":"2017-12-03T22:35:01Z","abbreviation":"","pmid":"10816184","statusUsableDate":"2013-08-01","title":"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005183422002","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005183422002","subspecialties":"Critical Care;Pulmonology","briefDesignDescription":"Scheduled daily sedation holidays in intubated patients"},{"trainingLevel":"Resident","pageName":"DANAMI-3 PRIMULTI","diseases":"Coronary Artery Disease","briefResultsDescription":"FFR-guided revascularization was superior to culprit-lesion only in multivessel CAD","pageid":3634,"citation":"Engstrom T, et al. \"Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease\". The Lancet. 2015. 386:665-71.","expansion":"Third Danish Study of Optimal Acute Treatment of Patients with STEMI: Primary PCI in Multivessel Disease","pdfurl":"https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60648-1.pdf","briefDesignDescription":"Culprit lesion PCI vs. FFR in multivessel CAD","fulltexturl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60648-1/fulltext","subspecialties":"Cardiology","abbreviation":"DANAMI-3 PRIMULTI","published":"2015-08-15","timestamp":"2018-05-31T17:39:19Z","title":"Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease","statusUsableDate":"2018-05-28","pmid":"26347918"},{"expansion":"Danish–German Cardiogenic Shock","citation":"Møller JE, et al. \"Microaxial flow pump or standard care in infarct-related cardiogenic shock\". The New England Journal of Medicine. 2024. 390(15):1382-1393.","pageid":5645,"pageName":"DanGer Shock","briefResultsDescription":"Impella lowers 180d mortality if STEMI w/shock","diseases":"Myocardial Infarction;Cardiogenic Shock","trainingLevel":"Resident","title":"Microaxial flow pump or standard care in infarct-related cardiogenic shock","statusUsableDate":"2024-12-15","pmid":"38587239","abbreviation":"DanGer Shock","timestamp":"2025-01-23T17:44:24Z","published":"2024-04-18","briefDesignDescription":"Impella in STEMI w/cardiogenic shock","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2312572","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312572"},{"abbreviation":"DANISH","timestamp":"2017-12-03T22:34:48Z","published":"2016-08-28","title":"Defibrillator implantation in patients with nonischemic systolic heart failure","statusUsableDate":"2016-09-01","pmid":"27571011","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1608029","briefDesignDescription":"ICD vs. standard care in NICM and LVEF ≤35%","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1608029","citation":"Kober L, et al. \"Defibrillator implantation in patients with nonischemic systolic heart failure\". The New England Journal of Medicine. 2016. epub 2016-08-28:1-10.","pageid":2815,"expansion":"Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality","trainingLevel":"Resident","pageName":"DANISH","briefResultsDescription":"ICD not better than standard of care in NICM and LVEF ≤35%","diseases":"Ventricular Tachycardia"},{"pageName":"DAPA-CKD","diseases":"Chronic Kidney Disease","briefResultsDescription":"Dapagliflozin in CKD reduces renal endpoints and CVD death","trainingLevel":"resident","expansion":"Dapagliflozin in Chronic Kidney Disease","pageid":4363,"citation":"Heerspink, et al. \"Dapagliflozin in patients with chronic kidney disease\". The New England Journal of Medicine. 2020. 383(13):1436-1446.","briefDesignDescription":"Dapagliflozin in CKD±T2DM","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2024816","subspecialties":"Nephrology;Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024816","title":"Dapagliflozin in patients with chronic kidney disease","pmid":"32970396","statusUsableDate":"2020-10-29","abbreviation":"DAPA-CKD","published":"2020-10-08","timestamp":"2021-05-28T02:47:35Z"},{"briefResultsDescription":"Dapagliflozin reduces CV complications in HFrEF","diseases":"Heart Failure","pageName":"DAPA-HF","trainingLevel":"Resident","expansion":"Dapagliflozin in Heart Failure","citation":"McMurray JJV, et al. \"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction\". The New England Journal of Medicine. 2019. 381(21):1995-2008.","pageid":4113,"subspecialties":"Cardiology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1911303","briefDesignDescription":"Dapagliflozin in HFrEF","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911303","pmid":"31535829","statusUsableDate":"2019-12-12","title":"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction","timestamp":"2022-10-13T18:58:46Z","published":"2019-11-21","abbreviation":"DAPA-HF"},{"pageName":"DAPT","diseases":"Coronary Artery Disease;Myocardial Infarction;Stroke","briefResultsDescription":"Longer duration reduces stent thrombosis, MI, stroke, but increases mortality/bleeding","trainingLevel":"Intern","expansion":"Dual Antiplatelet Therapy","pageid":2264,"citation":"Mauri L, et al. \"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents\". The New England Journal of Medicine. 2014. 371(23):2155-2166.","briefDesignDescription":"Aspirin/clopidogrel duration after PCI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409312","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312","title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","pmid":"25399658","statusUsableDate":"2014-11-01","abbreviation":"DAPT","published":"2014-11-16","timestamp":"2017-12-03T22:34:50Z"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199704173361601","subspecialties":"Cardiology;Nephrology","briefDesignDescription":"DASH diet in HTN","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601","pmid":"9099655","statusUsableDate":"2012-04-01","title":"A clinical trial of the effects of dietary patterns on blood pressure","published":"1997-04-17","timestamp":"2020-09-22T18:22:21Z","abbreviation":"DASH","diseases":"Hypertension","briefResultsDescription":"DASH diet reduces SBP and DBP","pageName":"DASH","trainingLevel":"Student","expansion":"Dietary Approaches to Stop Hypertension","pageid":90,"citation":"Appel LJ, et al. \"A clinical trial of the effects of dietary patterns on blood pressure\". The New England Journal of Medicine. 1997. 336(16):1117-1124."},{"citation":"Wilkoff BL, et al. \"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator\". Journal of the American Medical Association. 2002. 288(24):3115-3123.","pageid":2713,"expansion":"Dual-chamber pacing or ventricular backup pacing in ICD patients","trainingLevel":"Resident","pageName":"DAVID","briefResultsDescription":"Ventricular backup pacemaker superior to dual-chamber pacemaker","diseases":"Bradycardia","abbreviation":"DAVID","timestamp":"2017-12-03T22:34:54Z","published":"2002-12-25","title":"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator","statusUsableDate":"2016-08-01","pmid":"12495391","pdfurl":null,"briefDesignDescription":"Dual-chamber vs. ventricular backup pacing in ICD patients","subspecialties":"Cardiology","fulltexturl":"http://jama.jamanetwork.com/article.aspx?volume"},{"timestamp":"2020-01-25T11:34:00Z","published":"2018-01-04","abbreviation":"DAWN","pmid":"29129157","statusUsableDate":"2020-01-23","title":"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1706442","subspecialties":"Neurology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1706442","briefDesignDescription":"Thrombectomy 6-24 hours after stroke","citation":"Nogueira RG, et al. \"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct\". The New England Journal of Medicine. 2018. 378(1):11-21.","pageid":3529,"expansion":"DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo","trainingLevel":"Resident","briefResultsDescription":"Thrombectomy improved 90-day outcomes compared to standard care","diseases":"Stroke","pageName":"DAWN"},{"expansion":"Diabetes Control and Complications Trial","pageid":135,"citation":"DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". The New England Journal of Medicine. 1993. 329(14):977-986.","pageName":"DCCT","diseases":"Diabetes Mellitus","briefResultsDescription":"Intensive therapy delays microvascular but not macrovascular complications in T1DM","trainingLevel":"Student","title":"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus","pmid":"8366922","statusUsableDate":"2012-03-01","abbreviation":"DCCT","published":"1993-09-30","timestamp":"2012-09-16T11:23:12Z","briefDesignDescription":"Intensive glycemic therapy in T1DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309303291401","subspecialties":"Endocrinology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401"},{"expansion":"Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation","pageid":84,"citation":"Kadish A, et al. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". The New England Journal of Medicine. 2004. 350(21):2151-2158.","pageName":"DEFINITE","diseases":"Heart Failure","briefResultsDescription":"ICD reduced risk of arrhythmogenic sudden death, but not overall mortality","trainingLevel":"Resident","title":"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy","pmid":"15152060","statusUsableDate":"2012-03-01","abbreviation":"DEFINITE","published":"2004-05-20","timestamp":"2014-06-13T04:45:33Z","briefDesignDescription":"ICD vs. medical therapy in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa033088","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088"},{"pdfurl":"","fulltexturl":"http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1831407","subspecialties":"Psychiatry;Geriatrics","briefDesignDescription":"Ramelteon vs. placebo to prevent delirium","published":"2014-04-01","timestamp":"2021-10-04T20:25:15Z","abbreviation":"DELIRIA-J","statusUsableDate":"2021-09-30","pmid":"24554232","title":"Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial","trainingLevel":"Resident","diseases":"Delirium","briefResultsDescription":"Ramelteon decreased risk of delirium in elderly patients","pageName":"DELIRIA-J","pageid":2806,"citation":"Hatta K, et al. \"Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial\". JAMA Psychiatry. 2014. 71(4):397-403.","expansion":"Delirium Intervention Research for Improving Acute phase outcomes in Japan"},{"pmid":"36027570","statusUsableDate":"2022-10-13","title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","timestamp":"2023-05-04T03:39:40Z","published":"2022-09-22","abbreviation":"DELIVER","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2206286","briefDesignDescription":"Dapagliflozin in HFmrEF or HFpEF","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206286","expansion":"Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure","citation":"Solomon SD, et al. \"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction\". The New England Journal of Medicine. 2022. 387(12):1089-1098.","pageid":4921,"briefResultsDescription":"Dapagliflozin reduces HF events in HFmrEF or HFpEF","diseases":"Heart Failure","pageName":"DELIVER","trainingLevel":"Resident"},{"expansion":"Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction","citation":"Hofmann R, et al. \"Oxygen therapy in suspected acute myocardial infarction\". The New England Journal of Medicine. 2017. 377(13):1240-1249.","pageid":2970,"briefResultsDescription":"Oxygen doesn't improve 1 year survival in MI","diseases":"Myocardial Infarction","pageName":"DETO2X-AMI","trainingLevel":"Student","statusUsableDate":"2017-10-01","pmid":"28844200","title":"Oxygen therapy in suspected acute myocardial infarction","timestamp":"2018-02-01T20:15:39Z","published":"2017-09-28","abbreviation":"DETO2X-AMI","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1706222","briefDesignDescription":"Oxygen for suspected MI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1706222"},{"pageid":89,"citation":"Gorlin R, et al. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". The New England Journal of Medicine. 1997. 336(8):525-533.","expansion":"Digitalis Investigation Group","trainingLevel":"Resident","pageName":"DIG","diseases":"Heart Failure","briefResultsDescription":"Reduced hospitalizations, no mortality benefit","abbreviation":"DIG","published":"1997-02-20","timestamp":"2014-06-13T04:50:56Z","title":"The effect of digoxin on mortality and morbidity in patients with heart failure","pmid":"9036306","statusUsableDate":"2012-03-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801","briefDesignDescription":"Digoxin in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199702203360801","subspecialties":"Cardiology"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa041489","subspecialties":"Cardiology","briefDesignDescription":"ICD for ICM shortly after MI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa041489","pmid":"15590950","statusUsableDate":"2016-04-01","title":"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction","published":"2004-12-09","timestamp":"2020-09-14T19:26:41Z","abbreviation":"DINAMIT","diseases":"Heart Failure;Myocardial Infarction","briefResultsDescription":"ICD reduces arrhythmia but not mortality","pageName":"DINAMIT","trainingLevel":"Resident","expansion":"Defibrillator in Acute Myocardial Infarction Trial","pageid":1743,"citation":"Hohnloser SH, et al. \"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction\". The New England Journal of Medicine. 2004. 351(24):2481-2488."},{"briefDesignDescription":"BMS vs. DES for saphenous vein graft PCI","fulltexturl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30801-8/fulltext","subspecialties":"Cardiology","pdfurl":"","title":"Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial","pmid":"29759512","statusUsableDate":"2018-11-27","abbreviation":"DIVA","published":"2018-05-19","timestamp":"2019-10-17T17:40:21Z","pageName":"DIVA","diseases":"Coronary Artery Disease","briefResultsDescription":"BMS noninferior to DES for saphenous vein graft PCI","trainingLevel":"Resident","expansion":"Rationale and design of the drug-eluting stents vs bare-metal stents in saphenous vein graft angioplasty","pageid":3743,"citation":"Brilakis ES, et al. \"Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial\". Lancet. 2018. 391(10134):1997-2007."},{"citation":"Kearon C, et al. \"Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study\". Journal of Thrombosis and Hemostasis. 2019. 17(7):1144-52.","pageid":4089,"expansion":"D-dimer Optimal Duration Study","trainingLevel":"Fellow","pageName":"DODS","briefResultsDescription":"D-dimer based discontinuation effective in women, not for men","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","abbreviation":"DODS","timestamp":"2019-07-18T20:41:06Z","published":"2019-01-18","title":"Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study","pmid":"31033194","statusUsableDate":"2019-07-18","pdfurl":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14458","briefDesignDescription":"D-dimer based anticoagulation discontinuation","subspecialties":"Hematology","fulltexturl":"https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14458"},{"expansion":"Donors of Hepatitis C NAT Positive Thoracic Allografts for Transplantation Evaluation in Non-HCV Recipients","citation":"Woolley AE, et al. \"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients\". The New England Journal of Medicine. 2019. 380(17):1606-1617.","pageid":4066,"briefResultsDescription":"Donor HCV+ heart & lung transplant is feasible","diseases":"Heart Failure;Respiratory Failure","pageName":"DONATE-HCV","trainingLevel":"Resident","pmid":"30946553","statusUsableDate":"2019-05-17","title":"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients","timestamp":"2019-05-23T17:58:08Z","published":"2019-04-25","abbreviation":"DONATE HCV","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1812406","briefDesignDescription":"Donor HCV positive heart and lung transplant","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812406"},{"pmid":"21366472","statusUsableDate":"2013-06-01","title":"Diuretic strategies in patients with acute decompensated heart failure","timestamp":"2022-09-15T20:00:28Z","published":"2011-03-03","abbreviation":"DOSE","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005419","briefDesignDescription":"Diuretic dosing in acute HF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419","expansion":"Diuretic Optimization Strategies Evaluation","citation":"Felker GM, et al. \"Diuretic strategies in patients with acute decompensated heart failure\". The New England Journal of Medicine. 2011. 364(9):797-805.","pageid":1457,"briefResultsDescription":"High-dose better than low-dose, continuous infusions no better than intermittent IV boluses","diseases":"Heart Failure","pageName":"DOSE","trainingLevel":"Intern"},{"abbreviation":"DPP","published":"2002-02-07","timestamp":"2018-05-31T18:34:46Z","title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","pmid":"11832527","statusUsableDate":"2018-05-31","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa012512","briefDesignDescription":"Metformin and intensive lifestyle in prediabetes","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa012512","subspecialties":"Endocrinology","pageid":2494,"citation":"Knowler WC, et al. \"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin\". The New England Journal of Medicine. 2002. 346(6):393-403.","expansion":"Diabetes Prevention Program","trainingLevel":"Student","pageName":"DPP","diseases":"Prediabetes;Diabetes Mellitus","briefResultsDescription":"Metformin and intensive lifestyle reduce incidence of diabetes"},{"abbreviation":"","published":"2002-10-01","timestamp":"2017-12-03T22:35:03Z","title":"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)","statusUsableDate":"2013-07-01","pmid":"12361440","pdfurl":"http://archpedi.jamanetwork.com/data/Journals/PEDS/5052/POA20075.pdf","briefDesignDescription":"Duct tape vs. cryotherapy for warts","fulltexturl":"","subspecialties":"Pediatrics;Dermatology","pageid":1579,"citation":"Focht DR, et al. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". Archives of Pediatric and Adolescent Medicine. 2002. 156:971-974.","expansion":"","trainingLevel":"Student","pageName":"Duct Tape for Treatment of the Common Wart","diseases":"Warts","briefResultsDescription":"Duct tape superior to cryotherapy for wart resolution"},{"abbreviation":"","published":"2013-01-31","timestamp":"2018-03-29T18:30:43Z","title":"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile","statusUsableDate":"2013-02-01","pmid":"23323867","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205037","briefDesignDescription":"Fecal transplant in C. difficile","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1205037","subspecialties":"Gastroenterology;Infectious Disease","pageid":1226,"citation":"Van Nood E, et al. \"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile\". The New England Journal of Medicine. 2013. 368(5):407-415.","expansion":"","trainingLevel":"Intern","pageName":"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile","diseases":"Clostridium difficile","briefResultsDescription":"Fecal transplant better than vancomycin in C. difficile"},{"title":"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer","pmid":"20818875","statusUsableDate":"2012-06-01","abbreviation":null,"timestamp":"2017-12-03T22:35:32Z","published":"2010-08-19","briefDesignDescription":"Palliative care in NSCLC","subspecialties":"Oncology;Palliative Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000678","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678","expansion":null,"citation":"Temel JS, et al. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". The New England Journal of Medicine. 2010. 363(8):733-742.","pageid":466,"pageName":"Early Palliative Care","briefResultsDescription":"Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care","diseases":"Lung Cancer","trainingLevel":"Intern"},{"trainingLevel":"Resident","briefResultsDescription":"Early TIPS reduces rates of treatment failure and improves 1-year survival","diseases":"Cirrhosis;Gastrointestinal Hemorrhage","pageName":"Early TIPS","citation":"García-Pagán JC, et al. \"Early use of TIPS in patients with cirrhosis and variceal bleeding\". The New England Journal of Medicine. 2010. 362(25):2370-2379.","pageid":2661,"expansion":"","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910102","subspecialties":"Gastroenterology;Interventional Radiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0910102","briefDesignDescription":"Early TIPS in high-risk cirrhotic variceal bleeding","timestamp":"2018-08-30T17:24:07Z","published":"2010-06-24","abbreviation":"Early TIPS","statusUsableDate":"2018-08-30","pmid":"20573925","title":"Early use of TIPS in patients with cirrhosis and variceal bleeding"},{"abbreviation":"EARLY-AF","timestamp":"2021-11-08T18:52:31Z","published":"2021-01-28","title":"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation","statusUsableDate":"2021-10-14","pmid":"33197159","pdfurl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2029980","briefDesignDescription":"Cryoablation vs. antiarrhythmics in AF","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2029980","citation":"Andrade J, et al. \"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation\". The New England Journal of Medicine. 2021. 384(4):305-315.","pageid":4406,"expansion":"Early Aggressive Invasive Intervention for Atrial Fibrillation","trainingLevel":"Resident","pageName":"EARLY-AF","briefResultsDescription":"Cryoablation with lower tachyarrhythmia recurrence than antiarrhythmics.","diseases":"Atrial Fibrillation"},{"pmid":"22738096","statusUsableDate":"2019-09-19","title":"Early surgery versus conventional treatment for infective endocarditis","timestamp":"2019-09-19T17:42:49Z","published":"2012-06-28","abbreviation":"EASE","subspecialties":"Cardiology;Infectious Disease;Surgery","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1112843","briefDesignDescription":"Early surgery in endocarditis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112843","expansion":"Early Surgery versus Conventional Treatment in Infective Endocarditis","citation":"Kang DH, et al. \"Early surgery versus conventional treatment for infective endocarditis\". The New England Journal of Medicine. 2012. 366(26):2466-73.","pageid":2939,"briefResultsDescription":"Early surgery improves outcomes in infective endocarditis","diseases":"Endocarditis","pageName":"EASE","trainingLevel":"Resident"},{"citation":"Kirchhof P, et al. \"Early rhythm-control therapy in patients with atrial fibrillation\". The New England Journal of Medicine. 2020. 383(14):1305-1316.","pageid":4399,"expansion":"The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial","trainingLevel":"Resident","pageName":"EAST-AFNET 4","briefResultsDescription":"Early rhythm control with fewer CVD events.","diseases":"Atrial Fibrillation","abbreviation":"EAST-AFNET 4","timestamp":"2025-05-15T20:16:15Z","published":"2020-10-01","title":"Early rhythm-control therapy in patients with atrial fibrillation","statusUsableDate":"2021-01-28","pmid":"32865375","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422","briefDesignDescription":"Early rhythm vs. rate control in AF","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422"},{"pageName":"ECASS III","diseases":"Stroke","briefResultsDescription":"Alteplase improves neurological outcomes at 3 months","trainingLevel":"Intern","expansion":"European Cooperative Acute Stroke Study III","pageid":115,"citation":"Hacke W, et al. \"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke\". The New England Journal of Medicine. 2008. 359(13):1317-1329.","briefDesignDescription":"Alteplase 3-4.5h after stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804656","subspecialties":"Neurology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656","title":"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke","pmid":"18815396","statusUsableDate":"2012-03-01","abbreviation":"ECASS III","published":"2008-09-25","timestamp":"2017-04-20T01:11:46Z"},{"expansion":"Emergency treatment with Levetiracetam or Phenytoin in convulsive Status Epilepticus in children","citation":"Lyttle MD, et al. \"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.\". Lancet. 2019. 393(10186):2125-2134.","pageid":4086,"briefResultsDescription":"Levetiracetam is non-inferior to phenytoin","diseases":"Status Epilepticus","pageName":"EcLiPSE","trainingLevel":"Resident","statusUsableDate":"2024-05-16","pmid":"31005385","title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.","timestamp":"2024-06-27T17:56:09Z","published":"2019-05-25","abbreviation":"EcLiPSE","subspecialties":"Emergency Medicine;Pediatrics;Neurology","fulltexturl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30724-X/fulltext","briefDesignDescription":"Levetiracetam vs. phenytoin in status epilepticus","pdfurl":"https://www.thelancet.com/action/showPdf?pii"},{"pdfurl":"","briefDesignDescription":"CEA in symptomatic carotid stenosis","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2909292-1","subspecialties":"Surgery;Neurology","abbreviation":"ECST","published":"1998-05-09","timestamp":"2020-08-01T19:26:48Z","title":"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)","pmid":"9593407","statusUsableDate":"2015-08-01","trainingLevel":"Intern","pageName":"ECST","diseases":"Carotid Stenosis;Stroke","briefResultsDescription":"CEA improves outcomes in patients with ≥80% symptomatic carotid stenosis","pageid":2354,"citation":"ECST Writers. \"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)\". The Lancet. 1998. 351(9113):1379-1387.","expansion":"European Carotid Surgery Trial"},{"expansion":"Epidemiology of Diabetes Interventions and Complications","pageid":136,"citation":"Nathan DM, et al. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". The New England Journal of Medicine. 2005. 353(25):2643-2653.","diseases":"Diabetes Mellitus","briefResultsDescription":"Intensive therapy associated with fewer cardiovascular complications","pageName":"EDIC","trainingLevel":"intern","statusUsableDate":"2012-03-01","pmid":"16371630","title":"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes","published":"2005-12-22","timestamp":"2013-03-12T08:18:42Z","abbreviation":"EDIC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052187","subspecialties":"Endocrinology","briefDesignDescription":"Intensive glycemic therapy in T1DM","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052187"},{"briefDesignDescription":"Rivaroxaban after VTE treatment","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1700518","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700518","title":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","statusUsableDate":"2017-07-01","pmid":"28316279","abbreviation":"EINSTEIN CHOICE","timestamp":"2017-12-03T22:35:08Z","published":"2017-03-30","pageName":"EINSTEIN CHOICE","briefResultsDescription":"Rivaroxaban reduces recurrent VTE","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","trainingLevel":"Resident","expansion":"Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism","citation":"Weitz JI, et al. \"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism\". The New England Journal of Medicine. 2017. 376(13):1211-22.","pageid":2927},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113572","briefDesignDescription":"Rivaroxaban vs. warfarin in PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1113572","subspecialties":"Hematology;Pulmonology","abbreviation":"EINSTEIN-PE","published":"2012-04-05","timestamp":"2017-12-03T22:35:09Z","title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","pmid":"22449293","statusUsableDate":"2013-07-01","trainingLevel":"Student","pageName":"EINSTEIN-PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","briefResultsDescription":"Rivaroxaban is noninferior to warfarin in PE treatment","pageid":1519,"citation":"Büller HR, et al. \"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism\". The New England Journal of Medicine. 2012. 366(14):1287-1297.","expansion":""},{"trainingLevel":"Resident","briefResultsDescription":"Daclizumab, mycophenolate, steroids, and tacrolimus beneficial","diseases":"Kidney Transplant","pageName":"ELITE-Symphony","citation":"Ekberg H, et al. \"Reduced exposure to calcineurin inhibitors in renal transplantation\". The New England Journal of Medicine. 2007. 357(25):2562-2575.","pageid":2324,"expansion":"Efficacy Limiting Toxicity Elimination-Symphony","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa067411","subspecialties":"Nephrology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa067411","briefDesignDescription":"Immunosuppression after kidney transplant","timestamp":"2018-05-27T16:17:38Z","published":"2007-12-20","abbreviation":"ELITE-Symphony","pmid":"18094377","statusUsableDate":"2015-02-01","title":"Reduced exposure to calcineurin inhibitors in renal transplantation"},{"expansion":"30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event","pageid":2403,"citation":"Gladstone DJ, et al. \"Atrial Fibrillation in Patients with Cryptogenic Stroke\". The New England Journal of Medicine. 2014. 370(26):2467-2477.","pageName":"EMBRACE","diseases":"Stroke;Atrial Fibrillation","briefResultsDescription":"Extended EKG monitoring detects AF more frequently than 24-hour monitoring","trainingLevel":"Resident","title":"Atrial Fibrillation in Patients with Cryptogenic Stroke","statusUsableDate":"2018-09-13","pmid":"24963566","abbreviation":"EMBRACE","published":"2014-06-26","timestamp":"2018-09-13T17:28:08Z","briefDesignDescription":"Extended EKG monitoring after cryptogenic stroke","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1311376","subspecialties":"Neurology;Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1311376"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124","fulltexturl":"http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124","subspecialties":"Oncology","briefDesignDescription":"T-DM1 in metastatic breast cancer","published":"2012-11-08","timestamp":"2021-07-28T13:09:44Z","abbreviation":"EMILIA","statusUsableDate":"2013-04-01","pmid":"23020162","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","trainingLevel":"fellow","diseases":"Breast Cancer","briefResultsDescription":"T-DM1 prolongs PFS in metastatic breast cancer","pageName":"EMILIA","pageid":1257,"citation":"Verma S, et al. \"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer\". The New England Journal of Medicine. 2012. 367(19):1783-1791.","expansion":"Emtansine vs. Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer"},{"expansion":"","citation":"Zinman B, et al. \"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes\". The New England Journal of Medicine. 2015. 373(22):2117-28.","pageid":2448,"pageName":"EMPA-REG OUTCOME","briefResultsDescription":"Empagliflozin reduces mortality compared to placebo in patients with type 2 diabetes","diseases":"Diabetes Mellitus","trainingLevel":"intern","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","pmid":"26378978","statusUsableDate":"2015-10-01","abbreviation":"EMPA-REG OUTCOME","timestamp":"2023-12-14T18:27:14Z","published":"2015-09-17","briefDesignDescription":"Empagliflozin for CV outcomes in T2DM","subspecialties":"Cardiology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1504720","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720"},{"pmid":"34449189","statusUsableDate":"2021-09-09","title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","timestamp":"2022-10-13T18:59:03Z","published":"2021-08-27","abbreviation":"EMPEROR-Preserved","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107038","briefDesignDescription":"Empagliflozin in HFmrEF and HFpEF","pdfurl":null,"expansion":"Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction","citation":"Anker S, et al. \"Empagliflozin in Heart Failure with a Preserved Ejection Fraction\". New England Journal of Medicine. 2021. epub 2021-08-27:1-11.","pageid":4440,"briefResultsDescription":"Empagliflozin improved outcomes in HFpEF","diseases":"Heart Failure","pageName":"EMPEROR-Preserved","trainingLevel":"Resident"},{"abbreviation":"EMPHASIS-HF","timestamp":"2017-12-03T22:35:16Z","published":"2011-01-06","title":"Eplerenone in patients with systolic heart failure and mild symptoms","statusUsableDate":"2012-08-01","pmid":"21073363","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492","briefDesignDescription":"Eplerenone in HFrEF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009492","citation":"Zannad F, et al. \"Eplerenone in patients with systolic heart failure and mild symptoms\". The New England Journal of Medicine. 2011. 364(1):11-21.","pageid":120,"expansion":"Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure","trainingLevel":"Resident","pageName":"EMPHASIS-HF","briefResultsDescription":"Eplerenone reduces CV deaths and HF hospitalizations","diseases":"Heart Failure"},{"expansion":"Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48","citation":"Guigliano RP, et al. \"Edoxaban versus warfarin in patients with atrial fibrillation\". The New England Journal of Medicine. 2013. 369(22):2093-2104.","pageid":2471,"pageName":"ENGAGE AF-TIMI 48","briefResultsDescription":"Edoxaban is noninferior to warfarin to prevent stroke or thromboembolism","diseases":"Atrial Fibrillation","trainingLevel":"resident","title":"Edoxaban versus warfarin in patients with atrial fibrillation","statusUsableDate":"2017-02-01","pmid":"24251359","abbreviation":"ENGAGE AF-TIMI 48","timestamp":"2024-10-03T18:39:58Z","published":"2013-11-28","briefDesignDescription":"Edoxaban vs. warfarin in AF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1310907","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907"},{"pmid":"29466159","statusUsableDate":"2018-03-29","title":"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty","timestamp":"2019-04-18T17:47:16Z","published":"2018-02-22","abbreviation":"EPCAT II","subspecialties":"Orthopedics;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1712746","briefDesignDescription":"Aspirin vs. rivaroxaban for postoperative VTE prophylaxis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1712746","expansion":"Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II","citation":"Anderson DR, et al. \"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty\". The New England Journal of Medicine. 2018. 378(8):699-707.","pageid":3552,"briefResultsDescription":"Aspirin similar to rivaroxaban for prevention of VTE","diseases":"Deep Vein Thrombosis;Hip Fracture;Meniscal Tear;Osteoarthritis;Pulmonary Embolism;Venous Thromboembolism","pageName":"EPCAT II","trainingLevel":"Resident"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207","briefDesignDescription":"Eplerenone post-MI with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030207","subspecialties":"Cardiology","abbreviation":"EPHESUS","published":"2003-04-03","timestamp":"2015-12-24T15:08:03Z","title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","pmid":"12668699","statusUsableDate":"2012-03-01","trainingLevel":"Resident","pageName":"EPHESUS","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","briefResultsDescription":"Mortality benefit of eplerenone post MI with HFrEF","pageid":16,"citation":"Pitt B, et al. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". The New England Journal of Medicine. 2003. 348(14):1309-21.","expansion":"Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study"},{"citation":"Choo MS, et al. \"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease\". The New England Journal of Medicine. 2024. 1-13.","pageid":5576,"expansion":"Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease","trainingLevel":"resident","pageName":"EPIC-CAD","briefResultsDescription":"Edoxaban monotherapy has lower bleeding events in AF+stable CAD","diseases":"Coronary Artery Disease;Atrial Fibrillation","abbreviation":"EPIC-CAD","timestamp":"2024-10-03T19:17:59Z","published":"2024-09-01","title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","statusUsableDate":"2024-09-29","pmid":"39225258","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2407362","briefDesignDescription":"Edoxaban±antiplatelet in AF+stable CAD","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2407362"},{"briefResultsDescription":"Decrease in prostate cancer mortality but increased risk of overdiagnosis and overtreatment","diseases":"Prostate Cancer","pageName":"ERSPC","trainingLevel":"Intern","expansion":"European Randomized Study of Screening for Prostate Cancer","citation":"Schröder FH, et al. \"Screening and Prostate-Cancer Mortality in a Randomized European Study\". The New England Journal of Medicine. 2009. 360(13):1320-1328.","pageid":2796,"subspecialties":"Urology;Oncology;Preventive Medicine","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0810084","briefDesignDescription":"PSA for prostate cancer screening","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810084","statusUsableDate":"2016-07-01","pmid":"19297566","title":"Screening and Prostate-Cancer Mortality in a Randomized European Study","timestamp":"2017-12-03T22:35:20Z","published":"2009-07-09","abbreviation":"ERSPC"},{"pageName":"ESCAPE","diseases":"Heart Failure","briefResultsDescription":"Routine PA catheters no better than clinical assessment","trainingLevel":"Resident","expansion":"Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness","pageid":1407,"citation":"Binanay C, et al. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". JAMA. 2005. 294(13):1625-1633.","briefDesignDescription":"PA catheters in acute HF management","fulltexturl":null,"subspecialties":"Cardiology;Critical Care","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf","title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness","pmid":"16204662","statusUsableDate":"2013-06-01","abbreviation":"ESCAPE","published":"2005-10-05","timestamp":"2017-12-03T22:35:21Z"},{"pageName":"ESPRIT","briefResultsDescription":"ASA+dipyridamole better than ASA for secondary stroke prevention","diseases":"Stroke;Transient Ischemic Attack","trainingLevel":"Intern","expansion":"European/Australasian Stroke Prevention in Reversible Ischaemia Trial","citation":"Halkes PH, et al. \"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial\". The Lancet. 2006. 367(9523):1665-1673.","pageid":1726,"briefDesignDescription":"ASA+dipyridamole in secondary stroke prevention","subspecialties":"Neurology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf","title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial","statusUsableDate":"2013-11-01","pmid":"16714187","abbreviation":"ESPRIT","timestamp":"2017-12-03T22:35:22Z","published":"2006-05-20"},{"citation":"Cohen M, et al. \"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease\". The New England Journal of Medicine. 1997. 337(7):447-452.","pageid":1443,"expansion":"Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group","trainingLevel":"Intern","pageName":"ESSENCE","briefResultsDescription":"LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI","diseases":"Acute Coronary Syndrome","abbreviation":"ESSENCE","timestamp":"2017-12-03T22:35:24Z","published":"1997-08-14","title":"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease","pmid":"9250846","statusUsableDate":"2013-05-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199708143370702","briefDesignDescription":"LMWH vs. UFH in UA/NSTEMI","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199708143370702"},{"title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","statusUsableDate":"2017-01-01","pmid":"27959717","abbreviation":"EUCLID","timestamp":"2021-01-25T01:47:56Z","published":"2017-01-05","briefDesignDescription":"Ticagrelor vs. clopidogrel in symptomatic PAD","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611688","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611688","expansion":"Examining use of ticagrelor in peripheral artery disease","citation":"Hiatt WR et al. \"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease\". New Engl J Med. 2017. 376(1):32-40.","pageid":2878,"pageName":"EUCLID (Ticagrelor)","briefResultsDescription":"Ticagrelor not superior to clopidogrel in symptomatic PAD","diseases":"Peripheral Vascular Disease","trainingLevel":"Resident"},{"fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14286-9/fulltext","subspecialties":"Cardiology","briefDesignDescription":"Perindopril in patients with stable CAD","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14286-9.pdf","pmid":"13678872","statusUsableDate":"2018-02-08","title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease","published":"2003-09-06","timestamp":"2018-02-08T17:32:01Z","abbreviation":"EUROPA","diseases":"Coronary Artery Disease","briefResultsDescription":"Perindopril reduces composite of CV mortality, MI, or cardiac arrest","pageName":"EUROPA","trainingLevel":"intern","expansion":"European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease","pageid":2823,"citation":"Fox KM, et al. \"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease\". The Lancet. 2003. 362(9386):782–788."},{"trainingLevel":"Resident","pageName":"European Dexamethasone Study","diseases":"Meningitis","briefResultsDescription":"Dexamethasone reduces mortality in bacterial meningitis","pageid":306,"citation":"de Gans JD, et al. \"Dexamethasone in Adults with Bacterial Meningitis\". The New England Journal of Medicine. 2002. 347(20):1549-1556.","expansion":"European Dexamethasone Study","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021334","briefDesignDescription":"Dexamethasone in meningitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021334","subspecialties":"Infectious Disease;Neurology","abbreviation":"EDS","published":"2002-11-14","timestamp":"2017-12-03T22:35:34Z","title":"Dexamethasone in Adults with Bacterial Meningitis","pmid":"12432041","statusUsableDate":"2012-04-01"},{"trainingLevel":"Resident","briefResultsDescription":"No benefit from tolvaptan when given for 60 days after acute HF episode","diseases":"Heart Failure","pageName":"EVEREST-Outcomes","citation":"Konstam MA, et al. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". The Journal of the American Medical Association. 2007. 297(12):1319-1331.","pageid":1345,"expansion":"Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf","subspecialties":"Cardiology","fulltexturl":null,"briefDesignDescription":"Tolvaptan in acute HF in HFrEF","timestamp":"2017-12-03T22:35:27Z","published":"2007-03-28","abbreviation":"EVEREST","statusUsableDate":"2013-06-01","pmid":"17384437","title":"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure"},{"expansion":"","citation":"Popma JJ, et al. \"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients\". The New England Journal of Medicine. 2019. 380(18):1706-1715.","pageid":4061,"briefResultsDescription":"TAVR non-inferior to surgery at 24 months in low-risk patients","diseases":"Aortic Stenosis","pageName":"Evolut Low Risk","trainingLevel":"resident","statusUsableDate":"2024-06-27","pmid":"30883053","title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","timestamp":"2024-06-27T19:03:26Z","published":"2019-05-02","abbreviation":"","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816885","briefDesignDescription":"TAVR in low-risk patients","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1816885"},{"title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease","statusUsableDate":"2016-12-01","pmid":"27797291","abbreviation":"EXCEL","timestamp":"2017-12-03T22:35:29Z","published":"2016-12-08","briefDesignDescription":"CABG vs. PCI in left main CAD","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1610227","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1610227","expansion":"XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL)","citation":"Stone GW, et al. \"Everolimus-eluting stents or bypass surgery for left main coronary artery disease\". The New England Journal of Medicine. 2016. 375(23):2223-35.","pageid":2868,"pageName":"EXCEL","briefResultsDescription":"PCI noninferior to CABG in left main CAD with low-intermediate anatomic complexity","diseases":"Coronary Artery Disease","trainingLevel":"Resident"},{"expansion":"A Study of Omalizumab/Xolair in Subjects With Moderate to Severe Persistent Asthma","citation":"Hanania NA, et al. \"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial\". Annals of Internal Medicine. 2011. 154(9):573-582.","pageid":1434,"pageName":"EXTRA","briefResultsDescription":"Omalizumab reduces asthma exacerbations","diseases":"Asthma","trainingLevel":"Fellow","title":"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial","pmid":"21536936","statusUsableDate":"2013-10-01","abbreviation":"EXTRA","timestamp":"2017-12-03T22:35:31Z","published":"2011-05-03","briefDesignDescription":"Omalizumab in severe allergic asthma","subspecialties":"Allergy and Immunology;Pulmonology;Pediatrics","fulltexturl":null,"pdfurl":"http://annals.org/data/Journals/AIM/20231/0000605-201105030-00002.pdf"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa062200","subspecialties":"Critical Care","briefDesignDescription":"Fluid management in ARDS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa062200","statusUsableDate":"2012-03-01","pmid":"16714767","title":"Comparison of two fluid-management strategies in acute lung injury","published":"2006-06-15","timestamp":"2015-11-07T23:16:22Z","abbreviation":"FACTT","diseases":"Acute Respiratory Distress Syndrome","briefResultsDescription":"Mortality benefit of conservative fluid management in ALI/ARDS","pageName":"FACTT","trainingLevel":"Resident","expansion":"Fluids and Catheters Treatment Trial","pageid":24,"citation":"Wiedemann HP, et al. \"Comparison of two fluid-management strategies in acute lung injury\". The New England Journal of Medicine. 2006. 354(24):2564-75."},{"pageid":2691,"citation":"Anker SD, et al. \"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency\". The New England Journal of Medicine. 2009. 361(25):2436-48.","expansion":"IV Iron for Symptoms in Patients with HFrEF and Iron Deficiency","trainingLevel":"Intern","pageName":"FAIR-HF","diseases":"Heart Failure;Iron Deficiency Anemia","briefResultsDescription":"IV iron improves HFrEF symptoms in patients with HFrEF and iron deficiency","abbreviation":"FAIR-HF","published":"2009-12-17","timestamp":"2019-02-28T18:37:32Z","title":"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency","statusUsableDate":"2019-03-01","pmid":"19920054","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908355","briefDesignDescription":"Parenteral iron in HFrEF with iron deficiency","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa0908355","subspecialties":"Cardiology;Hematology"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807611","briefDesignDescription":"FFR-guided PCI in stable CAD","timestamp":"2018-01-03T20:13:15Z","published":"2009-01-15","abbreviation":"FAME","pmid":"19144937","statusUsableDate":"2012-10-01","title":"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention","trainingLevel":"resident","briefResultsDescription":"FFR reduces composite of death, nonfatal MI, urgent revascularization","diseases":"Coronary Artery Disease","pageName":"FAME","citation":"Tonino PAL, et al. \"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention\". The New England Journal of Medicine. 2009. 360(3):213-224.","pageid":998,"expansion":"Fractional Flow Reserve versus Angiography for Multivessel Evaluation"},{"title":"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease","statusUsableDate":"2012-11-01","pmid":"22924638","abbreviation":"FAME 2","timestamp":"2018-07-05T13:05:28Z","published":"2012-09-13","briefDesignDescription":"FFR-guided PCI vs. OMT in CAD","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1205361","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361","expansion":"FFR vs. Angiographyfor Multivessel Evaluation 2","citation":"De Bruyne B, et al. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". The New England Journal of Medicine. 2012. 367(11):991-1001.","pageid":1003,"pageName":"FAME 2","briefResultsDescription":"FFR-guided PCI reduces urgent revascularization","diseases":"Coronary Artery Disease","trainingLevel":"Resident"},{"pageName":"FEAST","briefResultsDescription":"Albumin and saline increase mortality when compared to no fluids in this patient population","diseases":"Shock","trainingLevel":"Resident","expansion":"Fluid Expansion as Supportive Therapy","citation":"Maitland K, et al. \"Mortality after fluid bolus in African children with severe infection\". The New England Journal of Medicine. 2011. 364(26):2483-2495.","pageid":1860,"briefDesignDescription":"Fluid resuscitation in Sub-Saharan Africa","subspecialties":"Pediatrics;Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1101549","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549","title":"Mortality after fluid bolus in African children with severe infection","pmid":"21615299","statusUsableDate":"2014-11-01","abbreviation":"FEAST","timestamp":"2017-12-03T22:35:38Z","published":"2011-06-30"},{"briefDesignDescription":"Fidaxomicin in C. difficile","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0910812","subspecialties":"Infectious Disease;Gastroenterology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812","title":"Fidaxomicin versus Vancomycin for Clostridium difficile Infection","pmid":"21288078","statusUsableDate":"2012-03-01","abbreviation":null,"published":"2011-02-03","timestamp":"2013-10-07T20:50:13Z","pageName":"Fidaxomicin in C. difficile Diarrhea","diseases":"Clostridium difficile","briefResultsDescription":"Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences","trainingLevel":"Resident","expansion":null,"pageid":255,"citation":"Louie TJ, et al. \"Fidaxomicin versus Vancomycin for Clostridium difficile Infection\". The New England Journal of Medicine. 2011. 365(5):422-431."},{"timestamp":"2024-10-17T17:57:15Z","published":"2020-10-23","abbreviation":"FIDELIO-DKD","statusUsableDate":"2024-10-17","pmid":"33264825","title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845","subspecialties":"Nephrology;Endocrinology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2025845","briefDesignDescription":"Mineralocorticoid antagonist in CKD/T2DM","citation":"Bakris GL, et al. \"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes\". The New England Journal of Medicine. 2020. 383(23):2219-2229.","pageid":4384,"expansion":"Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease","trainingLevel":"Resident","briefResultsDescription":"Mineralocorticoid antagonist slows CKD progression","diseases":"Chronic Kidney Disease;Diabetes Mellitus","pageName":"FIDELIO-DKD"},{"expansion":"","pageid":2776,"citation":"Tuomilehto J, et al. \"Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance\". The New England Journal of Medicine. 2001. 344(18):1343-1350.","diseases":"Diabetes Mellitus","briefResultsDescription":"Intensive lifestyle interventions prevent diabetes","pageName":"Finnish Diabetes Prevention Study","trainingLevel":"Resident","pmid":"11333990","statusUsableDate":"2025-06-01","title":"Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance","published":"2001-15-03","timestamp":"2025-06-05T17:26:20Z","abbreviation":"Finnish Diabetes Prevention Study","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200105033441801#t","subspecialties":"Endocrinology","briefDesignDescription":"Lifestyle interventions to prevent diabetes","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200105033441801"},{"title":"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation","statusUsableDate":"2016-07-01","pmid":"27042964","abbreviation":"FIRE AND ICE","timestamp":"2017-12-03T22:35:39Z","published":"2016-06-09","briefDesignDescription":"Cryoablation vs. RF ablation in pAF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602014","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602014","expansion":"","citation":"Kuck K, et al. \"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation\". The New England Journal of Medicine. 2016. 374(23):2235-45.","pageid":2795,"pageName":"FIRE AND ICE","briefResultsDescription":"Cryoablation equivalent to RF ablation in pAF","diseases":"Atrial Fibrillation","trainingLevel":"Resident"},{"published":"2016-06-09","timestamp":"2017-12-03T22:35:41Z","abbreviation":"FLAME COPD","pmid":"27181606","statusUsableDate":"2017-01-01","title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1516385","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1516385","subspecialties":"Pulmonology","briefDesignDescription":"LABA+LAMA vs. LABA+ICS in COPD","pageid":2871,"citation":"Wedzicha JA, et al. \"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD\". The New England Journal of Medicine. 2016. 374(23):2222-2234.","expansion":"Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations","trainingLevel":"Resident","diseases":"Emphysema;Chronic Bronchitis;Chronic Obstructive Pulmonary Disease","briefResultsDescription":"LABA+LAMA reduces COPD exacerbations","pageName":"FLAME (COPD)"},{"expansion":"Fluoxetine for Motor Recovery after Acute Ischaemic Stroke","citation":"Chollet F, et al. \"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial\". The Lancet Neurology. 2011. 10(2):123-130.","pageid":2370,"briefResultsDescription":"Early fluoxetine improved motor outcomes post stroke","diseases":"Stroke","pageName":"FLAME (Stroke)","trainingLevel":"Resident","statusUsableDate":"2015-08-01","pmid":"21216670","title":"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial","timestamp":"2018-10-08T21:47:35Z","published":"2011-02-01","abbreviation":"FLAME","subspecialties":"Neurology","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(10)70314-8","briefDesignDescription":"SSRI after CVA for motor recovery","pdfurl":""},{"expansion":"","pageid":2375,"citation":"Frat JP, et al. \"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure\". The New England Journal of Medicine. 2015. 372(23):2185-2196.","diseases":"Respiratory Failure","briefResultsDescription":"High-flow oxygen therapy reduces intubation need","pageName":"FLORALI","trainingLevel":"Intern","statusUsableDate":"2012-03-01","pmid":"25981908","title":"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure","published":"2015-06-04","timestamp":"2025-06-19T18:32:02Z","abbreviation":"FLORALI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1503326","subspecialties":"Pulmonology;Critical Care","briefDesignDescription":"High-flow oxygen in respiratory failure","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1503326"},{"pmid":"22168590","statusUsableDate":"2017-12-14","title":"Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery","timestamp":"2017-12-14T18:13:26Z","published":"2011-12-29","abbreviation":"FOCUS","subspecialties":"Hematology;Surgery","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1012452","briefDesignDescription":"Transfusion thresholds after hip surgery","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1012452","expansion":"Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair","citation":"Carson JL, et al. \"Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery\". The New england Journal of Medicine. 2011. 365(26):2453-62.","pageid":2985,"briefResultsDescription":"Liberal transfusions no better than restrictive","diseases":"Hip Fracture;Anemia","pageName":"FOCUS","trainingLevel":"Resident"},{"published":"2017-03-17","timestamp":"2020-11-05T18:42:16Z","abbreviation":"FOURIER","pmid":"28304224","statusUsableDate":"2017-03-01","title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1615664","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1615664","subspecialties":"Cardiology","briefDesignDescription":"Evolocumab for CVD events if atherosclerotic disease","pageid":2891,"citation":"Sabatine MS, et al. \"Evolocumab and clinical outcomes in patients with cardiovascular disease\". The New England Journal of Medicine. 2017. epub 2017-03-17:1-10.","expansion":"Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk","trainingLevel":"Resident","diseases":"Coronary Artery Disease","briefResultsDescription":"Evolocumab reduces CV events in patients with atherosclerotic disease","pageName":"FOURIER"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211585","subspecialties":"Cardiology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1211585","briefDesignDescription":"CABG vs. PCI for CAD in T2DM","timestamp":"2017-12-03T22:35:45Z","published":"2012-12-20","abbreviation":"FREEDOM","statusUsableDate":"2016-04-01","pmid":"23121323","title":"Strategies for multivessel revascularization in patients with diabetes","trainingLevel":"Resident","briefResultsDescription":"CABG reduces death and revascularization rates but causes more strokes","diseases":"Coronary Artery Disease;Diabetes Mellitus","pageName":"FREEDOM","citation":"Farkouh ME, et al. \"Strategies for multivessel revascularization in patients with diabetes\". The New England Journal of Medicine. 2012. 367(25):2375-2384.","pageid":2314,"expansion":"Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease"},{"subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07349-3/fulltext","briefDesignDescription":"Early invasive strategy in UA/NSTEMI","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)07349-3.pdf","pmid":"10475181","statusUsableDate":"2015-11-01","title":"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study","timestamp":"2021-06-01T13:47:49Z","published":"1999-08-28","abbreviation":"FRISC-II","briefResultsDescription":"Fewer recurrent MIs with early invasive strategy in high-risk patients","diseases":"Coronary Artery Disease;Myocardial Infarction;Acute Coronary Syndrome","pageName":"FRISC-II","trainingLevel":"Resident","expansion":"FRagmin and Fast Revascularisation during InStability in Coronary artery disease-II","citation":"FRISC Investigators. \"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study\". The Lancet. 1999. 354(9180):708-15.","pageid":2451},{"expansion":null,"pageid":391,"citation":"Cook DJ, et al. \"Risk factors for gastrointestinal bleeding in critically ill patients\". The New England Journal of Medicine. 1994. 330(6):337-381.","pageName":"GI bleeding in ICU patients","diseases":"Gastrointestinal Hemorrhage","briefResultsDescription":"Greatest risk for GI bleed with coagulopathy and mechanical ventilation","trainingLevel":"Intern","title":"Risk factors for gastrointestinal bleeding in critically ill patients","statusUsableDate":"2013-10-01","pmid":"8284001","abbreviation":null,"published":"1994-02-10","timestamp":"2017-12-03T22:35:49Z","briefDesignDescription":"Risk factors for GI bleeds in ICU patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199402103300601","subspecialties":"Critical Care;Gastroenterology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199402103300601"},{"pdfurl":"","briefDesignDescription":"Lisinopril in acute MI","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract","abbreviation":"GISSI-3","timestamp":"2014-09-24T22:28:37Z","published":"1994-05-07","title":"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","statusUsableDate":"2012-03-01","pmid":"7910229","trainingLevel":"Resident","pageName":"GISSI-3","briefResultsDescription":"Lisinopril improves 6-week mortality","diseases":"Acute Coronary Syndrome;Myocardial Infarction","citation":"GISSI-3 Group. \"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction\". The Lancet. 1994. 343(8906):1115-22.","pageid":258,"expansion":"Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico"},{"expansion":"Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione","pageid":2824,"citation":"Tavazzi L, et al. \"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure\". The Lancet. 2008. 372(9645):1223-1230.","pageName":"GISSI-HF","diseases":"Heart Failure","briefResultsDescription":"PUFA reduces all-cause mortality and admission for CV disease","trainingLevel":"intern","title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure","pmid":"18757090","statusUsableDate":"2023-07-31","abbreviation":"GISSI-HF","published":"2008-10-04","timestamp":"2025-05-22T17:32:19Z","briefDesignDescription":"PUFA in patients with heart failure","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext","subspecialties":"Cardiology","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)61239-8.pdf"},{"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309023291001","briefDesignDescription":"tPA in ACS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001","statusUsableDate":"2014-09-01","pmid":"8204123","title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","timestamp":"2017-12-03T22:35:51Z","published":"1993-09-03","abbreviation":"GUSTO","briefResultsDescription":"tPA reduces mortality in ACS","diseases":"Myocardial Infarction;Acute Coronary Syndrome","pageName":"GUSTO","trainingLevel":"Student","expansion":"Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries","citation":"Topol E, et al. \"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction\". The New England Journal of Medicine. 1993. 329(10):673-682.","pageid":2177},{"briefResultsDescription":"Hypothermia improves neurologic outcomes and reduces mortality","diseases":"Cardiac Arrest","pageName":"HACA","trainingLevel":"Resident","expansion":"Hypothermia After Cardiac Arrest","citation":"Holzer M, et al. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". The New England Journal of Medicine. 2002. 346(8):549-556.","pageid":410,"subspecialties":"Critical Care;Neurology;Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/nejmoa012689","briefDesignDescription":"Hypothermia for cardiac arrest","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa012689","statusUsableDate":"2012-03-01","pmid":"11856793","title":"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest","timestamp":"2024-08-25T20:47:09Z","published":"2002-02-21","abbreviation":"HACA"},{"pageName":"HEAAL","briefResultsDescription":"High-dose losartan improves HF outcomes","diseases":"Heart Failure","trainingLevel":"resident","expansion":"Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan","citation":"Konstam MA, et al. \"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure\". The Lancet. 2009. 374(9704):1840-1848.","pageid":2825,"briefDesignDescription":"High- vs. low-dose losartan in heart failure","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61913-9/fulltext","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)61913-9.pdf","title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure","pmid":"19922995","statusUsableDate":"2025-05-12","abbreviation":"HEAAL","timestamp":"2025-05-22T17:34:50Z","published":"2009-11-28"},{"abbreviation":"HEARTMATE II","published":"2009-12-03","timestamp":"2017-12-03T22:35:53Z","title":"Advanced heart failure treated with continuous-flow left ventricular assist device","statusUsableDate":"2016-09-01","pmid":"19920051","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909938","briefDesignDescription":"Continuous-flow LVAD in heart failure","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0909938#t","subspecialties":"Cardiology","pageid":2808,"citation":"Slaughter MS, et al. \"Advanced heart failure treated with continuous-flow left ventricular assist device\". The New England Journal of Medicine. 2009. 361(23):2241-2251.","expansion":"Advanced heart failure treated with continuous-flow left ventricular assist device","trainingLevel":"Fellow","pageName":"HEARTMATE II","diseases":"Heart Failure","briefResultsDescription":"Continuous-flow LVAD improved survival free from stroke and device failure"},{"diseases":"Sepsis;Fever","briefResultsDescription":"Acetaminophen does not improves ICU outcomes","pageName":"HEAT","trainingLevel":"Intern","expansion":"Permissive Hyperthermia through Avoidance of Acetaminophen in Known or Suspected Infection in the Intensive Care Unit","pageid":2690,"citation":"Young P, et al. \"Acetaminophen for Fever in Critically Ill Patients with Suspected Infection\". The New England Journal of Medicine. 2015. 373(23):2215-2224.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1508375","subspecialties":"Critical Care;Infectious Disease","briefDesignDescription":"Acetaminophen in febrile ICU patients","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1508375","pmid":"26436473","statusUsableDate":"2017-09-01","title":"Acetaminophen for Fever in Critically Ill Patients with Suspected Infection","published":"2015-12-03","timestamp":"2020-11-04T18:25:05Z","abbreviation":"HEAT"},{"pdfurl":"","briefDesignDescription":"Heparin vs. bivalirudin in PCI","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60924-7","subspecialties":"Cardiology","abbreviation":"HEAT-PPCI","published":"2014-11-22","timestamp":"2023-02-02T19:36:38Z","title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.","statusUsableDate":"2023-01-29","pmid":"25002178","trainingLevel":"Resident","pageName":"HEAT-PPCI","diseases":"Coronary Artery Disease","briefResultsDescription":"Heparin better than bivalirudin for PCI","pageid":2394,"citation":"Shahzad A, et al. \"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.\". The Lancet. 2014. 384(9957):1849-1858.","expansion":""},{"trainingLevel":"Fellow","diseases":"Chronic Kidney Disease","briefResultsDescription":"High dialysis dose and high-flux membrane did not reduce all-cause mortality","pageName":"HEMO","pageid":2771,"citation":"Rose EA, et al. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". The New England Journal of Medicine. 2002. 347(25):2020-2019.","expansion":"Hemodialysis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021583","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021583","subspecialties":"Nephrology","briefDesignDescription":"High dialysis dose and high-flux membrane in hemodialysis","published":"2002-12-19","timestamp":"2018-10-25T17:06:10Z","abbreviation":"HEMO","pmid":"12490682","statusUsableDate":"2018-03-15","title":"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis"},{"pageid":440,"citation":"Piccart-Gebhart MJ, et al. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". The New England Journal of Medicine. 2005. 353(16):1659-72.","expansion":"Herceptin Adjuvant Trial","trainingLevel":"Resident","diseases":"Breast Cancer","briefResultsDescription":"Trastuzumab improves survival","pageName":"HERA","published":"2005-10-20","timestamp":"2013-10-09T17:11:02Z","abbreviation":"HERA","statusUsableDate":"2012-03-01","pmid":"16236737","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052306","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052306","subspecialties":"Oncology","briefDesignDescription":"Trastuzumab in breast cancer"},{"abbreviation":"","timestamp":"2020-10-29T17:37:34Z","published":"2018-02-15","title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","pmid":"29231094","statusUsableDate":"2018-02-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711948","briefDesignDescription":"Edoxaban vs. LMWH in cancer VTE","subspecialties":"Hematology;Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1711948","citation":"Raskob GE, et al. \"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism\". The New England Journal of Medicine. 2018. 378(7):615-624.","pageid":3509,"expansion":"","trainingLevel":"Resident","pageName":"Hokusai-VTE","briefResultsDescription":"Edoxaban noninferior to dalteparin in cancer VTE","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis"},{"expansion":"Heart Outcomes Prevention Evaluation","citation":"Yusuf S, et al. \"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients\". The New England Journal of Medicine. 2000. 342(3):145-153.","pageid":1165,"pageName":"HOPE","briefResultsDescription":"Ramipril reduces death, MI, and stroke","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","trainingLevel":"intern","title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","statusUsableDate":"2012-03-01","pmid":"10639539","abbreviation":"HOPE","timestamp":"2013-08-15T18:50:04Z","published":"2000-01-20","briefDesignDescription":"Ramipril in patients with high CV risk","subspecialties":"Cardiology;Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200001203420301","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301"},{"pageid":4382,"citation":"Vichinsky E, et al. \"A phase 3 randomized trial of voxelotor in sickle cell disease\". The New England Journal of Medicine. 2019. 381(8):509-519.","expansion":"Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization","trainingLevel":"resident","diseases":"Sickle Cell Disease","briefResultsDescription":"Voxelotor increases hemoglobin and reduces evidence of hemolysis","pageName":"HOPE (Sickle Cell Disease)","published":"2019-08-08","timestamp":"2020-12-31T20:42:03Z","abbreviation":"HOPE","pmid":"31199090","statusUsableDate":"2020-12-10","title":"A phase 3 randomized trial of voxelotor in sickle cell disease","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1903212","fulltexturl":"https://www.nejm.org/doi/full/10.1056/nejmoa1903212","subspecialties":"Hematology","briefDesignDescription":"Voxelotor in sickle cell disease"},{"diseases":"Osteoporosis","briefResultsDescription":"Annual zoledronate reduces fracture risk in osteoporosis","pageName":"HORIZON-PFT","trainingLevel":"Resident","expansion":"Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial","pageid":2765,"citation":"Black DM, et al. \"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis\". The New England Journal of Medicine. 2007. 356(18):1809-22.","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa067312","subspecialties":"Endocrinology;Preventive Medicine","briefDesignDescription":"Zoledronate vs. placebo in osteoporosis","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa067312","pmid":"17476007","statusUsableDate":"2021-08-31","title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","published":"2007-05-03","timestamp":"2021-09-09T17:34:24Z","abbreviation":"HORIZON-PFT"},{"pdfurl":null,"subspecialties":"Infectious Disease;Hematology","fulltexturl":"https://doi.org/10.1016/S2352-3026(17)30211-9","briefDesignDescription":"Duration of empiric antibiotics in ↑risk neutropenic fever","timestamp":"2024-05-02T17:49:17Z","published":"2017-11-15","abbreviation":null,"pmid":"29153975","statusUsableDate":"2021-03-15","title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","trainingLevel":"Fellow","briefResultsDescription":"Shorter courses of antibiotics led to fewer days of antibiotics without excess harm","diseases":"Febrile Neutropenia","pageName":"How Long","citation":"Aguilar-Guisado M, et al. \"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial\". Lancet Haematology. 2017. 4(12):e573-e583.","pageid":4119,"expansion":null},{"citation":"Landray MJ et al. \"Effects of extended-release niacin with laropiprant in high-risk patients\". The New England Journal of Medicine. 2014. 371(3):203-212.","pageid":2329,"expansion":"Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events","trainingLevel":"Intern","briefResultsDescription":"Niacin is poorly tolerated, doesn't reduce major vascular events","diseases":"Coronary Artery Disease;Peripheral Vascular Disease","pageName":"HPS2-THRIVE","timestamp":"2017-12-03T22:35:56Z","published":"2014-07-17","abbreviation":"HPS2-THRIVE","statusUsableDate":"2015-02-01","pmid":"25014686","title":"Effects of extended-release niacin with laropiprant in high-risk patients","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300955","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300955","briefDesignDescription":"Niacin in atherosclerotic disease"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1105243","subspecialties":"Infectious Disease","briefDesignDescription":"Early ART in HIV","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243","pmid":"21767103","statusUsableDate":"2012-10-01","title":"Prevention of HIV-1 Infection with Early Antiretroviral Therapy","published":"2011-08-11","timestamp":"2017-12-03T22:35:58Z","abbreviation":"HPTN 052","diseases":"HIV","briefResultsDescription":"Reduced morbidity and HIV transmission","pageName":"HPTN 052","trainingLevel":"Resident","expansion":"HIV Prevention Trials Network 052 Study","pageid":1010,"citation":"Cohen MS, et al. \"Prevention of HIV-1 Infection with Early Antiretroviral Therapy\". The New England Journal of Medicine. 2011. 365(6):493-505."},{"timestamp":"2017-12-03T22:35:59Z","published":"2014-06-17","abbreviation":null,"statusUsableDate":"2015-03-01","pmid":"24694529","title":"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction","pdfurl":null,"subspecialties":"Emergency Medicine;Cardiology","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0735109714017264","briefDesignDescription":"High sensitivity troponin for acute chest pain","citation":"Bandstein N, et al. \"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction\". Journal of the American College of Cardiology. 2014. 63(23):2569-2578.","pageid":2343,"expansion":null,"trainingLevel":"Intern","briefResultsDescription":"HS troponin-T is associated with high NPV for MI at 30 days","diseases":"Acute Coronary Syndrome;Myocardial Infarction","pageName":"HS troponin-T to rule out MI"},{"expansion":null,"pageid":2142,"citation":"Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". The New England Journal of Medicine. 1992. 327(26):1832-1835.","pageName":"Hungarian Prenatal Vitamin Trial","diseases":"Neural Tube Defects","briefResultsDescription":"Perinatal vitamins reduce neural tube defects","trainingLevel":"Student","title":"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation","statusUsableDate":"2014-09-01","pmid":"1307234","abbreviation":null,"published":"1992-12-24","timestamp":"2017-12-03T22:36:04Z","briefDesignDescription":"Perinatal vitamins to prevent neural tube defects","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199212243272602","subspecialties":"Obstetrics;Preventive Medicine","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199212243272602"},{"pdfurl":"http://journal.chestnet.org/article/S0012-3692(16)62564-3/pdf","fulltexturl":"http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext","subspecialties":"Critical Care;Infectious Disease;Pulmonology","briefDesignDescription":"Hydrocortisone, Vit C, and thiamine in sepsis","published":"2017-06-01","timestamp":"2023-11-22T21:12:44Z","abbreviation":"","pmid":"27940189","statusUsableDate":"2018-08-13","title":"Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study","trainingLevel":"Resident","diseases":"Sepsis;Shock","briefResultsDescription":"Pilot study with impressive findings, low-quality data","pageName":"Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock","pageid":2946,"citation":"Marik PE, et al. \"Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study\". Chest. 2017. 151(6):1229-1238.","expansion":""},{"trainingLevel":"Resident","pageName":"HYPRESS","briefResultsDescription":"Hydrocortisone not superior to placebo in severe sepsis","diseases":"Sepsis","citation":"Keh D, et al. \"Effect of hydrocortisone on development of shock among patients with severe sepsis\". Journal of the American Medical Association. 2016. 316(17):1775-1785.","pageid":2860,"expansion":"","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMsa1410639","briefDesignDescription":"Hydrocortisone in severe sepsis","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMsa1410639","abbreviation":"HYPRESS","timestamp":"2018-02-08T17:14:46Z","published":"2016-10-03","title":"Effect of hydrocortisone on development of shock among patients with severe sepsis","statusUsableDate":"2016-11-01","pmid":"27695824"},{"published":"2008-05-01","timestamp":"2018-01-11T18:14:28Z","abbreviation":"HYVET","statusUsableDate":"2015-04-01","pmid":"18378519","title":"Treatment of hypertension in patients 80 years of age or older","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801369","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0801369","subspecialties":"Nephrology;Cardiology;Geriatrics","briefDesignDescription":"Elderly HTN treatment","pageid":2349,"citation":"Beckett NS, et al. \"Treatment of hypertension in patients 80 years of age or older\". The New England Journal of Medicine. 2008. 358(18):1887-1898.","expansion":"Hypertension in the Very Elderly Trial","trainingLevel":"Intern","diseases":"Hypertension","briefResultsDescription":"Trend towards reduction in stroke with treatment (P","pageName":"HYVET"},{"expansion":"Intraaortic Balloon Pump in Cardiogenic Shock II","pageid":1065,"citation":"Thiele H, et al. \"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock\". The New England Journal of Medicine. 2012. 367(14):1287-1296.","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","briefResultsDescription":"IABP did not reduce mortality at 30 days","pageName":"IABP-SHOCK II","trainingLevel":"Fellow","statusUsableDate":"2012-03-01","pmid":"22920912","title":"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock","published":"2012-10-10","timestamp":"2017-09-24T13:54:35Z","abbreviation":"IABP-SHOCK II","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208410","subspecialties":"Cardiology;Critical Care","briefDesignDescription":"IABP in MI and cardiogenic shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208410"},{"abbreviation":"IALT","timestamp":"2019-05-23T17:29:10Z","published":"2004-01-22","title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","pmid":"14736927","statusUsableDate":"2019-05-23","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa031644","briefDesignDescription":"Adjuvant cisplatin in resected NSCLC","subspecialties":"Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa031644","citation":"Arriagada R, et al. \"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer\". The New England Journal of Medicine. 2004. 350(4):351-360.","pageid":2503,"expansion":"International Adjuvant Lung Cancer Trial","trainingLevel":"Fellow","pageName":"IALT","briefResultsDescription":"Adjuvant cisplatin improves 5-year OS in resected NSCLC","diseases":"Lung Cancer"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501548","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501548","briefDesignDescription":"Second-line ibrutinib in WM","timestamp":"2021-11-04T17:33:05Z","published":"2015-04-09","abbreviation":null,"pmid":"25853747","statusUsableDate":"2015-12-01","title":"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia","trainingLevel":"Fellow","briefResultsDescription":"Ibrutinib is safe and effective in previously treated WM","diseases":"Lymphoma;Waldenström Macroglobulinemia","pageName":"Ibrutinib in Waldenstrom macroglobulinemia","citation":"Treon SP, et al. \"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia\". The New England Journal of Medicine. 2015. 372(15):1430-1440.","pageid":2660,"expansion":null},{"trainingLevel":"Fellow","pageName":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","briefResultsDescription":"IR improved survival over FCR in untreated CLL","diseases":"Chronic Lymphocytic Leukemia;Small Lymphocytic Lymphoma","citation":"Shanafelt TD, et al. \"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia\". The New England Journal of Medicine. 2019. 381(5):432-43.","pageid":4175,"expansion":"","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073","briefDesignDescription":"Ibrutinib-rituximab vs. FCR in untreated CLL","subspecialties":"Hematology;Oncology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1817073","abbreviation":"E1912","timestamp":"2020-02-10T07:03:58Z","published":"2019-08-01","title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","statusUsableDate":"2020-02-09","pmid":"31365801"},{"timestamp":"2018-10-16T05:02:38Z","published":"2013-10-17","abbreviation":"ICAP","pmid":"23992557","statusUsableDate":"2014-01-01","title":"A Randomized Trial of Colchicine for Acute Pericarditis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208536","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208536","briefDesignDescription":"Colchicine in the first episode of acute pericarditis","citation":"Imazio M, et al. \"A Randomized Trial of Colchicine for Acute Pericarditis\". The New England Journal of Medicine. 2013. 369(16):1522-1528.","pageid":1729,"expansion":"Evaluation of additive benefit of colchicine to conventional therapy in acute pericarditis","trainingLevel":"Intern","briefResultsDescription":"Colchicine reduces incessant or recurrent acute pericarditis when used in first episode","diseases":"Pericarditis","pageName":"ICAP"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000552","briefDesignDescription":"Early vs. late dialysis in CKD","subspecialties":"Nephrology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000552","abbreviation":"IDEAL","timestamp":"2017-12-03T22:36:07Z","published":"2010-08-12","title":"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis","pmid":"20581422","statusUsableDate":"2012-10-01","trainingLevel":"Resident","pageName":"IDEAL","briefResultsDescription":"No difference in survival or clinical outcomes","diseases":"Chronic Kidney Disease","citation":"Cooper BA, et al. \"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis\". The New England Journal of Medicine. 2010. 363(7):609-619.","pageid":1020,"expansion":"Initiating Dialysis Early and Late"},{"pmid":"30304656","statusUsableDate":"2019-03-27","title":"Timing of renal-replacement therapy in patients with acute kidney injury and sepsis","timestamp":"2025-06-19T18:33:35Z","published":"2018-10-11","abbreviation":"IDEAL-ICU","subspecialties":"Critical Care;Nephrology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1803213","briefDesignDescription":"Early vs. delayed RRT in septic shock","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803213","expansion":"Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit","citation":"Barbar SD, et al. \"Timing of renal-replacement therapy in patients with acute kidney injury and sepsis\". The New England Journal of Medicine. 2018. 379(15):1431-1442.","pageid":3746,"briefResultsDescription":"No benefit from early initiated RRT in septic shock","diseases":"Acute Kidney Injury;Shock;Sepsis","pageName":"IDEAL-ICU","trainingLevel":"Resident"},{"pageName":"IDNT","diseases":"Diabetic Nephropathy;Diabetes Mellitus","briefResultsDescription":"ARBs prevent progression of T2DM nephropathy","trainingLevel":"Resident","expansion":"Irbesartan Diabetic Nephropathy Trial","pageid":2670,"citation":"Lewis EJ, et al. \"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes\". The New England Journal of Medicine. 2001. 345(12):851-860.","briefDesignDescription":"ARBs in diabetic nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011303","subspecialties":"Nephrology;Endocrinology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011303","title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","statusUsableDate":"2016-01-01","pmid":"11565517","abbreviation":"IDNT","published":"2001-09-20","timestamp":"2017-12-03T22:36:08Z"},{"published":"2017-05-11","timestamp":"2017-12-03T22:36:10Z","abbreviation":"iFR-SWEDEHEART","statusUsableDate":"2017-05-01","pmid":"28317438","title":"Spontaneous wave-free ratio versus fractional flow reserve to guide PCI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1616540","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1616540","subspecialties":"Cardiology","briefDesignDescription":"iFR vs. FFR for PCI","pageid":2926,"citation":"Gotberg M, et al. \"Spontaneous wave-free ratio versus fractional flow reserve to guide PCI\". The New England Journal of Medicine. 2017. 376(19):1813-1823.","expansion":"Instantaneous Wave-free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome","trainingLevel":"Resident","diseases":"Coronary Artery Disease","briefResultsDescription":"iFR noninferior to FFR for PCI","pageName":"IFR-SWEDEHEART"},{"expansion":"IMProved Reduction of Outcomes: Vytorin Efficacy International Trial","pageid":2369,"citation":"Cannon CP, et al. \"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes\". The New England Journal of Medicine. 2015. 375(25):2387-2397.","diseases":"Hyperlipidemia;Acute Coronary Syndrome;Myocardial Infarction","briefResultsDescription":"Ezetimibe improves CV outcomes when added to statin","pageName":"IMPROVE-IT","trainingLevel":"Intern","statusUsableDate":"2015-06-01","pmid":"26039521","title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","published":"2015-06-18","timestamp":"2017-12-14T19:46:19Z","abbreviation":"IMPROVE-IT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1410489","subspecialties":"Cardiology","briefDesignDescription":"Ezetimibe+simvastatin after ACS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489"},{"expansion":"","pageid":2934,"citation":"Richeldi L, et al. \"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis\". The New England Journal of Medicine. 2014. 370(22):2071-2082.","pageName":"INPULSIS Trials","diseases":"Idiopathic Pulmonary Fibrosis","briefResultsDescription":"Nintedanib slows progression of IPF","trainingLevel":"Resident","title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","statusUsableDate":"2018-03-30","pmid":"24836310","abbreviation":"INPULSIS I and II","published":"2014-05-29","timestamp":"2018-03-30T14:11:39Z","briefDesignDescription":"Nintedanib in IPF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1402584","subspecialties":"Pulmonology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402584"},{"title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","statusUsableDate":"2016-01-01","pmid":"26192873","abbreviation":"START","published":"2015-08-27","timestamp":"2017-12-03T22:36:12Z","briefDesignDescription":"Early vs. delayed ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1506816","subspecialties":"Infectious Disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506816","expansion":null,"pageid":2468,"citation":"INSIGHT START Writers. \"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection\". The New England Journal of Medicine. 2015. 373(9):795-807.","pageName":"INSIGHT START","diseases":"HIV","briefResultsDescription":"Less complications with early ART","trainingLevel":"Student"},{"pageName":"IPrEx","diseases":"HIV","briefResultsDescription":"ART reduces tranmission of HIV among MSM","trainingLevel":"intern","expansion":"Iniciativa Profilaxis Pre Exposicion (\"Preexposure Prophylaxis Initiative\")","pageid":1100,"citation":"Grant RM, et al. \"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men\". The New England Journal of Medicine. 2010. 363(27):2587-2599.","briefDesignDescription":"ART in primary HIV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1011205","subspecialties":"Infectious Disease;Preventive Medicine","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205","title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","statusUsableDate":"2013-02-01","pmid":"21091279","abbreviation":"iPrEx","published":"2010-12-30","timestamp":"2017-12-03T22:36:14Z"},{"expansion":"International Randomized Study of Interferon and STI571","citation":"O'Brien SG, et al. \"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia\". The New England Journal of Medicine. 2003. 384(11):994-1004.","pageid":1076,"pageName":"IRIS","briefResultsDescription":"Imatinib delays disease progression","diseases":"Chronic Myeloid Leukemia;Myeloproliferative Neoplasms","trainingLevel":"Student","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","pmid":"12637609","statusUsableDate":"2012-11-01","abbreviation":"IRIS","timestamp":"2017-12-03T22:36:15Z","published":"2003-03-13","briefDesignDescription":"Imatinib vs. IFNα/cytarabine in CML","subspecialties":"Hematology;Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa022457","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457"},{"expansion":"","citation":"Litton E, et al. \"Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial\". Intensive Care Med. 2016. 42:1715-1722.","pageid":3651,"pageName":"IRONMAN","briefResultsDescription":"IV iron did not reduce transfusion requirements","diseases":"Anemia;Critical Illness","trainingLevel":"Fellow","title":"Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial","statusUsableDate":"2024-04-30","pmid":"27686346","abbreviation":"IRONMAN","timestamp":"2024-05-20T13:33:05Z","published":"2016-11-01","briefDesignDescription":"IV iron in critical illness","subspecialties":"Critical Care;Hematology","fulltexturl":"https://link.springer.com/article/10.1007%2Fs00134-016-4465-6","pdfurl":"https://link.springer.com/content/pdf/10.1007/s00134-016-4465-6.pdf"},{"trainingLevel":"Resident","diseases":"Heart Failure","briefResultsDescription":"Oral iron not superior to placebo in HFrEF","pageName":"IRONOUT-HF","pageid":2941,"citation":"Lewis GD, et al. \"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency\". JAMA. 2017. 317(19):1958-66.","expansion":"Iron Repletion Effects on Oxygen Uptake in Heart Failure","pdfurl":"http://jamanetwork.com/journals/jama/article-abstract/2626574","fulltexturl":"http://jamanetwork.com/journals/jama/article-abstract/2626574","subspecialties":"Cardiology","briefDesignDescription":"Oral iron vs. placebo in HFrEF and iron deficiency","published":"2017-07-09","timestamp":"2017-12-03T22:36:17Z","abbreviation":"IRONOUT-HF","statusUsableDate":"2017-07-01","pmid":"28510680","title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency"},{"pmid":"31475799","statusUsableDate":"2019-10-17","title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","published":"2019-09-01","timestamp":"2019-10-17T17:39:50Z","abbreviation":"ISAR-REACT 5","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1908973","subspecialties":"Cardiology","briefDesignDescription":"Ticagrelor vs. prasugrel in ACS","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908973","expansion":"Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial","pageid":4100,"citation":"Schupke S et al. \"Ticagrelor or prasugrel in patients with acute coronary syndromes\". New Engl J Med. 2019. 1-11.","diseases":"Coronary Artery Disease","briefResultsDescription":"Prasugrel superior to ticagrelor in acute coronary syndromes","pageName":"ISAR-REACT 5","trainingLevel":"Resident"},{"subspecialties":"Cardiology","fulltexturl":"http://content.onlinejacc.org/article.aspx?articleID","briefDesignDescription":"Triple therapy for 6w vs. 6m after DES","pdfurl":"https://www.jacc.org/doi/pdf/10.1016/j.jacc.2015.02.050","statusUsableDate":"2016-10-01","pmid":"25908066","title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","timestamp":"2021-01-30T20:57:06Z","published":"2015-04-28","abbreviation":"ISAR-TRIPLE","briefResultsDescription":"Triple therapy for 6 weeks not superior to 6 months in regards to net clinical outcome","diseases":"Coronary Artery Disease;Atrial Fibrillation","pageName":"ISAR-TRIPLE","trainingLevel":"Intern","expansion":"Triple therapy in Patients who Require Oral Anticoagulation After Drug-Eluting Stent Implantation","citation":"Fiedler KA et al. \"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation\". J Am Coll Cardiol. 2015. 65(16):1619-30.","pageid":2812},{"title":"Initial Invasive or Conservative Strategy for Stable Coronary Disease","statusUsableDate":"2021-01-28","pmid":"32227755","abbreviation":"ISCHEMIA","published":"2020-04-09","timestamp":"2021-04-07T17:13:36Z","briefDesignDescription":"PCI/CABG vs. medical therapy in stable CAD","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1915922","subspecialties":"Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915922","expansion":"International Study of Comparative Health Effectiveness with Medical and Invasive Approaches","pageid":4153,"citation":"Maron DJ, et al. \"Initial Invasive or Conservative Strategy for Stable Coronary Disease\". The New England Journal of Medicine. 2020. 382(15):1395-1407.","pageName":"ISCHEMIA","diseases":"Coronary Artery Disease","briefResultsDescription":"No difference between PCI/CABG and medical therapy in stable CAD with moderate-severe ischemia","trainingLevel":"Resident"},{"expansion":"Second International Study of Infarct Survival","citation":"ISIS-2 Collaborative Group. \"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction\". The Lancet. 1988. 332(8607):349-360.","pageid":133,"briefResultsDescription":"Mortality benefit of aspirin within 24 hours of acute MI","diseases":"Acute Coronary Syndrome;Myocardial Infarction","pageName":"ISIS-2","trainingLevel":"Resident","pmid":"2899772","statusUsableDate":"2012-03-01","title":"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction","timestamp":"2017-12-20T19:04:02Z","published":"1988-08-13","abbreviation":"ISIS-2","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract","briefDesignDescription":"Aspirin ± streptokinase in acute MI","pdfurl":""},{"expansion":"International Stroke Trial","citation":"IST Collaborative Group. \"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke\". The Lancet. 1997. 349(9065):1569-1581.","pageid":132,"pageName":"IST","briefResultsDescription":"Mortality benefit with aspirin","diseases":"Stroke","trainingLevel":"Intern","title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","statusUsableDate":"2012-03-01","pmid":"9174558","abbreviation":"IST","timestamp":"2016-03-07T04:46:48Z","published":"1997-05-31","briefDesignDescription":"Aspirin in acute ischemic stroke","subspecialties":"Neurology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)04011-7/fulltext","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673697040117.pdf"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807646","briefDesignDescription":"Rosuvastatin for primary CV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807646","subspecialties":"Cardiology;Preventive Medicine","abbreviation":"JUPITER","published":"2008-11-20","timestamp":"2017-12-03T22:36:21Z","title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","statusUsableDate":"2012-06-01","pmid":"18997196","trainingLevel":"resident","pageName":"JUPITER","diseases":"Hyperlipidemia;Coronary Artery Disease;Stroke;Transient Ischemic Attack","briefResultsDescription":"Rosuvastatin delays major CV events","pageid":445,"citation":"Ridker PM, et al. \"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein\". The New England Journal of Medicine. 2008. 359(21):2195-2207.","expansion":"Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin"},{"expansion":"","citation":"Reck M, et al. \"Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer\". The New England Journal of Medicine. 2016. 375(19):1824-1833.","pageid":2846,"pageName":"KEYNOTE-024","briefResultsDescription":"Pembrolizumab improves survival in advanced NSCLC over chemotherapy","diseases":"Lung Cancer","trainingLevel":"Resident","title":"Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer","pmid":"27718847","statusUsableDate":"2016-11-01","abbreviation":"KEYNOTE-024","timestamp":"2017-12-03T22:36:23Z","published":"2016-11-10","briefDesignDescription":"Pembrolizumab vs. chemotherapy in NSCLC","subspecialties":"Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1606774","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774"},{"abbreviation":"LAAOS III","timestamp":"2025-05-15T20:40:37Z","published":"2021-06-03","title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","statusUsableDate":"2025-04-19","pmid":"33999547","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101897","briefDesignDescription":"Surgical LAA occlusion in AF","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2101897","citation":"Whitlock RP, et al. \"Left atrial appendage occlusion during cardiac surgery to prevent stroke\". The New England Journal of Medicine. 2021. 384(22):2081-2091.","pageid":4425,"expansion":"Left Atrial Appendage Occlusion Study III","trainingLevel":"resident","pageName":"LAAOS III","briefResultsDescription":"Surgical LAA associated with fewer AF events","diseases":"Atrial Fibrillation"},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1300439","briefDesignDescription":"Lenalidomide/dexamethasone in smoldering MM","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1300439","subspecialties":"Hematology;Oncology","abbreviation":"","published":"2013-08-01","timestamp":"2018-10-25T17:05:24Z","title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","statusUsableDate":"2018-10-25","pmid":"23902483","trainingLevel":"Fellow","pageName":"LenDex in High-Risk Smoldering Myeloma","diseases":"Multiple Myeloma","briefResultsDescription":"In flawed trial, LenDex improved OS compared to observation","pageid":3706,"citation":"Mateos MV, et al. \"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma\". The New England Journal of Medicine. 2013. 369(5):438-47.","expansion":""},{"statusUsableDate":"2014-07-01","pmid":"24988555","title":"A randomized trial of epidural glucocorticoid injections for spinal stenosis","timestamp":"2017-12-03T22:36:26Z","published":"2014-07-03","abbreviation":"LESS","subspecialties":"Pain Medicine;Physical Medicine and Rehabilitation;Radiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313265","briefDesignDescription":"Epidural steroids in spinal stenosis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313265","expansion":"Lumbar Epidural Steroid Injections for Spinal Stenosis","citation":"Friedly JL, et al. \"A randomized trial of epidural glucocorticoid injections for spinal stenosis\". The New England Journal of Medicine. 2014. 371(1):11-21.","pageid":1883,"briefResultsDescription":"Epidural steroids don't improve pain or disability at six weeks","diseases":"Spinal Stenosis","pageName":"LESS","trainingLevel":"Resident"},{"briefDesignDescription":"Intensive glycemic therapy in the surgical ICU","subspecialties":"Critical Care;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011300","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011300","title":"Intensive Insulin Therapy in Critically Ill Patients","pmid":"11794168","statusUsableDate":"2012-03-01","abbreviation":"Leuven Surgical Trial","timestamp":"2017-01-19T20:18:41Z","published":"2001-11-08","pageName":"Leuven Surgical Trial","briefResultsDescription":"Intensive glycemic control reduces mortality","diseases":"Stress Hyperglycemia","trainingLevel":"Resident","expansion":"","citation":"Van den Berghe G, et al. \"Intensive Insulin Therapy in Critically Ill Patients\". The New England Journal of Medicine. 2001. 345(19):1359-1367.","pageid":139},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300874","briefDesignDescription":"ATRA-ATO vs. ATRA-chemotherapy in APL","subspecialties":"Hematology;Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300874","abbreviation":"","timestamp":"2017-12-03T22:36:27Z","published":"2013-07-11","title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","pmid":"23841729","statusUsableDate":"2014-12-01","trainingLevel":"Fellow","pageName":"Lo-Coco 2013","briefResultsDescription":"ATRA-ATO is noninferior, possibly superior to ATRA-chemotherapy in APL","diseases":"Leukemia","citation":"Lo-Coco F, et al. \"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia\". The New England Journal of Medicine. 2013. 369(2):111-21.","pageid":2285,"expansion":""},{"abbreviation":"LoDoCo","published":"2013-01-29","timestamp":"2021-02-18T20:36:25Z","title":"Low-dose colchicine for secondary prevention of cardiovascular disease","pmid":"23265346","statusUsableDate":"2013-08-01","pdfurl":null,"briefDesignDescription":"Colchicine for stable CAD","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0735109712054782","subspecialties":"Cardiology","pageid":1583,"citation":"Nidorf SM, et al. \"Low-dose colchicine for secondary prevention of cardiovascular disease\". Journal of the American College of Cardiology. 2013. 61(4):404-410.","expansion":"Low-Dose Colchicine","trainingLevel":"Resident","pageName":"LoDoCo","diseases":"Coronary Artery Disease","briefResultsDescription":"Colcicine may reduce complications in stable CAD"},{"statusUsableDate":"2021-02-18","pmid":"32865380","title":"Colchicine in patients with chronic coronary disease","timestamp":"2024-08-08T17:36:48Z","published":"2020-11-05","abbreviation":"LoDoCo2","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2021372","briefDesignDescription":"Colchicine in stable CAD","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021372","expansion":"Low Dose Colchicine 2","citation":"Nidorf SM, et al. \"Colchicine in patients with chronic coronary disease\". The New England Journal of Medicine. 2020. 383(19):1838-1847.","pageid":4359,"briefResultsDescription":"Colchicine with fewer CV events","diseases":"Coronary Artery Disease","pageName":"LoDoCo2","trainingLevel":"Resident"},{"pageName":"LOVIT","briefResultsDescription":"Vitamin C associated with greater risk of poor ICU outcomes","diseases":"Sepsis;Shock","trainingLevel":"Resident","expansion":"Lessening Organ Dysfunction with Vitamin C","citation":"Lamontagne, F, et al. \"Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit\". New England Journal of Medicine. 2022. 386(25):2387-2398.","pageid":5147,"briefDesignDescription":"Vitamin C in sepsis","subspecialties":"Critical Care;Infectious Disease","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2200644","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200644","title":"Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit","statusUsableDate":"2023-10-28","pmid":"35704292","abbreviation":"LOVIT","timestamp":"2025-06-19T18:33:56Z","published":"2022-06-23"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431","briefDesignDescription":"CRT in HFrEF with QRS ≥130 msec and mild symptoms","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906431","subspecialties":"Cardiology","abbreviation":"MADIT-CRT","published":"2009-10-01","timestamp":"2017-12-03T22:37:23Z","title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","pmid":"19723701","statusUsableDate":"2014-04-01","trainingLevel":"Resident","pageName":"MADIT-CRT","diseases":"Heart Failure","briefResultsDescription":"CRT reduces mortality or HF complications in mildly symptomatic HFrEF with prolonged QRS","pageid":1780,"citation":"Moss AJ, et al. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". The New England Journal of Medicine. 2009. 361(14):1329-1338.","expansion":"Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy"},{"pageName":"MADIT-II","briefResultsDescription":"ICD improves survival in post-MI patients with LVEF≤30%","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","trainingLevel":"Resident","expansion":"Multicenter Automatic Defibrillator Implantation Trial II","citation":"Moss AJ, et al. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". The New England Journal of Medicine. 2002. 346(12):877-883.","pageid":385,"briefDesignDescription":"ICD post-MI with HFrEF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013474","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474","title":"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction","pmid":"11907286","statusUsableDate":"2012-03-01","abbreviation":"MADIT-II","timestamp":"2019-03-07T17:25:42Z","published":"2002-03-21"},{"expansion":"Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin","citation":"Cohen AT, et al. \"Rivaroxaban for thromboprophylaxis in acutely ill medical patients\". The New England Journal of Medicine. 2013. 368(6):513-523.","pageid":1272,"pageName":"MAGELLAN","briefResultsDescription":"Rivaroxaban similar to LMWH for prophylaxis, caused more bleeding","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","trainingLevel":"Resident","title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","pmid":"23388003","statusUsableDate":"2013-10-01","abbreviation":"MAGELLAN","timestamp":"2017-12-03T22:37:25Z","published":"2013-02-07","briefDesignDescription":"Rivaroxaban vs. LMWH for VTE prophylaxis","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1111096","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111096"},{"timestamp":"2018-10-08T21:48:25Z","published":"2017-08-27","abbreviation":"MARINER","statusUsableDate":"2018-09-13","pmid":"30145946","title":"Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805090","subspecialties":"Hematology;Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1805090","briefDesignDescription":"Rivaroxaban VTE ppx after medical admission","citation":"Spyropoulos AC, et al. \"Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness\". The New England Journal of Medicine. 2018. e-published 2018-08-26:1-10.","pageid":3699,"expansion":"Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk","trainingLevel":"Resident","briefResultsDescription":"Rivaroxaban does not prevent VTE in medically ill patients","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","pageName":"MARINER"},{"title":"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study","pmid":"19553269","statusUsableDate":"2015-10-01","abbreviation":"MASS","published":"2009-06-24","timestamp":"2017-12-03T22:37:27Z","briefDesignDescription":"US screening for AAA in men","fulltexturl":"http://www.bmj.com/content/338/bmj.b2307.long","subspecialties":"Preventive Medicine;Radiology","pdfurl":"http://www.bmj.com/content/338/bmj.b2307.full.pdf","expansion":"Multicentre Aneurysm Screening Study","pageid":2397,"citation":"Thompson SG, et al. \"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study\". BMJ. 2009. 338:b2307.","pageName":"MASS","diseases":"Abdominal Aortic Aneurysm","briefResultsDescription":"US screening reduces AAA mortality in men","trainingLevel":"Intern"},{"trainingLevel":"resident","pageName":"MASTER DAPT","diseases":"Coronary Artery Disease","briefResultsDescription":"Abbreviated DAPT non-inferior or superior for CVD and/or bleeding events","pageid":4443,"citation":"Valgimigli M, et al. \"Dual antiplatelet therapy after PCI in patients at high bleeding risk\". The New England Journal of Medicine. 2021. 385(18):1643-1655.","expansion":"Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation with an Abbreviated versus Standard DAPT Regimen","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2108749","briefDesignDescription":"Abbreviated DAPT in high-risk bleeding","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2108749","subspecialties":"Cardiology;Hematology","abbreviation":"MASTER DAPT","published":"2021-10-28","timestamp":"2021-11-06T00:38:08Z","title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","pmid":"34449185","statusUsableDate":"2021-10-31"},{"trainingLevel":"student","pageName":"MATCH","diseases":"Stroke","briefResultsDescription":"More major bleeding but no greater efficacy with combination therapy","pageid":1125,"citation":"Diener HC, et al. \"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial\". The Lancet. 2004. 364(9431):331-337.","expansion":"Management of Atherothrombosis with Clopidogrel in High-risk patients","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673604167214.pdf","briefDesignDescription":"ASA/clopidogrel vs. clopidogrel in stroke","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16721-4/fulltext","subspecialties":"Neurology","abbreviation":"MATCH","published":"2004-07-24","timestamp":"2017-12-03T22:37:28Z","title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","pmid":"15276392","statusUsableDate":"2013-04-01"},{"abbreviation":"MATRIX Antithrombin","timestamp":"2023-08-03T18:17:01Z","published":"2015-09-10","title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","pmid":"26324049","statusUsableDate":"2023-07-29","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1507854","briefDesignDescription":"Heparin vs. bivalirudin in PCI","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1507854","citation":"Valgimigli M, et al. \"Bivalirudin or unfractionated heparin in acute coronary syndromes\". New England Journal of Medicine. 2015. 373(11):997-1009.","pageid":2485,"expansion":"Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX)","trainingLevel":"Resident","pageName":"MATRIX Antithrombin","briefResultsDescription":"Bivalirudin equivalent to heparin for PCI","diseases":"Coronary Artery Disease"},{"citation":"Harris PNA, et al. \"Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae Bloodstream Infection and ceftriaxone resistance: A randomized clinical trial\". JAMA. 2018. 320(10):984-994.","pageid":4422,"expansion":"","trainingLevel":"Resident","briefResultsDescription":"Piperacillin-tazobactam is inferior to meropenem for ESBL bacteremia","diseases":"ESBL Bacteremia","pageName":"MERINO","timestamp":"2022-04-21T19:13:41Z","published":"2018-09-11","abbreviation":"MERINO","statusUsableDate":"2022-04-21","pmid":"30208454","title":"Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae Bloodstream Infection and ceftriaxone resistance: A randomized clinical trial","pdfurl":"","subspecialties":"Infectious Disease","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/2702145","briefDesignDescription":"Piperacillin-tazobactam for ESBL bacteremia"},{"abbreviation":"MERIT-HF","published":"1999-06-12","timestamp":"2015-08-24T03:51:03Z","title":"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure","pmid":"10376614","statusUsableDate":"2012-03-01","pdfurl":"","briefDesignDescription":"Metoprolol in HFrEF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402","subspecialties":"Cardiology","pageid":130,"citation":"Fagerberg B, et al. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". The Lancet. 1999. 353(9169):2001-7.","expansion":"Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure","trainingLevel":"Resident","pageName":"MERIT-HF","diseases":"Heart Failure","briefResultsDescription":"Metoprolol improves survival in NYHA II-IV HFrEF"},{"briefDesignDescription":"Surgery vs. PT in OA with meniscal tear","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301408","subspecialties":"Surgery;Physical Medicine and Rehabilitation","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301408","title":"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis","statusUsableDate":"2013-09-01","pmid":"23506518","abbreviation":"METEOR","published":"2013-05-02","timestamp":"2017-12-03T22:37:29Z","pageName":"METEOR","diseases":"Meniscal Tear;Osteoarthritis","briefResultsDescription":"Surgery no better than PT alone","trainingLevel":"Student","expansion":"Meniscal Tear in Osteoarthritis Research","pageid":1429,"citation":"Katz JN, et al. \"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis\". The New England Journal of Medicine. 2013. 368(18):1675-1684."},{"fulltexturl":"","subspecialties":"Cardiology","briefDesignDescription":"Early surgery for MR","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/927436/joi130034.pdf","statusUsableDate":"2014-02-01","pmid":"23942679","title":"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets","published":"2013-08-14","timestamp":"2017-12-03T22:37:31Z","abbreviation":"MIDA","diseases":"Mitral Regurgitation","briefResultsDescription":"Early surgery reduces mortality in MR","pageName":"MIDA","trainingLevel":"Resident","expansion":"Mitral Regurgitation International Database","pageid":1787,"citation":"Suri RM, et al. \"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets\". JAMA. 2013. 310(6):609-616."},{"expansion":"Modifying the Impact of ICU-Associated Neurological Dysfunction–USA","citation":"Girard TD, et al. \"Haloperidol and ziprasidone for treatment of delirium in critical illness\". The New England Journal of Medicine. 2018. ePub 2018-10-22:1-12.","pageid":3741,"pageName":"MIND-USA","briefResultsDescription":"Antipsychotics don't reduce days without delirium or coma in ICU","diseases":"Delirium;Critical Illness","trainingLevel":"resident","title":"Haloperidol and ziprasidone for treatment of delirium in critical illness","pmid":"30346242","statusUsableDate":"2018-11-30","abbreviation":"MIND-USA","timestamp":"2022-11-02T14:33:46Z","published":"2018-10-22","briefDesignDescription":"Antipsychotics in ICU delirium","subspecialties":"Psychiatry;Critical Care","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1808217","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1808217"},{"timestamp":"2020-10-29T17:14:07Z","published":"2001-04-04","abbreviation":"MIRACL","pmid":"11277825","statusUsableDate":"2012-03-01","title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes","pdfurl":"http://jama.ama-assn.org/content/285/13/1711.full.pdf","subspecialties":"Cardiology","fulltexturl":"http://jama.ama-assn.org/content/285/13/1711.long","briefDesignDescription":"Atorvastatin in UA/NSTEMI","citation":"Schwartz GG, et al. \"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes\". Journal of the American Medical Association. 2001. 285(13):1711-1718.","pageid":432,"expansion":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering","trainingLevel":"Resident","briefResultsDescription":"Atorvastatin reduced rate of CV events after UA/NSTEMI","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Hyperlipidemia","pageName":"MIRACL"},{"briefDesignDescription":"tPA and/or DNase for pleural infection","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1012740","subspecialties":"Pulmonology;Infectious Disease","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1012740","title":"Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection","statusUsableDate":"2020-12-31","pmid":"21830966","abbreviation":"MIST2","published":"2011-08-11","timestamp":"2021-01-06T13:53:52Z","pageName":"MIST2","diseases":"Pleural Infection","briefResultsDescription":"tPA+DNase with greatest reduction in size of effusion","trainingLevel":"Fellow","expansion":"Second MIST trial","pageid":3757,"citation":"Rahman NM, et al. \"Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection\". The New England Journal of Medicine. 2011. 365(6):518-526."},{"trainingLevel":"Resident","pageName":"MITIGATE","diseases":"Acute Respiratory Infection","briefResultsDescription":"Antibiotic stewardship reduced unnecessary prescriptions","pageid":4102,"citation":"Yadav K, et al. \"A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings\". Academic Emergency Medicine. 2019. 26(7):719-731.","expansion":"A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings","pdfurl":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acem.13690?download","briefDesignDescription":"Antibiotic stewardship in respiratory infections","fulltexturl":"https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.13690","subspecialties":"Emergency Medicine;Infectious Disease","abbreviation":"MITIGATE","published":"2019-07-01","timestamp":"2024-05-18T01:31:16Z","title":"A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings","statusUsableDate":"2024-04-29","pmid":"31215721"},{"abbreviation":"MODIFY I and II","published":"2017-01-26","timestamp":"2023-04-12T13:12:04Z","title":"Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection","statusUsableDate":"2017-05-01","pmid":"28121498","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602615","briefDesignDescription":"Bezlotoxumab for C. diff recurrence prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602615","subspecialties":"Gastroenterology;Infectious Disease","pageid":2931,"citation":"Wilcox MH, et al. \"Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection\". New England Journal of Medicine. 2017. 376(4):305-317.","expansion":"","trainingLevel":"Resident","pageName":"MODIFY I and II","diseases":"Clostridium difficile","briefResultsDescription":"Bezlotoxumab lowers recurrence rate of C. diff infection"},{"citation":"Mehra MR, et al. \"Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure\". The New England Journal of Medicine. 2018. 378(15):1386-95.","pageid":3605,"expansion":"Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3","trainingLevel":"Resident","briefResultsDescription":"Centrifugal-flow LVAD superior to axial-flow LVAD in advanced HF","diseases":"Heart Failure","pageName":"MOMENTUM 3","timestamp":"2018-06-29T18:08:40Z","published":"2018-04-12","abbreviation":"MOMENTUM 3","statusUsableDate":"2018-06-29","pmid":"29526139","title":"Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800866","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1800866","briefDesignDescription":"Centrifugal-flow LVAD vs. axial-flow LVAD in advanced HF"},{"pageName":"MOPETT","briefResultsDescription":"Low-dose tPA reduces pulmonary HTN in submassive PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","trainingLevel":"Intern","expansion":"Moderate Pulmonary Embolism Treated with Thrombolysis","citation":"Sharifi M, et al. \"Moderate pulmonary embolism treated with thrombolysis\". The American Journal of Cardiology. 2013. 111(2):273-277.","pageid":1785,"briefDesignDescription":"Low-dose tPA for submassive PE","subspecialties":"Critical Care;Pulmonology;Cardiology","fulltexturl":"http://www.ajconline.org/article/S0002-9149%2812%2902205-9/fulltext","pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914912022059.pdf","title":"Moderate pulmonary embolism treated with thrombolysis","pmid":"23102885","statusUsableDate":"2014-02-01","abbreviation":"MOPETT","timestamp":"2017-12-03T22:37:34Z","published":"2013-01-15"},{"pageid":1055,"citation":"Moseley JB, et al. \"A controlled trial of arthroscopic surgery for osteoarthritis of the knee\". The New England Journal of Medicine. 2002. 347(2):81-88.","expansion":"","trainingLevel":"Resident","diseases":"Osteoarthritis","briefResultsDescription":"No difference between groups at 2 years","pageName":"Moseley Trial","published":"2002-07-11","timestamp":"2017-12-03T22:37:42Z","abbreviation":"","statusUsableDate":"2012-11-01","pmid":"12110735","title":"A controlled trial of arthroscopic surgery for osteoarthritis of the knee","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013259","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013259","subspecialties":"Surgery;Physical Medicine and Rehabilitation","briefDesignDescription":"Arthroscopy in knee OA"},{"pmid":"12063369","statusUsableDate":"2023-03-30","title":"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction","timestamp":"2023-03-30T22:49:47Z","published":"2002-06-13","abbreviation":"MOST","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013040","briefDesignDescription":"Dual- vs. single-chamber pacing in bradycardia","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013040","expansion":"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction","citation":"Lamas GA, et al. \"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction\". The New England Journal of Medicine. 2002. 346(24):1854-62.","pageid":2710,"briefResultsDescription":"Dual-chamber pacing superior to single-chamber ventricular pacing","diseases":"Bradycardia","pageName":"MOST","trainingLevel":"Resident"},{"pageid":2816,"citation":"Von Hoff DD, et al. \"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine\". The New England Journal of Medicine. 2013. 369(18):1691-1703.","expansion":"Metastatic Pancreatic Adenocarcinoma Clinical Trial","trainingLevel":"Resident","diseases":"Pancreatic Cancer","briefResultsDescription":"Gemcicabine/nab-paclitaxel improves OS in metastatic pancreatic cancer compared to gemcitabine","pageName":"MPACT","published":"2013-10-31","timestamp":"2017-12-03T22:37:36Z","abbreviation":"MPACT","statusUsableDate":"2016-08-01","pmid":"24131140","title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1304369","subspecialties":"Oncology","briefDesignDescription":"Gemcitabine/nab-paclitaxel in pancreatic cancer"},{"abbreviation":"MR CLEAN","timestamp":"2016-03-10T04:00:44Z","published":"2015-01-01","title":"A randomized trial of intraarterial treatment for acute ischemic stroke","pmid":"25517348","statusUsableDate":"2012-03-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411587","briefDesignDescription":"IA therapy for proximal large artery strokes","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1411587","citation":"Berkhemer OA, et al. \"A randomized trial of intraarterial treatment for acute ischemic stroke\". The New England Journal of Medicine. 2015. 372(1):11-20.","pageid":2373,"expansion":"","trainingLevel":"Intern","pageName":"MR CLEAN","briefResultsDescription":"IA therapy improves outcome without increased mortality or ICH","diseases":"Stroke"},{"title":"A trial of imaging selection and endovascular treatment for ischemic stroke","statusUsableDate":"2015-05-01","pmid":"23394476","abbreviation":"MR RESCUE","published":"2013-03-07","timestamp":"2017-12-03T22:37:37Z","briefDesignDescription":"Thrombectomy vs. standard care in stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1212793","subspecialties":"Neurology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212793","expansion":"","pageid":2363,"citation":"Kidwell CS, et al. \"A trial of imaging selection and endovascular treatment for ischemic stroke\". The New England Journal of Medicine. 2013. 368(10):914-923.","pageName":"MR RESCUE","diseases":"Stroke","briefResultsDescription":"Imaging did not id pts who would benefit from endovascular thrombectomy for acute ischemic stroke.","trainingLevel":"Fellow"},{"subspecialties":"Cardiology;Preventive Medicine","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/377969","briefDesignDescription":"CHD risk modification for CHD mortality prevention","pdfurl":"","pmid":"7050440","statusUsableDate":"2021-06-24","title":"Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group","timestamp":"2021-06-25T23:51:15Z","published":"1982-09-24","abbreviation":"MRFIT","briefResultsDescription":"CHD risk modification did not lower 7 year mortality","diseases":"Coronary Artery Disease","pageName":"MRFIT","trainingLevel":"Student","expansion":"Multiple Risk Factor Intervention Trial","citation":"MRFIT Writers. \"Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group\". JAMA. 1982. 248(12):1465-1477.","pageid":2455},{"expansion":"Multicenter Study of Hydroxyurea in Sickle-Cell Anemia","citation":"Charache S, et al. \"Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia\". The New England Journal of Medicine. 1995. 332(20):1317-1322.","pageid":2797,"briefResultsDescription":"Hydroxyurea ↓frequency of painful crises in SCD","diseases":"Sickle Cell Disease","pageName":"MSH","trainingLevel":"Student","pmid":"7715639","statusUsableDate":"2016-07-01","title":"Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia","timestamp":"2021-01-05T21:08:12Z","published":"1995-05-18","abbreviation":"MSH","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199505183322001","briefDesignDescription":"Hydroxyurea in sickle-cell disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199505183322001"},{"fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1310460","subspecialties":"Surgery;Oncology","briefDesignDescription":"SLNB vs. surveillance in melanoma","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1310460","statusUsableDate":"2024-03-28","pmid":"24521106","title":"Multicenter Selective Lymphadenectomy Trial","published":"2014-02-13","timestamp":"2024-03-28T20:26:52Z","abbreviation":"MSLT-I","diseases":"Melanoma","briefResultsDescription":"SLBN did not improve melanoma-specific survival compared to observation","pageName":"MSLT-1","trainingLevel":"Fellow","expansion":"Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma","pageid":3521,"citation":"Morton DL, et al. \"Multicenter Selective Lymphadenectomy Trial\". The New England Journal of Medicine. 2014. 370(7):599-609."},{"briefResultsDescription":"ICD placement better than antiarrhythmics in mild HF with NSVT","diseases":"Ventricular Tachycardia","pageName":"MUSTT","trainingLevel":"Resident","expansion":"Multicenter Unsustained Tachycardia Trial","citation":"Buxton AE et al. \"A randomized study of the prevention of sudden death in patients with coronary artery disease\". New Engl J Med. 1999. 341(25):1882-90.","pageid":2872,"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199912163412503","briefDesignDescription":"ICD and antiarrhythmics in mild HFrEF and NSVT","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199912163412503","pmid":"10601507","statusUsableDate":"2016-12-01","title":"A randomized study of the prevention of sudden death in patients with coronary artery disease","timestamp":"2022-12-01T19:00:15Z","published":"1999-12-16","abbreviation":"MUSTT"},{"abbreviation":"NA-ACCORD","published":"2009-04-30","timestamp":"2017-12-03T22:37:44Z","title":"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival","pmid":"19339714","statusUsableDate":"2014-11-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807252","briefDesignDescription":"Early vs. delayed ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807252","subspecialties":"Infectious Disease","pageid":1039,"citation":"Kitahata MM, et al. \"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival\". The New England Journal of Medicine. 2009. 360(18):1815-1826.","expansion":"North American AIDS Cohort Collaboration on Research and Design","trainingLevel":"Resident","pageName":"NA-ACCORD","diseases":"HIV","briefResultsDescription":"Early ART in HIV improves survival"},{"expansion":"","pageid":4063,"citation":"Wong A. \"The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose\". Hepatology. 2019. 69(2):774-784.","diseases":"Acetaminophen Overdose","briefResultsDescription":"No difference between 12 vs. 20 hours of NAC for APAP overdose","pageName":"NACSTOP","trainingLevel":"resident","statusUsableDate":"2022-07-15","pmid":"30125376","title":"The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose","published":"2019-02-02","timestamp":"2022-07-29T01:52:18Z","abbreviation":"NACSTOP","fulltexturl":"https://doi.org/10.1002/hep.30224","subspecialties":"Emergency Medicine;Critical Care","briefDesignDescription":"12 vs. 20 hours of NAC in APAP overdose","pdfurl":"https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30224"},{"briefDesignDescription":"CEA in symptomatic carotid stenosis","subspecialties":"Surgery;Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199811123392002","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199811123392002","title":"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis","pmid":"9811916","statusUsableDate":"2012-03-01","abbreviation":"NASCET","timestamp":"2020-08-01T21:47:56Z","published":"1998-11-12","pageName":"NASCET","briefResultsDescription":"CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis","diseases":"Carotid Stenosis;Stroke","trainingLevel":"Intern","expansion":"North American Symptomatic Carotid Endarterectomy Trial","citation":"Barnett HJ, et al. \"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis\". The New England Journal of Medicine. 1998. 339(20):1415-25.","pageid":128},{"timestamp":"2022-10-19T13:06:44Z","published":"2018-06-07","abbreviation":"NAVIGATE ESUS","statusUsableDate":"2022-07-28","pmid":"29766772","title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1802686","subspecialties":"Neurology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1802686","briefDesignDescription":"Rivaroxaban vs. ASA for ESUS (stroke)","citation":"Hart RG, et al. \"Rivaroxaban for stroke prevention after embolic stroke of undetermined source\". The New England Journal of Medicine. 2018. 378(23):2191-2201.","pageid":3665,"expansion":"New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source\nof Undetermined Source","trainingLevel":"Resident","briefResultsDescription":"Rivaroxaban is not superior to ASA for stroke","diseases":"Stroke","pageName":"NAVIGATE ESUS"},{"published":"1981-11-12","timestamp":"2017-12-03T22:37:45Z","abbreviation":"NCDS","pmid":"7027040","statusUsableDate":"2013-07-01","title":"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198111123052003","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198111123052003","subspecialties":"Nephrology","briefDesignDescription":"Dialysis prescriptions in ESRD","pageid":504,"citation":"Lowrie EG, et al. \"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study\". The New England Journal of Medicine. 1981. 305(20):1176-1181.","expansion":"The National Cooperative Dialysis Study","trainingLevel":"Fellow","diseases":"Chronic Kidney Disease","briefResultsDescription":"Low BUN better tolerated, fewer hospitalizations","pageName":"NCDS"},{"published":"2015-12-10","timestamp":"2017-12-03T22:37:47Z","abbreviation":"NEAT-HFpEF","pmid":"26549714","statusUsableDate":"2016-04-01","title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510774","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1510774","subspecialties":"Cardiology","briefDesignDescription":"Nitrates for activity tolerance in HFpEF","pageid":2668,"citation":"Redfield MM, et al. \"Isosorbide mononitrate in heart failure with preserved ejection fraction\". New England Journal of Medicine. 2015. 373(24):2314-2324.","expansion":"Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction","trainingLevel":"Resident","diseases":"Heart Failure","briefResultsDescription":"Nitrates do not improve activity tolerance in HFpEF","pageName":"NEAT-HFpEF"},{"expansion":"National Emphysema Treatment Trial","pageid":1604,"citation":"Fishman A, et al. \"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema\". The New England Journal of Medicine. 2003. 348(21):2059-2073.","diseases":"Chronic Obstructive Pulmonary Disease;Emphysema","briefResultsDescription":"LVRS benefits apical emphysema and those with low exercise function","pageName":"NETT","trainingLevel":"Resident","pmid":"12759479","statusUsableDate":"2013-08-01","title":"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","published":"2003-05-22","timestamp":"2017-12-03T22:37:49Z","abbreviation":"NETT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030287","subspecialties":"Surgery;Pulmonology","briefDesignDescription":"Lung volume reduction in COPD","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030287"},{"briefResultsDescription":"Increased mortality targeting euglycemia","diseases":"Stress Hyperglycemia","pageName":"NICE-SUGAR","trainingLevel":"Intern","expansion":"Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation","citation":"Finfer S, et al. \"Intensive versus conventional glucose control in critically ill patients\". The New England Journal of Medicine. 2009. 360(13):1283-1297.","pageid":26,"subspecialties":"Critical Care;Endocrinology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0810625","briefDesignDescription":"Intensive glycemic therapy in ICU","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810625","statusUsableDate":"2012-03-01","pmid":"19318384","title":"Intensive versus conventional glucose control in critically ill patients","timestamp":"2020-02-06T15:48:50Z","published":"2009-03-26","abbreviation":"NICE-SUGAR"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199512143332401","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199512143332401","subspecialties":"Neurology;Critical Care","briefDesignDescription":"tPA in ischemic stroke","published":"1995-12-14","timestamp":"2015-08-24T19:41:34Z","abbreviation":"NINDS","pmid":"7477192","statusUsableDate":"2012-03-01","title":"Tissue Plasminogen Activator for Acute Ischemic Stroke","trainingLevel":"MedicalStudent","diseases":"Stroke","briefResultsDescription":"tPA within 3 hours improved outcomes","pageName":"NINDS","pageid":131,"citation":"Marler JR, et al. \"Tissue Plasminogen Activator for Acute Ischemic Stroke\". The New England Journal of Medicine. 1995. 333(24):1581-1587.","expansion":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study"},{"briefDesignDescription":"CT vs. CXR in lung cancer screening","subspecialties":"Pulmonology;Oncology;Preventive Medicine","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102873","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102873","title":"Reduced lung cancer mortality with low-dose computed tomographic screening","pmid":"21714641","statusUsableDate":"2012-10-01","abbreviation":"NLST","timestamp":"2017-12-03T22:37:50Z","published":"2011-08-04","pageName":"NLST","briefResultsDescription":"Low-dose CT reduces lung cancer mortality compared to CXR","diseases":"Lung Cancer","trainingLevel":"Resident","expansion":"National Lung Screening Trial","citation":"Berg CD, et al. \"Reduced lung cancer mortality with low-dose computed tomographic screening\". The New England Journal of Medicine. 2011. 365(5):395-409.","pageid":980},{"fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2208375","subspecialties":"Preventive Medicine","briefDesignDescription":"Invitations for screening colonoscopy","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208375","statusUsableDate":"2022-10-14","pmid":"36214590","title":"Effect of colonoscopy screening on risks of colorectal cancer and related death","published":"2022-10-09","timestamp":"2022-12-01T20:16:39Z","abbreviation":"NordICC","diseases":"Colorectal Cancer","briefResultsDescription":"Invitations for screening colonoscopy don't lower mortality","pageName":"NordICC","trainingLevel":"resident","expansion":"Nordic-European Initiative on Colorectal Cancer","pageid":5065,"citation":"Bretthauer M, et al. \"Effect of colonoscopy screening on risks of colorectal cancer and related death\". The New England Journal of Medicine. 2022. 1-10."},{"subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1607991","briefDesignDescription":"Drug-eluting stent vs. bare-metal stent in CAD","pdfurl":"http://www.nejm.org/pdf/full/10.1056/NEJMoa1607991","pmid":"27572953","statusUsableDate":"2016-10-01","title":"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease","timestamp":"2021-01-30T21:12:28Z","published":"2016-08-30","abbreviation":"NORSTENT","briefResultsDescription":"Drug-eluting stent superior to bare-metal stent in CAD","diseases":"Coronary Artery Disease","pageName":"NORSTENT","trainingLevel":"Resident","expansion":"Drug-Eluting or Bare-Metal Stents for Percutaneous Coronary Intervention in Stable or Unstable Coronary Artery Disease","citation":"Bonaa KH, et al. \"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease\". The New England Journal of Medicine. 2016. 375:1242-1252.","pageid":2832},{"trainingLevel":"Student","diseases":"Chronic Obstructive Pulmonary Disease","briefResultsDescription":"Continuous oxygen reduces mortality in COPD with hypoxemia","pageName":"NOTT","pageid":1788,"citation":"NOTT Group. \"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group\". Annals of Internal Medicine. 1980. 93(3):91-398.","expansion":"Nocturnal Oxygen Therapy Trial","pdfurl":"","fulltexturl":"http://annals.org/article.aspx?articleid","subspecialties":"Pulmonology","briefDesignDescription":"Continuous vs. nocturnal oxygen in COPD","published":"1980-09-01","timestamp":"2017-12-03T22:37:53Z","abbreviation":"NOTT","statusUsableDate":"2014-01-01","pmid":"6776858","title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group"},{"pageName":"Novel START","briefResultsDescription":"ICS+LABA PRN with fewer overall, but more severe exacerbations","diseases":"Asthma","trainingLevel":"resident","expansion":"Novel Symbicort Turbuhaler Asthma Reliever Therapy","citation":"Beasley R, et al. \"Controlled trial of budesonide+formoterol as needed for mild asthma\". The New England Journal of Medicine. 2019. 380(21):2020-2030.","pageid":4142,"briefDesignDescription":"ICS+LABA PRN in mild asthma","subspecialties":"Pulmonology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1901963","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901963","title":"Controlled trial of budesonide+formoterol as needed for mild asthma","pmid":"31112386","statusUsableDate":"2021-05-20","abbreviation":"Novel START","timestamp":"2021-05-31T17:57:36Z","published":"2019-05-23"},{"briefResultsDescription":"Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND","diseases":"Breast Cancer","pageName":"NSABP B-32","trainingLevel":"Student","expansion":"National Surgical Adjuvant Breast and Bowel Project Trial B-32","citation":"Krag DN, et al. \"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial\". Lancet Oncology. 2010. 11(10):927-933.","pageid":1167,"subspecialties":"Oncology","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/","briefDesignDescription":"Sentinel LN biopsy in breast cancer","pdfurl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/pdf/nihms-250175.pdf","statusUsableDate":"2013-02-01","pmid":"20863759","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","timestamp":"2018-09-06T17:17:20Z","published":"2010-10-01","abbreviation":"NSABP B-32"},{"published":"1998-09-16","timestamp":"2017-12-03T22:37:56Z","abbreviation":"NSABP P-1","pmid":"9747868","statusUsableDate":"2012-10-01","title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","pdfurl":"http://jnci.oxfordjournals.org/content/90/18/1371.full.pdf+html","fulltexturl":"http://jnci.oxfordjournals.org/content/90/18/1371.long","subspecialties":"Oncology;Preventive Medicine","briefDesignDescription":"Tamoxifen in breast cancer prevention","pageid":1049,"citation":"Fisher B, et al. \"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study\". Journal of the National Cancer Institute. 1998. 90(18):1371-1388.","expansion":"National Surgical Adjuvant Breast and Bowel Project, Prevention-1","trainingLevel":"resident","diseases":"Breast Cancer","briefResultsDescription":"Tamoxifen reduces breast cancer incidence by 48%","pageName":"NSABP P-1"},{"briefDesignDescription":"Fondaparinux vs. enoxaparin in NSTE-ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa055443","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa055443","title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","pmid":"16537663","statusUsableDate":"2018-04-27","abbreviation":"OASIS-5","published":"2006-04-06","timestamp":"2018-04-26T20:18:28Z","pageName":"OASIS-5","diseases":"Acute Coronary Syndrome;Myocardial Infarction","briefResultsDescription":"Fondaparinux is non-inferior to enoxaparin in NSTE-ACS","trainingLevel":"intern","expansion":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes","pageid":2484,"citation":"Yusuf S, et al. \"Comparison of fondaparinux and enoxaparin in acute coronary syndromes\". The New England Journal of Medicine. 2006. 354(14):1464-1476."},{"expansion":"Occluded Artery Trial","citation":"Hochman J.S., et al. \"Coronary Intervention for Persistent Occlusion after Myocardial Infarction\". The New England Journal of Medicine. 2006. 355(23):2395-2407.","pageid":2676,"briefResultsDescription":"PCI+OMT no better than OMT 3-28 days after MI","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","pageName":"OAT","trainingLevel":"Intern","pmid":"17105759","statusUsableDate":"2016-06-01","title":"Coronary Intervention for Persistent Occlusion after Myocardial Infarction","timestamp":"2020-09-14T19:27:00Z","published":"2006-12-07","abbreviation":"OAT","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa066139","briefDesignDescription":"PCI+OMT vs. OMT 3-28 days after MI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa066139"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501031","subspecialties":"Cardiology","briefDesignDescription":"PCSK9 inhibitor alirocumab for HLD","published":"2015-04-16","timestamp":"2017-12-14T19:48:32Z","abbreviation":"ODYSSEY LONG TERM","statusUsableDate":"2015-09-01","pmid":"25773378","title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","trainingLevel":"Student","diseases":"Hyperlipidemia","briefResultsDescription":"Alirocumab lowers LDL, reduces non-fatal MI","pageName":"ODYSSEY LONG TERM","pageid":2423,"citation":"Robinson JG, et al. \"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events\". The New England Journal of Medicine. 2015. 372(16):1489-1499.","expansion":"Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not\nAdequately Controlled with Their Lipid Modifying Therapy"},{"briefDesignDescription":"IV PPI for GI bleeds","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200008033430501","subspecialties":"Gastroenterology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200008033430501","title":"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer","pmid":"10922420","statusUsableDate":"2012-03-01","abbreviation":null,"published":"2000-08-03","timestamp":"2016-04-01T23:27:21Z","pageName":"Omeprazole in Peptic Ulcer Bleeding","diseases":"Gastrointestinal Hemorrhage","briefResultsDescription":"IV omeprazole reduced 30-day rebleeding","trainingLevel":"Resident","expansion":null,"pageid":247,"citation":"Lau JYW, et al. \"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer\". The New England Journal of Medicine. 2000. 343(5):310-316."},{"citation":"Wazni OM, et al. \"Left atrial appendage closure after ablation for atrial fibrillation\". The New England Journal of Medicine. 2025. 392(13):1277-1287.","pageid":5693,"expansion":"cOmParison of anTIcoagulation with left atrial appendage clOsure after atrial fibrillation ablatioN","trainingLevel":"Student","briefResultsDescription":"LAA closure non-inferior or superior for AF outcomes vs. anticoagulation","diseases":"Atrial Fibrillation","pageName":"OPTION","timestamp":"2025-05-16T15:04:11Z","published":"2025-04-03","abbreviation":"OPTION","statusUsableDate":"2025-04-20","pmid":"39555822","title":"Left atrial appendage closure after ablation for atrial fibrillation","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2408308","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2408308","briefDesignDescription":"LAA closure vs. anticoagulation in AF"},{"title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","pmid":"23861512","statusUsableDate":"2014-06-01","abbreviation":"ORBIT-AF","published":"2013-08-13","timestamp":"2019-04-23T20:57:22Z","briefDesignDescription":"ASA/warfarin vs. warfarin in AF","fulltexturl":"http://circ.ahajournals.org/content/128/7/721.long","subspecialties":"Cardiology;Neurology","pdfurl":"http://circ.ahajournals.org/content/128/7/721.full.pdf","expansion":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation","pageid":1769,"citation":"Steinberg BA, et al. \"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry\". Circulation. 2013. 128(7):721-8.","pageName":"ORBIT-AF","diseases":"Atrial Fibrillation;Stroke","briefResultsDescription":"ASA/warfarin associated with more bleeding, fewer CV events","trainingLevel":"Fellow"},{"diseases":"Coronary Artery Disease","briefResultsDescription":"PCI not superior to medical therapy in stable angina","pageName":"ORBITA","trainingLevel":"Resident","expansion":"Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina","pageid":3499,"citation":"Al-Lamee R, et al. \"Percutaneous coronary intervention in stable angina\". Lancet. 2017. epub 2017-11-02:1-11.","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32714-9/fulltext","subspecialties":"Cardiology","briefDesignDescription":"PCI vs. medical therapy in stable angina","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32714-9.pdf","statusUsableDate":"2017-12-14","pmid":"29103656","title":"Percutaneous coronary intervention in stable angina","published":"2017-11-02","timestamp":"2018-03-08T17:42:17Z","abbreviation":"ORBITA"},{"expansion":"Oscillation for Acute Respiratory Distress Syndrome Treated Early","citation":"Ferguson ND, et al. \"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome\". The New England Journal of Medicine. 2013. 368(9):795-805.","pageid":1254,"pageName":"OSCILLATE","briefResultsDescription":"High-frequency oscillatory vent may harm in early ARDS","diseases":"Acute Respiratory Distress Syndrome","trainingLevel":"Resident","title":"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome","pmid":"23339639","statusUsableDate":"2013-09-01","abbreviation":"Oscillate","timestamp":"2017-12-03T22:38:05Z","published":"2013-02-28","briefDesignDescription":"High-frequency oscillatory vent in early ARDS","subspecialties":"Critical Care;Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215554","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215554"},{"abbreviation":"OVIVA","timestamp":"2019-10-08T15:46:44Z","published":"2019-01-31","title":"Oral versus Intravenous Antibiotics for Bone and Joint Infection","statusUsableDate":"2019-04-11","pmid":"30699315","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1710926","briefDesignDescription":"PO vs. IV antibiotics for bone/joint infection","subspecialties":"Infectious Disease","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1710926","citation":"Li HK, et al. \"Oral versus Intravenous Antibiotics for Bone and Joint Infection\". The New England Journal of Medicine. 2019. 380(5):425-436.","pageid":3542,"expansion":"Oral versus Intravenous Antibiotics for Bone and Joint Infection","trainingLevel":"student","pageName":"OVIVA","briefResultsDescription":"PO non-inferior to IV antibiotics for selected bone/joint infections","diseases":"Osteomyelitis"},{"pmid":"28885881","statusUsableDate":"2025-06-12","title":"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer","published":"2017-09-08","timestamp":"2025-06-05T18:03:47Z","abbreviation":"PACIFIC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1709937","subspecialties":"Oncology;Radiation Oncology","briefDesignDescription":"Durvalumab vs. placebo as consolidation in NSCLC","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709937","expansion":"","pageid":2969,"citation":"Antonia SJ et al. \"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer\". The New England Journal of Medicine. 2017. 377(20):1919-1929.","diseases":"Lung Cancer","briefResultsDescription":"Durvalumab increases PFS in NSCLC","pageName":"PACIFIC","trainingLevel":"Fellow"},{"pdfurl":"https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2806976/jamainternal_copaescu_2023_oi_230043_1693517098.10841.pdf","subspecialties":"Infectious Disease","fulltexturl":"https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2806976","briefDesignDescription":"Penicillin allergy rule-out","timestamp":"2025-01-30T20:34:51Z","published":"2023-09-01","abbreviation":"PALACE","statusUsableDate":"2025-01-29","pmid":"37459086","title":"Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy","trainingLevel":"student","briefResultsDescription":"Penicillin 1-step rule out noninferior to 2-step","diseases":"Penicillin Allergy","pageName":"PALACE","citation":"Copaescu AM, et al. \"Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy\". JAMA Internal Med. 2023. 183(9):944-952.","pageid":5406,"expansion":"The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0908821","subspecialties":"Surgery;Gastroenterology","briefDesignDescription":"Step-up approach to pancreatitis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0908821","statusUsableDate":"2012-03-01","pmid":"20410514","title":"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis","published":"2010-04-22","timestamp":"2019-08-31T19:06:09Z","abbreviation":"PANTER","diseases":"Pancreatitis","briefResultsDescription":"Step-up approach reduces major complications and death","pageName":"PANTER","trainingLevel":"Fellow","expansion":"Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis","pageid":398,"citation":"van Santvoort HC, et al. \"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis\". The New England Journal of Medicine. 2010. 362(16):1491-502."},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409077","subspecialties":"Cardiology","briefDesignDescription":"ARNI vs. enalapril in HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409077","pmid":"25176015","statusUsableDate":"2014-09-01","title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","published":"2014-08-30","timestamp":"2021-07-28T06:20:24Z","abbreviation":"PARADIGM-HF","diseases":"Heart Failure","briefResultsDescription":"ARNI reduces mortality in HFrEF","pageName":"PARADIGM-HF","trainingLevel":"Resident","expansion":"Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure","pageid":2163,"citation":"McMurray JJV, et al. \"Angiotensin-neprilysin inhibition versus enalapril in heart failure\". The New England Journal of Medicine. 2014. 371(11):993-1004."},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908655","briefDesignDescription":"ARNI in symptomatic HFpEF","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1908655","subspecialties":"Cardiology","abbreviation":"PARAGON-HF","published":"2019-10-24","timestamp":"2020-07-02T17:06:36Z","title":"Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction","statusUsableDate":"2020-07-02","pmid":"32187481","trainingLevel":"Resident","pageName":"PARAGON-HF","diseases":"Heart Failure","briefResultsDescription":"No benefit from ARNI in HFpEF","pageid":4184,"citation":"Solomon SD, et al. \"Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction\". The New England Journal of Medicine. 2019. 381(17):1609-1620.","expansion":"Prospective Comparison of ARNI Global Outcomes in HF with Preserved Ejection Fraction"},{"expansion":"","citation":"Paz-Ares LG, et al. \"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer\". Journal of Clinical Oncology. 2013. 31(23):2895-902.","pageid":1606,"pageName":"PARAMOUNT","briefResultsDescription":"Maintenance pemetrexed improves PFS and OS following induction with cisplatin/pemetrexed","diseases":"Lung Cancer","trainingLevel":"Fellow","title":"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer","statusUsableDate":"2014-01-01","pmid":"23835707","abbreviation":"PARAMOUNT","timestamp":"2017-12-03T22:38:08Z","published":"2013-08-10","briefDesignDescription":"Maintenance pemetrexed in lung cancer","subspecialties":"Oncology","fulltexturl":"http://jco.ascopubs.org/content/31/23/2895.long","pdfurl":"http://jco.ascopubs.org/content/31/23/2895.full.pdf"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1514616","briefDesignDescription":"TAVI for AS in intermediate-risk surgical candidates","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1514616","subspecialties":"Cardiology","abbreviation":"PARTNER 2","published":"2016-04-28","timestamp":"2017-12-03T22:38:09Z","title":"Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients","statusUsableDate":"2016-05-01","pmid":"27040324","trainingLevel":"Resident","pageName":"PARTNER 2","diseases":"Aortic Stenosis","briefResultsDescription":"TAVI noninferior to surgical AVR in intermediate-risk surgical candidates","pageid":2753,"citation":"Leon MB, et al. \"Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients\". The New England Journal of Medicine. 2016. 374(17):1609-20.","expansion":"Placement of Aortic Transcatheter Valves, Cohort A"},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814052","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1814052","briefDesignDescription":"TAVR for AS in low-risk surgical candidates","timestamp":"2019-10-17T18:34:54Z","published":"2019-03-16","abbreviation":"PARTNER 3","pmid":"30883058","statusUsableDate":"2019-10-16","title":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients","trainingLevel":"Resident","briefResultsDescription":"TAVR superior to surgical AVR in low-risk surgical candidates","diseases":"Aortic Stenosis","pageName":"PARTNER 3","citation":"Mack MJ, et al. \"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients\". The New England Journal of Medicine. 2019. 380(18):1695-1705.","pageid":3949,"expansion":"Placement of Aortic Transcatheter Valves 3"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103510","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1103510","subspecialties":"Cardiology","briefDesignDescription":"TAVI for AS in high-risk surgical candidates","published":"2011-06-09","timestamp":"2017-12-03T22:38:10Z","abbreviation":"PARTNER A","statusUsableDate":"2016-05-01","pmid":"21639811","title":"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients","trainingLevel":"Intern","diseases":"Aortic Stenosis","briefResultsDescription":"TAVI noninferior to surgical AVR in high-risk surgical candidates","pageName":"PARTNER A","pageid":2741,"citation":"Smith CR, et al. \"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients\". The New England Journal of Medicine. 2011. 364(23):2187-98.","expansion":"Placement of Aortic Transcatheter Valves, Cohort A"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008232","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1008232","subspecialties":"Cardiology","briefDesignDescription":"TAVI for AS in poor surgical candidates","published":"2010-10-21","timestamp":"2017-12-03T22:38:12Z","abbreviation":"PARTNER B","statusUsableDate":"2013-12-01","pmid":"20961243","title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","trainingLevel":"Intern","diseases":"Aortic Stenosis","briefResultsDescription":"TAVI reduces all-cause mortality ± rehospitalization, increased stroke","pageName":"PARTNER B","pageid":1674,"citation":"Leon MB, et al. \"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery\". The New England Journal of Medicine. 2010. 363(17):1597-1607.","expansion":"Placement of Aortic Transcatheter Valves, Cohort B"},{"fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)00257-3","subspecialties":"Cardiology;Nephrology;Preventive Medicine","briefDesignDescription":"Spironolactone for resistant HTN","pdfurl":"http://bit.ly/pathway-2-pdf","pmid":"26414968","statusUsableDate":"2021-02-11","title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","published":"2015-11-21","timestamp":"2021-02-12T16:58:50Z","abbreviation":"PATHWAY-2","diseases":"Hypertension","briefResultsDescription":"Spironolactone improved BP control compared to placebo, doxazosin, or bisoprolol","pageName":"PATHWAY-2","trainingLevel":"Resident","expansion":"Prevention and Treatment of Hypertension with Algorithm-Based Therapy (PATHWAY)","pageid":2733,"citation":"Williams B, et al. \"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial\". The Lancet. 2015. 386(10008):2059-2068."},{"expansion":"Perioperative Anticoagulation Use for Surgery Evaluation","pageid":4421,"citation":"Douketis JD, et al. \"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant\". JAMA Internal Medicine. 2019. 179(11):1469-1478.","pageName":"PAUSE","diseases":"Atrial Fibrillation","briefResultsDescription":"Holding DOAC by this protocol has little bleeding and events","trainingLevel":"fellow","title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","pmid":"31380891","statusUsableDate":"2021-04-29","abbreviation":"PAUSE","published":"2019-08-05","timestamp":"2021-05-12T12:54:33Z","briefDesignDescription":"Perioperative DOAC holding protocols in AF","fulltexturl":"https://doi.org/10.1001/jamainternmed.2019.2431","subspecialties":"Cardiology","pdfurl":""},{"expansion":"Prostate Cancer Prevention Trial","pageid":1786,"citation":"Thompson IM, et al. \"The influence of finasteride on the development of prostate cancer\". The New England Journal of Medicine. 2003. 349(3):215-224.","diseases":"Prostate Cancer","briefResultsDescription":"Finasteride reduces all-grade prostate cancer risk, increases high-grade disease","pageName":"PCPT","trainingLevel":"Intern","statusUsableDate":"2014-02-01","pmid":"12824459","title":"The influence of finasteride on the development of prostate cancer","published":"2003-07-13","timestamp":"2017-12-03T22:38:13Z","abbreviation":"PCPT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030660","subspecialties":"Urology;Oncology","briefDesignDescription":"Finasteride for prostate cancer prophylaxis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030660"},{"trainingLevel":"Intern","pageName":"PEGASUS-TIMI 54","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction","briefResultsDescription":"Extended ticagrelor+ASA reduces CVD events after MI","pageid":2469,"citation":"Bonaca MP, et al. \"Long-term use of ticagrelor in patients with prior myocardial infarction\". The New England Journal of Medicine. 2015. 372(19):1791-1800.","expansion":"","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500857","briefDesignDescription":"Extended ticagrelor+ASA after MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1500857","subspecialties":"Cardiology","abbreviation":"PEGASUS-TIMI 54","published":"2015-05-07","timestamp":"2020-09-14T19:27:22Z","title":"Long-term use of ticagrelor in patients with prior myocardial infarction","statusUsableDate":"2015-12-01","pmid":"25773268"},{"briefDesignDescription":"tPA for submassive PE","subspecialties":"Critical Care;Pulmonology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302097","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302097","title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","statusUsableDate":"2014-04-01","pmid":"24716681","abbreviation":"PEITHO","timestamp":"2021-06-08T19:31:33Z","published":"2014-04-10","pageName":"PEITHO","briefResultsDescription":"tPA reduces hemodynamic decomp, not mortality, also increases bleeding in submassive PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","trainingLevel":"resident","expansion":"Pulmonary Embolism Thrombolysis trial","citation":"Meyer G, et al. \"Fibrinolysis for patients with intermediate-risk pulmonary embolism\". The New England Journal of Medicine. 2014. 370(15):1402-1411.","pageid":1778},{"citation":"Akriviadis E, et al. \"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial\". Gastroenterology. 2000. 119(6):1637-48.","pageid":53,"expansion":"","trainingLevel":"Resident","briefResultsDescription":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis","diseases":"Alcoholic Hepatitis","pageName":"Pentoxifylline in Severe Alcoholic Hepatitis","timestamp":"2015-07-06T21:57:52Z","published":"2000-12-20","abbreviation":"","statusUsableDate":"2012-03-01","pmid":"11113085","title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508500511834.pdf","subspecialties":"Gastroenterology","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(00)51183-4/fulltext","briefDesignDescription":"Pentoxifylline in alcoholic hepatitis"},{"expansion":"Pulmonary Embolism Rule-Out Criteria","pageid":2657,"citation":"Kline JA, et al. \"Prospective multicenter evaluation of the pulmonary embolism rule-out criteria\". J Thromb Haemost. 2008. 6(5):772-780.","pageName":"PERC","diseases":"Pulmonary Embolism","briefResultsDescription":"Low probability of PE mortality with low PERC probability","trainingLevel":"Resident","title":"Prospective multicenter evaluation of the pulmonary embolism rule-out criteria","pmid":"18318689","statusUsableDate":"2021-05-20","abbreviation":"PERC","published":"2008-05-06","timestamp":"2021-05-31T17:58:55Z","briefDesignDescription":"PE rule-out criteria","fulltexturl":"http://dx.doi.org/10.1111/j.1538-7836.2008.02944.x","subspecialties":"Emergency Medicine;Pulmonology;Hematology","pdfurl":"http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2008.02944.x/epdf"},{"expansion":"Pulmonary Embolism in Syncope Italian Trial","citation":"Prandoni P, et al. \"Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope\". The New England Journal of Medicine. 2016. 375(16):1524-31.","pageid":2843,"briefResultsDescription":"PE found in 1 of 6 patients with syncope","diseases":"Pulmonary Embolism;Venous Thromboembolism;Syncope","pageName":"PESIT","trainingLevel":"Resident","statusUsableDate":"2016-11-01","pmid":"27797317","title":"Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope","timestamp":"2017-12-03T22:38:18Z","published":"2016-10-20","abbreviation":"PESIT","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602172","briefDesignDescription":"Prevalence of PE in syncope","pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602172"},{"pageid":2861,"citation":"Gibson CM, et al. \"Prevention of bleeding in patients with AF undergoing PCI\". The New England Journal of Medicine. 2016. epub 2016-11-14:1-12.","expansion":"Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with AF who Undergo Percutaneous Coronary Intervention","trainingLevel":"Resident","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","briefResultsDescription":"Rivaroxaban with lower bleeding","pageName":"PIONEER AF-PCI","published":"2016-11-14","timestamp":"2017-12-03T22:38:19Z","abbreviation":"PIONEER AF-PCI","statusUsableDate":"2016-12-01","pmid":"27959713","title":"Prevention of bleeding in patients with AF undergoing PCI","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611594","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611594","subspecialties":"Cardiology","briefDesignDescription":"DOAC, VKA, antiplatelets after PCI with stent"},{"diseases":"Heart Failure","briefResultsDescription":"Sacubitril-valsartan reduces NT-ProBNP","pageName":"PIONEER-HF","trainingLevel":"Student","expansion":"comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode","pageid":3740,"citation":"Velazquez EJ, et al. \"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure\". The New England Journal of Medicine. 2018. ePub 2018-11-11:1-10.","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1812851","subspecialties":"Cardiology","briefDesignDescription":"ARNI started in ADHF hospitalization","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812851","pmid":"30415601","statusUsableDate":"2019-01-31","title":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure","published":"2018-11-11","timestamp":"2019-02-14T22:49:17Z","abbreviation":"PIONEER-HF"},{"briefResultsDescription":"CT sensitive and specific in detecting acute PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","pageName":"PIOPED II","trainingLevel":"MedicalStudent","expansion":"Prospective Investigation of Pulmonary Embolism Diagnosis II","citation":"Stein PD, et al. \"Multidetector Computed Tomography for Acute Pulmonary Embolism\". The New England Journal of Medicine. 2006. 354(22):2317-2327.","pageid":161,"subspecialties":"Pulmonology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052367#t","briefDesignDescription":"Accuracy of CT for PE","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052367#t","statusUsableDate":"2012-03-01","pmid":"16738268","title":"Multidetector Computed Tomography for Acute Pulmonary Embolism","timestamp":"2016-04-05T13:46:19Z","published":"2006-06-01","abbreviation":"PIOPED II"},{"expansion":"","citation":"Allen SJ, et al. \"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial\". The Lancet. 2013. 382(9900):1249-1257.","pageid":1770,"briefResultsDescription":"Probiotics do not reduce diarrhea including C. diff with antibiotics","diseases":"Clostridium difficile","pageName":"PLACIDE","trainingLevel":"Resident","statusUsableDate":"2014-05-01","pmid":"23932219","title":"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial","timestamp":"2019-12-20T10:41:43Z","published":"2013-10-12","abbreviation":"PLACIDE","subspecialties":"Gastroenterology;Infectious Disease;Preventive Medicine","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961218-0/abstract","briefDesignDescription":"Probiotics to prevent CDAD","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673613612180.pdf"},{"briefDesignDescription":"Ticagrelor vs. clopidogrel in ACS","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904327","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904327","title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","statusUsableDate":"2013-09-01","pmid":"19717846","abbreviation":"PLATO","timestamp":"2017-12-03T22:38:22Z","published":"2009-09-10","pageName":"PLATO","briefResultsDescription":"Ticagrelor reduces mortality, increases bleeding","diseases":"Acute Coronary Syndrome;Coronary Artery Disease","trainingLevel":"Resident","expansion":"Platelet Inhibition and Patient Outcomes","citation":"Wallentin L, et al. \"Ticagrelor versus clopidogrel in patients with acute coronary syndromes\". The New England Journal of Medicine. 2009. 361(11):1045-1057.","pageid":1629},{"title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","pmid":"14625336","statusUsableDate":"2012-03-01","abbreviation":"PneumA","published":"2003-11-19","timestamp":"2012-05-07T02:36:42Z","briefDesignDescription":"8 vs. 15 days of antibiotics in VAP","fulltexturl":"http://jama.ama-assn.org/content/290/19/2588.long","subspecialties":"Critical Care;Infectious Disease;Pulmonology","pdfurl":"http://jama.ama-assn.org/content/290/19/2588.full.pdf","expansion":"","pageid":118,"citation":"Chastre J. \"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial\". Journal of the American Medical Association. 2003. 290(19):2588-98.","pageName":"PneumA","diseases":"Pneumonia","briefResultsDescription":"8 days of antibiotics are equivalent to 15 days","trainingLevel":"Intern"},{"trainingLevel":"Student","briefResultsDescription":"PO abx after IV abx non-inferior to IV abx only","diseases":"Endocarditis","pageName":"POET","citation":"Iversen K, et al. \"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis\". The New England Journal of Medicine. 2019. 380(5):415-424.","pageid":3722,"expansion":"Partial Oral Treatment of Endocarditis","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1808312","subspecialties":"Infectious Disease","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1808312","briefDesignDescription":"PO abx after 10d IV abx for left-sided endocarditis","timestamp":"2019-08-26T14:27:41Z","published":"2019-01-31","abbreviation":"POET","statusUsableDate":"2019-04-10","pmid":"30152252","title":"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis"},{"pageName":"POINT","diseases":"Stroke;Transient Ischemic Attack","briefResultsDescription":"Aspirin/clopidogrel reduces stroke recurrence, increases bleeding compared to aspirin","trainingLevel":"Resident","expansion":"Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial","pageid":3659,"citation":"Johnston SC, et al. \"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA\". The New England Journal of Medicine. 2018. 379(3):215-225.","briefDesignDescription":"Aspirin/clopidogrel vs. aspirin in stroke/TIA","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1800410","subspecialties":"Neurology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800410","title":"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA","pmid":"29766750","statusUsableDate":"2018-08-09","abbreviation":"POINT","published":"2018-05-16","timestamp":"2018-11-07T06:34:44Z"},{"timestamp":"2024-10-23T13:45:05Z","published":"2008-05-31","abbreviation":"POISE","pmid":"18479744","statusUsableDate":"2012-03-01","title":"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673608606017.pdf","subspecialties":"Surgery;Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60601-7/fulltext","briefDesignDescription":"Perioperative metoprolol","citation":"Devereaux PJ, et al. \"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial\". The Lancet. 2008. 371(9627):1839-1847.","pageid":173,"expansion":"PeriOperative ISchemic Evaluation","trainingLevel":"Intern","briefResultsDescription":"Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke","diseases":"Cardiac Risk Assessment;Coronary Artery Disease","pageName":"POISE"},{"pageid":1777,"citation":"Devereaux PJ, et al. \"Aspirin in patients undergoing noncardiac surgery\". The New England Journal of Medicine. 2014. 370(16):1494-1503.","expansion":"Perioperative ischemic evaluation 2 aspirin arm","trainingLevel":"Intern","diseases":"Cardiac Risk Assessment","briefResultsDescription":"Perioperative ASA doesn't modify MI rates but increases major bleeding","pageName":"POISE-2 ASA","published":"2014-03-31","timestamp":"2017-12-03T22:38:24Z","abbreviation":"POISE-2 ASA","pmid":"24679062","statusUsableDate":"2014-04-01","title":"Aspirin in patients undergoing noncardiac surgery","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401105","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401105","subspecialties":"Cardiology;Surgery","briefDesignDescription":"Perioperative ASA"},{"pageName":"POP-UP","diseases":"Stress Ulcer","briefResultsDescription":"PPIs do not reduce risk of stress ulcer bleeding in enterally fed patients","trainingLevel":"Resident","expansion":"Pantoprazole or Placebo for Stress Ulcer Prophylaxis","pageid":2866,"citation":"Selvanderan SP, et al. \"Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study\". Critical Care Medicine. 2016. 44(10):1842-1850.","briefDesignDescription":"PPIs for stress ulcer prophylaxis","fulltexturl":"https://dx.doi.org/10.1097/CCM.0000000000001819","subspecialties":"Critical Care","pdfurl":"http://ovidsp.tx.ovid.com/sp-3.26.1a/ovidweb.cgi?&S","title":"Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study","pmid":"27635481","statusUsableDate":"2017-09-01","abbreviation":"POP-UP","published":"2016-10-01","timestamp":"2017-12-03T22:38:25Z"},{"abbreviation":"PRAETORIAN","published":"2020-08-06","timestamp":"2021-01-11T18:51:08Z","title":"Subcutaneous or Transvenous Defibrillator Therapy","pmid":"32757521","statusUsableDate":"2021-01-08","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915932","briefDesignDescription":"Transvenous vs. subq ICD to prevent sudden cardiac death","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1915932","subspecialties":"Cardiology","pageid":4394,"citation":"Knops RE, et al. \"Subcutaneous or Transvenous Defibrillator Therapy\". The New England Journal of Medicine. 2020. 383(6):526-36.","expansion":"Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy","trainingLevel":"Resident","pageName":"PRAETORIAN","diseases":"Unstable Arrhythmia","briefResultsDescription":"Subcutaneous ICD non-inferior to transvenous ICD"},{"expansion":"Preventative Angioplasty in Acute Myocardial Infarction","citation":"Wald DS, et al. \"Randomized trial of preventative angioplasty in myocardial infarction\". The New England Journal of Medicine. 2013. 369(12):1115-1123.","pageid":1748,"pageName":"PRAMI","briefResultsDescription":"PCI to high-risk non infarct arteries in STEMI improves CV outcomes","diseases":"Myocardial Infarction","trainingLevel":"Resident","title":"Randomized trial of preventative angioplasty in myocardial infarction","statusUsableDate":"2013-11-01","pmid":"23991625","abbreviation":"PRAMI","timestamp":"2018-11-18T20:26:21Z","published":"2013-09-19","briefDesignDescription":"PCI to high-risk non-infarct arteries in STEMI","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305520","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305520"},{"pageName":"PRECISION","diseases":"Coronary Artery Disease;Rheumatoid Arthritis;Osteoarthritis;Stroke","briefResultsDescription":"Celecoxib noninferior to ibuprofen or naproxen with regard to CV safety","trainingLevel":"Resident","expansion":"Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen","pageid":2888,"citation":"Nissen SE, et al. \"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis\". The New England Journal of Medicine. 2016. 375(26):2519-2529.","briefDesignDescription":"Celecoxib, naproxen, or ibuprofen for CV safety in arthritis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611593","subspecialties":"Cardiology;Rheumatology;Neurology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611593","title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","statusUsableDate":"2017-03-01","pmid":"27959716","abbreviation":"PRECISION","published":"2016-12-29","timestamp":"2018-06-01T20:19:38Z"},{"briefDesignDescription":"Mediterranean diet in CVD prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200303","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200303","title":"Primary prevention of cardiovascular disease with a mediterranean diet","pmid":"23432189","statusUsableDate":"2013-06-01","abbreviation":"PREDIMED","published":"2013-02-25","timestamp":"2018-06-14T20:17:40Z","pageName":"PREDIMED","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","briefResultsDescription":"Mediterranean diet reduces composite rate of MI/CVA/CV death","trainingLevel":"Student","expansion":"Prevención con Dieta Mediterránea","pageid":1247,"citation":"Estruch R, et al. \"Primary prevention of cardiovascular disease with a mediterranean diet\". The New England Journal of Medicine. 2013. 368(14):1279-1290."},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199202203260802","subspecialties":"Gastroenterology","briefDesignDescription":"Prednisolone vs. placebo in alcoholic hepatitis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199202203260802","pmid":"1531090","statusUsableDate":"2012-03-01","title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","published":"1992-02-20","timestamp":"2015-07-06T21:57:28Z","abbreviation":"","diseases":"Alcoholic Hepatitis","briefResultsDescription":"Prednisolone improves short-term survival","pageName":"Prednisolone in Severe Alcoholic Hepatitis","trainingLevel":"Intern","expansion":"","pageid":1113,"citation":"Ramond MJ, et al. \"A randomized trial of prednisolone in patients with severe alcoholic hepatitis\". The New England Journal of Medicine. 1992. 362(8):507-512."},{"pageName":"PREPIC","diseases":"Deep Vein Thrombosis;Venous Thromboembolism;Pulmonary Embolism","briefResultsDescription":"IVC filters reduce future PE risk but increase DVT risk","trainingLevel":"Resident","expansion":"Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group","pageid":2697,"citation":"Decousus H, et al. \"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis\". The New England Journal of Medicine. 1998. 338(7):409-416.","briefDesignDescription":"IVC filters for proximal DVT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199802123380701","subspecialties":"Pulmonology;Hematology;Interventional Radiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701","title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis","statusUsableDate":"2016-03-01","pmid":"9459643","abbreviation":"PREPIC","published":"1998-02-12","timestamp":"2017-12-03T22:38:31Z"},{"citation":"Mismetti P, et al. \"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial\". The Journal of the American Medical Association. 2015. 313(16):1627-35.","pageid":2405,"expansion":"Prevention du Risque d'Embolie Pulmonaire par Interruption Cave 2","trainingLevel":"Intern","pageName":"PREPIC 2","briefResultsDescription":"IVC filters do not improve outcomes in acute high-risk PE","diseases":"Venous Thromboembolism","abbreviation":"PREPIC 2","timestamp":"2017-12-03T22:38:33Z","published":"2015-04-28","title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","pmid":"25919526","statusUsableDate":"2015-07-01","pdfurl":"http://bit.ly/1ONs0iA","briefDesignDescription":"IVC filters for high-risk PE","subspecialties":"Hematology;Pulmonology;Interventional Radiology","fulltexturl":"http://bit.ly/1Jti6Ct"},{"pageName":"PREVAIL","briefResultsDescription":"LAA noninferior to warfarin in AF","diseases":"Atrial Fibrillation","trainingLevel":"Resident","expansion":"Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy","citation":"Holmes DR, et al. \"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial\". Journal of the American College of Cardiology. 2014. 64(1):1-12.","pageid":3535,"briefDesignDescription":"LAA closure vs. warfarin in AF","subspecialties":"Cardiology","fulltexturl":"https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02341-9","pdfurl":"https://www.sciencedirect.com/science/article/pii/S0735109714023419/pdfft?download","title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","statusUsableDate":"2021-07-29","pmid":"24998121","abbreviation":"PREVAIL","timestamp":"2021-07-30T04:27:31Z","published":"2014-07-08"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1104875","briefDesignDescription":"Rifapentine/isoniazid in latent TB","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1104875","subspecialties":"Infectious Disease","abbreviation":"PREVENT TB","published":"2011-12-08","timestamp":"2017-12-03T22:38:34Z","title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","pmid":"22150035","statusUsableDate":"2012-08-01","trainingLevel":"fellow","pageName":"PREVENT TB","diseases":"Tuberculosis","briefResultsDescription":"Rifapentine/isoniazid x3 months is noninferior to isoniazid x9 months","pageid":928,"citation":"Sterling TR, et al. \"Three months of rifapentine and isoniazid for latent tuberculosis infection.\". The New England Journal of Medicine. 2011. 365(23):2155-66.","expansion":null},{"abbreviation":"ProCESS","timestamp":"2017-12-03T22:38:46Z","published":"2014-05-01","title":"A randomized trial of protocol-based care for early septic shock","pmid":"24635773","statusUsableDate":"2014-03-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401602","briefDesignDescription":"EGDT in septic shock","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401602","citation":"Angus DC, et al. \"A randomized trial of protocol-based care for early septic shock\". The New England Journal of Medicine. 2014. 370(10):1683-1693.","pageid":1782,"expansion":"Protocolized Care for Early Septic Shock","trainingLevel":"Intern","pageName":"ProCESS","briefResultsDescription":"No difference for EGDT vs. standard protocol vs. usual care for septic shock","diseases":"Sepsis"},{"citation":"Conroy T, et al. \"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer\". The New England Journal of Medicine. 2011. 364(19):1817-1825.","pageid":2819,"expansion":"PRODIGE 4 Actions concertées dans les Cancers COloRectaux et Digestifs","trainingLevel":"Resident","pageName":"PRODIGE 4 ACCORD 11","briefResultsDescription":"FOLFIRINOX improves OS in metastatic pancreatic cancer compared to gemcitabine","diseases":"Pancreatic Cancer","abbreviation":"PRODIGE 4 ACCORD 11","timestamp":"2017-12-03T22:38:35Z","published":"2011-05-12","title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","statusUsableDate":"2016-09-01","pmid":"21561347","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011923","briefDesignDescription":"FOLFIRINOX in pancreatic cancer","subspecialties":"Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1011923"},{"trainingLevel":"Resident","pageName":"PRoFESS","briefResultsDescription":"Similar efficacy but less bleeding with clopidogrel","diseases":"Stroke","citation":"Sacco RL, et al. \"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke\". The New England Journal of Medicine. 2008. 359(12):1238-1251.","pageid":1082,"expansion":"Prevention Regimen for Effectively Avoiding Second Strokes","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805002","briefDesignDescription":"ASA-dipyridamole vs. clopidogrel in stroke","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805002","abbreviation":"PROFESS","timestamp":"2017-12-03T22:38:44Z","published":"2008-09-18","title":"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke","pmid":"18753638","statusUsableDate":"2012-11-01"},{"expansion":"Protection Against Recurrent Stroke Study","pageid":2450,"citation":"PROGRESS Collaborative Group. \"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack\". Lancet. 2001. 358(9287):1033–1041.","diseases":"Stroke;Hypertension","briefResultsDescription":"Perindopril+indapamide lowers recurrent stroke risk among those with prior stroke","pageName":"PROGRESS","trainingLevel":"Intern","statusUsableDate":"2023-01-21","pmid":"11589932","title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","published":"2001-09-29","timestamp":"2023-07-20T03:15:45Z","abbreviation":"PROGRESS","fulltexturl":"https://doi.org/10.1016/S0140-6736(01)06178-5","subspecialties":"Neurology","briefDesignDescription":"Perindopril±indapamide after stroke","pdfurl":""},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa054444","subspecialties":"Hematology","briefDesignDescription":"D-Dimer testing after VTE","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa054444","statusUsableDate":"2017-10-01","pmid":"17065639","title":"d-Dimer Testing to Determine the Duration of Anticoagulation Therapy","published":"2006-10-26","timestamp":"2017-12-03T22:38:37Z","abbreviation":"PROLONG","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","briefResultsDescription":"Abnormal D-dimer predicts VTE recurrence","pageName":"PROLONG","trainingLevel":"Resident","expansion":"","pageid":2967,"citation":"Palareti G, et al. \"d-Dimer Testing to Determine the Duration of Anticoagulation Therapy\". The New England Journal of Medicine. 2006. 355(17):1780-1789."},{"expansion":"","pageid":2385,"citation":"Mouncey PR, et al. \"Trial of early, goal-directed resuscitation for septic shock\". The New England Journal of Medicine. 2015. 372(14):1301-1311.","diseases":"Sepsis;Shock","briefResultsDescription":"Multicenter trial shows no benefit to EGDT in severe sepsis","pageName":"ProMISe","trainingLevel":"Resident","pmid":"25776532","statusUsableDate":"2019-02-27","title":"Trial of early, goal-directed resuscitation for septic shock","published":"2015-04-02","timestamp":"2019-02-28T18:12:36Z","abbreviation":"ProMISe","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1500896","subspecialties":"Critical Care;Emergency Medicine","briefDesignDescription":"Multicenter EGDT trial in severe sepsis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500896"},{"title":"Outcomes of anatomical versus functional testing for coronary artery disease","pmid":"25773919","statusUsableDate":"2024-08-05","abbreviation":"PROMISE","published":"2015-04-02","timestamp":"2025-08-07T19:37:56Z","briefDesignDescription":"Coronary CT for chest pain","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1415516","subspecialties":"Cardiology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1415516","expansion":"Prospective Multicenter Imaging Study for Evaluation of Chest Pain","pageid":3720,"citation":"Douglas PS, et al. \"Outcomes of anatomical versus functional testing for coronary artery disease\". The New England Journal of Medicine. 2015. 372(14):1291-1300.","pageName":"PROMISE","diseases":"Coronary Artery Disease","briefResultsDescription":"Coronary CT no different from other modalities","trainingLevel":"Resident"},{"pageid":3548,"citation":"Freund Y, et al. \"Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial\". Journal of the American Medical Association. 2018. 319(6):559-566.","expansion":"Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients","trainingLevel":"Resident","pageName":"PROPER","diseases":"Pulmonary Embolism","briefResultsDescription":"PERC score excludes PE in low-risk patients","abbreviation":"PROPER","published":"2018-02-13","timestamp":"2023-04-21T16:19:29Z","title":"Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial","pmid":"29450523","statusUsableDate":"2023-04-20","pdfurl":null,"briefDesignDescription":"Validation of PERC score in PE","fulltexturl":"https://jamanetwork.com/journals/jama/article-abstract/2672630","subspecialties":"Emergency Medicine"},{"subspecialties":"Emergency Medicine;Critical Care;Hematology","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/2107789","briefDesignDescription":"Transfusion ratios in hemorrhagic shock","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/2107789/joi150002.pdf","statusUsableDate":"2023-09-28","pmid":"25647203","title":"Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial","timestamp":"2023-09-28T19:19:28Z","published":"2015-02-03","abbreviation":"PROPPR","briefResultsDescription":"1:1:1 ratio of FFP:PLT:RBC no better than 1:1:2","diseases":"Hemorrhage;Trauma;Shock","pageName":"PROPPR","trainingLevel":"Resident","expansion":"Pragmatic, Randomized Optimal Platelet and Plasma Ratios","citation":"Holcomb JB, et al. \"Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial\". JAMA. 2015. 313(5):471-482.","pageid":2504},{"pageName":"PRORATA","briefResultsDescription":"Procalcitonin noninferior and led to fewer days on antibiotics","diseases":"Critical Illness","trainingLevel":"resident","expansion":"Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients","citation":"Bouadma L, et al. \"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units\". The Lancet. 2010. 375(9713):463-74.","pageid":434,"briefDesignDescription":"Procalcitonin-guided antibiotics","subspecialties":"Critical Care;Infectious Disease","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61879-1/fulltext","pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673609618791.pdf","title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units","statusUsableDate":"2012-03-01","pmid":"20097417","abbreviation":"PRORATA","timestamp":"2017-08-06T02:15:05Z","published":"2010-02-06"},{"subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1214103","briefDesignDescription":"Prone ventilation in ARDS","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214103","pmid":"23688302","statusUsableDate":"2013-06-01","title":"Prone positioning in severe acute respiratory distress syndrome","timestamp":"2020-11-12T18:32:26Z","published":"2013-06-06","abbreviation":"PROSEVA","briefResultsDescription":"Intermittent prone positioning improves survival in severe ARDS","diseases":"Acute Respiratory Distress Syndrome","pageName":"PROSEVA","trainingLevel":"fellow","expansion":"Proning Severe ARDS Patients","citation":"Guérin C, et al. \"Prone positioning in severe acute respiratory distress syndrome\". The New England Journal of Medicine. 2013. 368(23):2159-2168.","pageid":1479},{"abbreviation":"PROTECT AF","timestamp":"2025-05-15T20:05:21Z","published":"2009-11-07","title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","pmid":"19683639","statusUsableDate":"2018-01-18","pdfurl":"","briefDesignDescription":"LAA closure vs. warfarin in AF","subspecialties":"Cardiology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61343-X/fulltext","citation":"Holmes DR, et al. \"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial\". Lancet. 2009. 374(9689):534-42.","pageid":2459,"expansion":"WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation","trainingLevel":"Intern","pageName":"PROTECT AF","briefResultsDescription":"LAA closure was noninferior to warfarin therapy","diseases":"Atrial Fibrillation;Stroke"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040583","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040583","subspecialties":"Cardiology","briefDesignDescription":"Pravastatin vs. atorvastatin after ACS","published":"2004-04-08","timestamp":"2017-12-14T19:39:45Z","abbreviation":"PROVE IT-TIMI 22","statusUsableDate":"2013-04-01","pmid":"15007110","title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","trainingLevel":"Intern","diseases":"Acute Coronary Syndrome;Hyperlipidemia","briefResultsDescription":"High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS","pageName":"PROVE IT-TIMI 22","pageid":1338,"citation":"Cannon CP, et al. \"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes\". The New England Journal of Medicine. 2004. 350(15):1495-1504.","expansion":"Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200103083441001","briefDesignDescription":"Activated protein C in severe sepsis","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200103083441001","abbreviation":"PROWESS","timestamp":"2017-12-03T22:38:41Z","published":"2001-03-08","title":"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis","statusUsableDate":"2012-09-01","pmid":"11236773","trainingLevel":"Resident","pageName":"PROWESS","briefResultsDescription":"Improved survival with APC but not seen in subsequent larger PROWESS-SHOCK trial","diseases":"Sepsis;Shock","citation":"Bernard GR, et al. \"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis\". The New England Journal of Medicine. 2001. 344(10):699-709.","pageid":983,"expansion":"Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis"},{"trainingLevel":"Resident","pageName":"PROWESS-SHOCK","briefResultsDescription":"No survival benefit at 28 or 90 days, in contrast to PROWESS","diseases":"Sepsis;Shock","citation":"Ranieri VM, et al. \"Drotrecogin Alfa (Activated) in Adults with Septic Shock\". The New England Journal of Medicine. 2012. 366(22):2055-2064.","pageid":977,"expansion":"Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1202290","briefDesignDescription":"Activated protein C in septic shock","subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1202290","abbreviation":"PROWESS-SHOCK","timestamp":"2017-12-03T22:38:43Z","published":"2012-05-31","title":"Drotrecogin Alfa (Activated) in Adults with Septic Shock","statusUsableDate":"2012-09-01","pmid":"22616830"},{"abbreviation":"RABBIT 2","timestamp":"2018-12-24T16:50:42Z","published":"2007-09-30","title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","pmid":"17513708","statusUsableDate":"2018-06-14","pdfurl":"http://care.diabetesjournals.org/content/30/9/2181.full-text.pdf","briefDesignDescription":"Basal-bolus insulin in inpatients with DM","subspecialties":"Critical Care;Endocrinology","fulltexturl":"http://bit.ly/29xvPia","citation":"Umpierrez GE, et al. \"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)\". Diabetes Care. 2007. 30(9):2181-2186.","pageid":2720,"expansion":"Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes","trainingLevel":"Intern","pageName":"RABBIT 2","briefResultsDescription":"Basal-bolus more effective for glycemic control compared to sliding-scale insulin","diseases":"Diabetes Mellitus"},{"expansion":"Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See","citation":"Pluymaekers NAHA, et al. \"Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation\". The New England Journal of Medicine. 2019. 380(16):1499-1508.","pageid":4062,"pageName":"RACE 7 ACWAS","briefResultsDescription":"Delayed is noninferior to early cardioversion in obtaining sinus rhythm","diseases":"Atrial Fibrillation","trainingLevel":"Resident","title":"Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation","statusUsableDate":"2025-05-25","pmid":"30883054","abbreviation":"RACE 7 ACWAS","timestamp":"2025-05-22T17:30:01Z","published":"2019-04-18","briefDesignDescription":"Delayed vs. early cardioversion in AF","subspecialties":"Emergency Medicine;Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1900353","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1900353"},{"diseases":"Atrial Fibrillation","briefResultsDescription":"Lenient rate control is as effective as strict rate control","pageName":"RACE II","trainingLevel":"Resident","expansion":"Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II","pageid":181,"citation":"Van Gelder IC, et al. \"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation\". The New England Journal of Medicine. 2010. 362(15):1363-73.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001337","subspecialties":"Cardiology","briefDesignDescription":"Lenient vs. strict rate control in AF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001337","statusUsableDate":"2012-03-01","pmid":"20231232","title":"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation","published":"2010-04-15","timestamp":"2025-05-15T20:17:08Z","abbreviation":"RACE II"},{"trainingLevel":"Intern","pageName":"Radiograph vs. MRI for low back pain","diseases":"Low Back Pain","briefResultsDescription":"No differences in pain or disability related to back pain, possibly more surgeries in MRI group","pageid":2665,"citation":"Jarvik JG, et al. \"Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.\". The Journal of the American Medical Association. 2003. 289(21):2810-8.","expansion":"","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/196680/joc22401.pdf","briefDesignDescription":"Radiograph vs. MRI for low back pain","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/196680","subspecialties":"Physical Medicine and Rehabilitation","abbreviation":"Radiograph vs. MRI for low back pain","published":"2003-06-04","timestamp":"2025-06-19T18:35:37Z","title":"Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.","statusUsableDate":"2018-10-31","pmid":"12783911"},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009540","subspecialties":"Cardiology","briefDesignDescription":"CRT+ICD for mild-moderate HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009540","statusUsableDate":"2016-09-01","pmid":"21073365","title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","published":"2010-12-16","timestamp":"2017-12-03T22:38:47Z","abbreviation":"RAFT","diseases":"Heart Failure","briefResultsDescription":"CRT+ICD reduces mortality but increased the rate of adverse events","pageName":"RAFT","trainingLevel":"Resident","expansion":"Resynchronization–Defibrillation for Ambulatory Heart Failure","pageid":2731,"citation":"Tang AS, et al. \"Cardiac-resynchronization therapy for mild-to-moderate heart failure\". The New England Journal of Medicine. 2010. 363(25):2385-2395."},{"title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","pmid":"10471456","statusUsableDate":"2012-03-01","abbreviation":"RALES","published":"1999-09-02","timestamp":"2015-08-24T04:40:44Z","briefDesignDescription":"Spironolactone in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199909023411001","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001","expansion":"Randomized Aldactone Evaluation Study","pageid":11,"citation":"Pitt B, et al. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". New England Journal of Medicine. 1999. 341(10):709-717.","pageName":"RALES","diseases":"Heart Failure","briefResultsDescription":"Spironolactone reduces all-cause mortality by 30% in severe HFrEF","trainingLevel":"Intern"},{"citation":"Silbergleit R, et al. \"Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus\". The New England Journal of Medicine. 2012. 366(7):591-600.","pageid":2505,"expansion":"Rapid Anticonvulsant Medication Prior to Arrival Trial","trainingLevel":"Intern","pageName":"RAMPART","briefResultsDescription":"IM midazolam is as safe and efficacious as IV lorazepam","diseases":"Epilepsy;Seizure","abbreviation":"RAMPART","timestamp":"2021-08-12T22:54:12Z","published":"2012-02-22","title":"Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus","pmid":"22335736","statusUsableDate":"2019-08-31","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107494","briefDesignDescription":"Midazolam vs. lorazepam for status epilepticus","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1107494"},{"briefDesignDescription":"Chemo-RT vs. chemo in rectal cancer","subspecialties":"Oncology","fulltexturl":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext","pdfurl":"https://www.thelancet.com/action/showPdf?pii","title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","statusUsableDate":"2025-05-22","pmid":"33301740","abbreviation":"RAPIDO","timestamp":"2025-05-22T17:14:03Z","published":"2021-01-01","pageName":"RAPIDO","briefResultsDescription":"Fewer treatment failures with chemo-RT","diseases":"Colorectal Cancer","trainingLevel":"Fellow","expansion":"Rectal Cancer and Preoperative Induction Therapy Followed by Dedicated Operation Trial","citation":"Bahadoer RR, et al. \"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial\". The Lancet Oncology. 2021. 22(1):29-42.","pageid":5600},{"fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0909905","subspecialties":"Rheumatology","briefDesignDescription":"Rituximab vs. cyclophosphamide in ANCA-associated vasculitis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909905","pmid":"20647199","statusUsableDate":"2013-02-01","title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","published":"2010-07-15","timestamp":"2017-12-03T22:38:49Z","abbreviation":"RAVE","diseases":"Vasculitis","briefResultsDescription":"Rituximab noninferior to cyclophosphamide in ANCA-associated vasculitis","pageName":"RAVE","trainingLevel":"Fellow","expansion":"Rituximab in ANCA-Associated Vasculitis","pageid":1214,"citation":"Stone JH, et al. \"Rituximab versus cyclophosphamide for ANCA-associated vasculitis\". The New England Journal of Medicine. 2010. 363(3):221-232."},{"briefResultsDescription":"Dabigatran has more thromboembolism and bleeding than warfarin","diseases":"Valvular Disease","pageName":"RE-ALIGN","trainingLevel":"Resident","expansion":"Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement","citation":"Eikelboom JW, et al. \"Dabigatran versus warfarin in patients with mechanical heart valves\". The New England Journal of Medicine. 2013. 369(13):1206-1214.","pageid":1707,"subspecialties":"Cardiology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300615","briefDesignDescription":"Dabigatran in mechanical heart valves","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300615","pmid":"23991661","statusUsableDate":"2013-10-01","title":"Dabigatran versus warfarin in patients with mechanical heart valves","timestamp":"2017-12-03T22:38:51Z","published":"2013-09-26","abbreviation":"RE-ALIGN"},{"abbreviation":"RE-COVER","timestamp":"2017-12-03T22:38:52Z","published":"2009-12-10","title":"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism","statusUsableDate":"2012-08-01","pmid":"19966341","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906598","briefDesignDescription":"Dabigatran vs. warfarin in VTE","subspecialties":"Hematology;Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906598","citation":"Schulman S, et al. \"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism\". New England Journal of Medicine. 2009. 361(24):2342-52.","pageid":973,"expansion":"Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism","trainingLevel":"fellow","pageName":"RE-COVER","briefResultsDescription":"Dabigatran non-inferior to warfarin for VTE recurrence, but dabigatran yielded less bleeding","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism"},{"pageName":"RE-DUAL","briefResultsDescription":"Aspirin and dabigatran nonferior to triple therapy in patients with AF undergoing PCI","diseases":"Coronary Artery Disease","trainingLevel":"Resident","expansion":"Randomized evaluation of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin in patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention","citation":"Cannon CP, et al. \"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation\". The New England Journal of Medicine. 2017. 377(16):1513-1524.","pageid":3527,"briefDesignDescription":"Triple therapy vs. ASA+dabigatran in PCI if AF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1708454","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1708454","title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","statusUsableDate":"2018-01-29","pmid":"28844193","abbreviation":"RE-DUAL PCI","timestamp":"2018-01-30T17:09:14Z","published":"2017-10-19"},{"citation":"Connolly SJ, et al. \"Dabigatran versus warfarin in patients with atrial fibrillation\". The New England Journal of Medicine. 2009. 361(12):1139-51.","pageid":178,"expansion":"Randomized Evaluation of Long-Term Anticoagulation Therapy","trainingLevel":"Resident","briefResultsDescription":"High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","pageName":"RE-LY","timestamp":"2015-04-18T21:22:31Z","published":"2009-09-17","abbreviation":"RE-LY","statusUsableDate":"2012-03-01","pmid":"19717844","title":"Dabigatran versus warfarin in patients with atrial fibrillation","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905561","subspecialties":"Cardiology;Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905561","briefDesignDescription":"Dabigatran vs. warfarin in AF"},{"pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1502000","briefDesignDescription":"Idarucizumab for dabigatran reversal","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1502000","abbreviation":"RE-VERSE AD","timestamp":"2017-12-03T22:38:54Z","published":"2015-08-06","title":"Idarucizumab for Dabigatran Reversal","statusUsableDate":"2016-01-01","pmid":"26095746","trainingLevel":"Intern","pageName":"RE-VERSE AD","briefResultsDescription":"Idarucizumab reversed the dabigatran effect in minutes","diseases":"Hemorrhage","citation":"Pollack CV, et al. \"Idarucizumab for Dabigatran Reversal\". The New England Journal of Medicine. 2015. 373(6):511-520.","pageid":2421,"expansion":""},{"pageid":4431,"citation":"Ducrocq G, et al. \"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia\". Journal of the American Medical Association. 2021. 325(6):552-560.","expansion":"Restrictive and Liberal Transfusion Strategies in Patients With Acute Myocardial Infarction trial","trainingLevel":"Resident","diseases":"Acute Coronary Syndrome","briefResultsDescription":"Restrictive threshold non-inferior to liberal transfusion threshold","pageName":"REALITY","published":"2021-02-09","timestamp":"2021-08-05T18:21:13Z","abbreviation":"REALITY","statusUsableDate":"2021-07-31","pmid":"33560322","title":"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia","pdfurl":null,"fulltexturl":"https://doi.org/10.1001/jama.2021.0135","subspecialties":"Cardiology","briefDesignDescription":"Transfusion thresholds in MI"},{"trainingLevel":"Student","pageName":"RECOVERY (Covid-19)","diseases":"Covid-19","briefResultsDescription":"Dexamethasone improved survival in a subset of patients with Covid-19","pageid":4273,"citation":"Horby P, et al. \"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report\". The New England Journal of Medicine. 2020. e-pub 2020-07-17:1-11.","expansion":"Randomized Evaluation of Covid-19 Therapy","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436","briefDesignDescription":"Dexamethasone vs. usual care in Covid-19","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2021436","subspecialties":"Infectious Disease","abbreviation":"RECOVERY","published":"2020-07-17","timestamp":"2020-10-29T17:10:25Z","title":"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report","statusUsableDate":"2020-08-20","pmid":"32678530"},{"pmid":"23473338","statusUsableDate":"2014-06-01","title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","published":"2013-03-28","timestamp":"2017-12-03T22:38:55Z","abbreviation":"RED-HF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1214865","subspecialties":"Cardiology;Hematology","briefDesignDescription":"Darbepoetin in HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214865","expansion":"Reduction of Events by Darbepoetin Alfa in Heart Failure","pageid":1842,"citation":"Swedberg K, et al. \"Treatment of anemia with darbepoetin alfa in systolic heart failure\". The New England Journal of Medicine. 2013. 368(13):1210-9.","diseases":"Heart Failure;Anemia","briefResultsDescription":"Darbepoetin does not improve clinical outcomes in HF with anemia","pageName":"RED-HF","trainingLevel":"Fellow"},{"expansion":"Reduction in the Use of Corticosteroids in Exacerbated COPD","pageid":1615,"citation":"Leuppi JD, et al. \"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial\". JAMA. 2013. 309(21):2223-2231.","diseases":"Chronic Obstructive Pulmonary Disease","briefResultsDescription":"5d steroids noninferior to 14d in acute COPD","pageName":"REDUCE","trainingLevel":"Intern","statusUsableDate":"2013-09-01","pmid":"23695200","title":"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial","published":"2013-06-05","timestamp":"2017-12-03T22:38:56Z","abbreviation":"REDUCE","fulltexturl":"http://bit.ly/1BQhpuy","subspecialties":"Pulmonology","briefDesignDescription":"5d vs. 14d steroids in acute COPD","pdfurl":null},{"expansion":"","citation":"Yndigegn T, et al. \"Beta-blockers after myocardial infarction and preserved ejection fraction\". The New England Journal of Medicine. 2024. 390(15):1372-1381.","pageid":5504,"briefResultsDescription":"Beta-Blockers no better than no beta-blockers in MI with normal LVEF","diseases":"Myocardial Infarction","pageName":"REDUCE-AMI","trainingLevel":"students","statusUsableDate":"2024-05-16","pmid":"38587241","title":"Beta-blockers after myocardial infarction and preserved ejection fraction","timestamp":"2024-05-16T18:52:20Z","published":"2024-04-18","abbreviation":"REDUCE-AMI","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2401479","briefDesignDescription":"Beta-blockers if post-AMI LVEF ≥50%","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401479"},{"expansion":"Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial","citation":"Bhatt DL, et al. \"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia\". The New England Journal of Medicine. 2018. epub 2018-11-10:1-12.","pageid":3748,"pageName":"REDUCE-IT","briefResultsDescription":"Icosapent ethyl superior to placebo in CAD with hypertriglyceridemia","diseases":"Coronary Artery Disease","trainingLevel":"Resident","title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","statusUsableDate":"2018-12-27","pmid":"30415628","abbreviation":"REDUCE-IT","timestamp":"2019-10-17T17:47:07Z","published":"2018-11-10","briefDesignDescription":"Icosapent ethyl in CAD","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1812792","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812792"},{"pageid":2973,"citation":"Redfield MM, et al. \"Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction\". JAMA. 2013. 309(12):1268-1277.","expansion":"Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction","trainingLevel":"Resident","pageName":"RELAX","diseases":"Heart Failure","briefResultsDescription":"Sildenafil not superior to placebo in HFpEF","abbreviation":"RELAX","published":"2013-03-11","timestamp":"2017-12-03T22:38:58Z","title":"Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction","pmid":"23478662","statusUsableDate":"2017-10-01","pdfurl":"https://jamanetwork.com/journals/jama/articlepdf/1663257/joc130025_1268_1277.pdf","briefDesignDescription":"Sildenafil vs. placebo in HFpEF","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/1663257","subspecialties":"Cardiology"},{"trainingLevel":"Fellow","pageName":"REMATCH","briefResultsDescription":"LVAD reduced all-cause mortality in end-stage heart failure","diseases":"Heart Failure","citation":"Rose EA, et al. \"Long-term use of a left ventricular assist device for end-stage heart failure\". The New England Journal of Medicine. 2001. 345(20):1435-43.","pageid":2822,"expansion":"Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa012175","briefDesignDescription":"Destination LVAD in end-stage heart failure","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa012175","abbreviation":"REMATCH","timestamp":"2019-04-11T17:01:50Z","published":"2001-11-15","title":"Long-term use of a left ventricular assist device for end-stage heart failure","pmid":"11794191","statusUsableDate":"2019-04-11"},{"pageName":"RENAAL","briefResultsDescription":"ARBs reduce progression to","diseases":"Diabetes Mellitus;Chronic Kidney Disease","trainingLevel":"Intern","expansion":"Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan","citation":"Brenner BM, et al. \"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy\". The New England Journal of Medicine. 2001. 345(12):861-869.","pageid":1030,"briefDesignDescription":"ARBs in diabetic nephropathy","subspecialties":"Endocrinology;Nephrology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011161","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011161","title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","statusUsableDate":"2013-01-01","pmid":"11565518","abbreviation":"RENAAL","timestamp":"2017-12-03T22:38:59Z","published":"2001-09-20"},{"pageName":"RESCUEicp","briefResultsDescription":"Craniectomy reduced mortality by 22% compared to usual care","diseases":"Intracranial Hypertension;Traumatic Brain Injury","trainingLevel":"Resident","expansion":"Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure","citation":"Hutchinson PJ, et al. \"Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension\". The New England Journal of Medicine. 2016. 375(12):1119-30.","pageid":3596,"briefDesignDescription":"Craniectomy vs. medical care for intracranial hypertension","subspecialties":"Surgery;Neurology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1605215","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1605215","title":"Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension","statusUsableDate":"2018-07-19","pmid":"27602507","abbreviation":"RESCUEicp","timestamp":"2018-07-22T21:45:32Z","published":"2016-09-22"},{"abbreviation":"RESPECT","timestamp":"2017-12-03T22:39:00Z","published":"2013-03-21","title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","statusUsableDate":"2013-05-01","pmid":"23514286","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301440","briefDesignDescription":"PFO closure in cryptogenic stroke","subspecialties":"Neurology;Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301440","citation":"Carroll JD, et al. \"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke\". The New England Journal of Medicine. 2013. 368(12):1092-1100.","pageid":1334,"expansion":"Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment","trainingLevel":"Intern","pageName":"RESPECT","briefResultsDescription":"PFO closure does not reduce recurrent CVA after cryptogenic CVA","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack"},{"pdfurl":"http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf","fulltexturl":"http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html","subspecialties":"Gastroenterology","briefDesignDescription":"Rifaximin/lactulose vs. lactulose for acute HE","published":"2013-09-01","timestamp":"2017-12-03T22:39:03Z","abbreviation":"","statusUsableDate":"2014-03-01","pmid":"23877348","title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","trainingLevel":"Intern","diseases":"Hepatic Encephalopathy","briefResultsDescription":"Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS","pageName":"Rifaximin and Lactulose for HE","pageid":1784,"citation":"Sharma BC, et al. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". The American Journal of Gastroenterology. 2013. 108(9):1458-1463.","expansion":""},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169","subspecialties":"Rheumatology;Nephrology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/nejmoa0909169","briefDesignDescription":"Rituximab in ANCA-Renal Vasculitis","timestamp":"2022-03-10T21:09:46Z","published":"2010-07-15","abbreviation":"RITUXVAS","statusUsableDate":"2022-03-10","pmid":"20647198","title":"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","trainingLevel":"fellow","briefResultsDescription":"Rituximab not superior to cyclophosphamide","diseases":"Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis","pageName":"RITUXVAS","citation":"Jones RB, et al. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". The New England Journal of Medicine. 2010. 363(3):211-232.","pageid":4459,"expansion":""},{"title":"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock","statusUsableDate":"2012-03-01","pmid":"11794169","abbreviation":"","published":"2001-11-08","timestamp":"2022-04-19T13:00:26Z","briefDesignDescription":"Early goal-directed therapy in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010307","subspecialties":"Critical Care;Emergency Medicine","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010307","expansion":"","pageid":60,"citation":"Rivers E, et al. \"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock\". The New England Journal of Medicine. 2001. 345(19):1368-1377.","pageName":"Rivers Trial","diseases":"Sepsis;Shock","briefResultsDescription":"Early goal-directed therapy decreased mortality and morbiditiy in sepsis","trainingLevel":"Student"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009638","briefDesignDescription":"Rivaroxaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009638","subspecialties":"Cardiology;Neurology","abbreviation":"ROCKET AF","published":"2011-09-08","timestamp":"2017-12-03T22:39:02Z","title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","statusUsableDate":"2013-04-01","pmid":"21830957","trainingLevel":"Student","pageName":"ROCKET AF","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","briefResultsDescription":"Rivaroxaban is noninferior to warfarin for stroke/embolization prevention in nonvalvular AF","pageid":1358,"citation":"Patel MR, et al. \"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation\". The New England Journal of Medicine. 2011. 365(10):883-891.","expansion":"Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation"},{"expansion":"Reevaluation of Systemic Early Neuromuscular Blockade","pageid":4070,"citation":"National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. \"Early neuromuscular blockade in the acute respiratory distress syndrome\". The New England Journal of Medicine. 2019. 380(21):1997-2008.","pageName":"ROSE","diseases":"Acute Respiratory Distress Syndrome","briefResultsDescription":"Cisatracurium blockade doesn't improve outcomes in ARDS","trainingLevel":"Resident","title":"Early neuromuscular blockade in the acute respiratory distress syndrome","pmid":"31112383","statusUsableDate":"2019-06-14","abbreviation":"ROSE","published":"2019-05-23","timestamp":"2020-07-12T00:30:51Z","briefDesignDescription":"Cisatracurium NM blockade in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1901686","subspecialties":"Critical Care","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901686"},{"subspecialties":"Infectious Disease;Urology;Gynecology","fulltexturl":"https://doi.org/10.1001/jamainternmed.2018.4204","briefDesignDescription":"Water intake to prevent UTI","pdfurl":"","pmid":"30285042","statusUsableDate":"2019-09-15","title":"Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections","timestamp":"2022-12-01T20:14:11Z","published":"2018-10-01","abbreviation":"","briefResultsDescription":"Drinking more water reduces recurrent UTIs in premenopausal women","diseases":"Urinary Tract Infections","pageName":"S-HYDRACYST","trainingLevel":"Student","expansion":"","citation":"Hooton TM, et al. \"Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections\". JAMA Internal Medicine. 2018. 178(11):1509-1515.","pageid":4072},{"expansion":"Sertraline Antidepressant Heart Attack Randomized Trial","citation":"Glassman AH, et al. \"Sertraline treatment of major depression in patients with acute MI or unstable angina\". Journal of the American Medical Association. 2002. 288(6):701-709.","pageid":423,"pageName":"SADHART","briefResultsDescription":"Sertraline improves symptoms without adverse CV effects","diseases":"Depression;Acute Coronary Syndrome","trainingLevel":"Resident","title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","statusUsableDate":"2012-05-01","pmid":"12169073","abbreviation":"SADHAT","timestamp":"2018-09-04T17:00:07Z","published":"2002-08-14","briefDesignDescription":"Sertraline for depression post-ACS","subspecialties":"Psychiatry;Cardiology","fulltexturl":"http://jama.ama-assn.org/content/288/6/701.full","pdfurl":"http://jama.ama-assn.org/content/288/6/701.full.pdf"},{"pageName":"SAFE","diseases":"Critical Illness","briefResultsDescription":"No mortality difference (except worse mortality with albumin for TBI)","trainingLevel":"Intern","expansion":"Saline versus Albumin Fluid Evaluation","pageid":285,"citation":"Finfer S, et al. \"A comparison of albumin and saline for fluid resuscitation in the intensive care unit\". The New England Journal of Medicine. 2004. 350(22):2247-2256.","briefDesignDescription":"Albumin vs. saline in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040232","subspecialties":"Critical Care","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040232","title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","pmid":"15163774","statusUsableDate":"2012-03-01","abbreviation":"SAFE","published":"2004-05-27","timestamp":"2017-01-19T20:07:27Z"},{"expansion":"Saline Against Lactated Ringer's or Plasma-Lyte in the Emergency Department","pageid":3556,"citation":"Self WH, et al. \"Balanced crystalloids versus saline in noncritically ill adults\". The New England Journal of Medicine. 2018. 378(10):819-828.","pageName":"SALT-ED","diseases":"Hypovolemia;Acute Kidney Injury","briefResultsDescription":"Balanced crystalloids result in fewer renal abnormalities","trainingLevel":"Student","title":"Balanced crystalloids versus saline in noncritically ill adults","pmid":"29485926","statusUsableDate":"2018-04-05","abbreviation":"SALT-ED","published":"2018-03-01","timestamp":"2018-04-05T18:17:47Z","briefDesignDescription":"Balanced crystalloids vs. NS in non-critical ED patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1711586","subspecialties":"Critical Care;Nephrology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711586"},{"briefDesignDescription":"Stenting in intracranial stenosis","subspecialties":"Neurology;Interventional Radiology","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335","title":"Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis","pmid":"24168957","statusUsableDate":"2016-03-01","abbreviation":"SAMMPRIS","timestamp":"2019-06-27T16:40:34Z","published":"2011-09-15","pageName":"SAMMPRIS","briefResultsDescription":"Medical therapy superior to stenting in IC stenosis","diseases":"Stroke","trainingLevel":"Intern","expansion":"","citation":"Chimowitz MI, et al. \"Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis\". The New England Journal of Medicine. 2015. 365(11):993-1003.","pageid":2420},{"expansion":"Survival and Ventricular Enlargement Trial","pageid":150,"citation":"Pfeffer MA, et al. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". The New England Journal of Medicine. 1992. 327(10):669-677.","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Heart Failure","briefResultsDescription":"Captopril improves survival","pageName":"SAVE","trainingLevel":"Resident","pmid":"1386652","statusUsableDate":"2012-03-01","title":"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial","published":"1992-09-03","timestamp":"2015-08-24T04:52:18Z","abbreviation":"SAVE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199209033271001","subspecialties":"Cardiology","briefDesignDescription":"Captopril in MI with LV dysfunction","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001"},{"expansion":"Sudden Cardiac Death in Heart Failure Trial","citation":"Bardy GH, et al. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". The New England Journal of Medicine. 2005. 252(3):225-37.","pageid":40,"briefResultsDescription":"ICD reduces mortality by 23% in class II-III HFrEF","diseases":"Heart Failure","pageName":"SCD-HeFT","trainingLevel":"Intern","statusUsableDate":"2012-03-01","pmid":"15659722","title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","timestamp":"2019-05-16T20:18:55Z","published":"2005-01-20","abbreviation":"SCD-HeFT","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa043399","briefDesignDescription":"Amiodarone or ICD in severe HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399"},{"briefDesignDescription":"Dexmedetomidine vs. midazolam for sedation","fulltexturl":"http://jama.ama-assn.org/content/301/5/489.long","subspecialties":"Critical Care","pdfurl":"http://jama.ama-assn.org/content/301/5/489.full.pdf","title":"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients","pmid":"19188334","statusUsableDate":"2012-04-01","abbreviation":"SEDCOM","published":"2009-02-04","timestamp":"2021-02-14T17:21:07Z","pageName":"SEDCOM","diseases":"Critical Illness","briefResultsDescription":"↓ delirium, ↓ ventilator days with dexmedetomidine","trainingLevel":"Resident","expansion":"Safety and Efficacy of Dexmedetomidine Compared with Midazolam","pageid":353,"citation":"Riker RR, et al. \"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients\". Journal of American Medical Association. 2009. 301(5):489-499."},{"briefResultsDescription":"Rivaroxaban noninferior to dalteparin in cancer VTE","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","pageName":"SELECT-D","trainingLevel":"Resident","expansion":"Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism","citation":"Young AM, et al. \"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)\". Journal of Clinical Oncology. 2018. 36(20):2017-23.","pageid":3717,"subspecialties":"Hematology;Oncology","fulltexturl":"http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034","briefDesignDescription":"Rivaroxaban vs. LMWH in cancer VTE","pdfurl":"http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.78.8034","pmid":"29746227","statusUsableDate":"2018-12-20","title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","timestamp":"2024-08-29T19:21:15Z","published":"2018-07-10","abbreviation":"SELECT-D"},{"subspecialties":"Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1312173","briefDesignDescription":"MAP 65-70 vs. 80-85 mmHg in sepsis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1312173","pmid":"24635770","statusUsableDate":"2014-04-01","title":"High versus low blood-pressure target in patients with septic shock","timestamp":"2019-04-24T01:13:29Z","published":"2014-04-23","abbreviation":"SEPSISPAM","briefResultsDescription":"No difference for higher MAP in sepsis except renal protection in vascular disease","diseases":"Sepsis;Shock","pageName":"SEPSISPAM","trainingLevel":"Resident","expansion":"Sepsis and Mean Arterial Pressure","citation":"Asfar P, et al. \"High versus low blood-pressure target in patients with septic shock\". The New England Journal of Medicine. 2014. 370(17):1583-1593.","pageid":1779},{"citation":"Swedberg K et al. \"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study\". Lancet. 2010. 376(10):875-885.","pageid":2735,"expansion":"Systolic Heart failure treatment with the If inhibitor ivabradine Trial","trainingLevel":"Resident","briefResultsDescription":"Ivabradine improves mortality and heart failure hospitalization in HFrEF","diseases":"Heart Failure","pageName":"SHIFT","timestamp":"2017-12-03T22:39:10Z","published":"2010-09-11","abbreviation":"SHIFT","pmid":"20801500","statusUsableDate":"2016-05-01","title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(10)61198-1.pdf","subspecialties":"Cardiology","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0140673610611981","briefDesignDescription":"Ivabradine in HFrEF"},{"pageid":388,"citation":"Hochman JS, et al. \"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock\". The New England Journal of Medicine. 1999. 341(9):625-634.","expansion":"SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK","trainingLevel":"Resident","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","briefResultsDescription":"Early PCI/CABG improves survival in acute MI and cardiogenic shock","pageName":"SHOCK","published":"1999-08-26","timestamp":"2017-12-03T22:39:12Z","abbreviation":"SHOCK","statusUsableDate":"2012-04-01","pmid":"10460813","title":"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199908263410901","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199908263410901","subspecialties":"Cardiology;Critical Care","briefDesignDescription":"Early PCI/CABG in MI + shock"},{"briefResultsDescription":"Salmeterol increases death in subgroups","diseases":"Asthma","pageName":"SMART","trainingLevel":"intern","expansion":"Salmeterol Multicenter Asthma Research Trial","citation":"Nelson HS, et al. \"The salmeterol multicenter asthma research trial\". Chest. 2006. 129(1):15-26.","pageid":512,"subspecialties":"Pulmonology","fulltexturl":"http://bit.ly/1VSBfoL","briefDesignDescription":"Salmeterol in asthma","pdfurl":"http://journal.publications.chestnet.org/data/Journals/CHEST/22038/15.pdf","pmid":"16424409","statusUsableDate":"2012-08-01","title":"The salmeterol multicenter asthma research trial","timestamp":"2017-12-03T22:39:13Z","published":"2006-01-01","abbreviation":"SMART"},{"briefDesignDescription":"NS vs. balanced crystalloids in ICU","subspecialties":"Critical Care;Nephrology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1711584","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711584","title":"Balanced Crystalloids versus Saline in Critically Ill Adults","statusUsableDate":"2018-04-05","pmid":"29485925","abbreviation":"SMART","timestamp":"2018-04-05T17:39:53Z","published":"2018-03-01","pageName":"SMART-MED and SMART-SURG","briefResultsDescription":"Balanced crystalloids slightly reduced composite rate of death, RRT, or CKD","diseases":"Critical Illness","trainingLevel":"student","expansion":"Isotonic Solutions and Major Adverse Renal Events Trial","citation":"Semler MW, et al. \"Balanced Crystalloids versus Saline in Critically Ill Adults\". The New England Journal of Medicine. 2018. 378(9):829-839.","pageid":3555},{"statusUsableDate":"2012-03-01","pmid":"20200382","title":"Comparison of dopamine and norepinephrine in the treatment of shock","timestamp":"2017-01-19T19:50:29Z","published":"2010-03-04","abbreviation":"SOAP II","subspecialties":"Critical Care;Emergency Medicine","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907118","briefDesignDescription":"Dopamine vs. norepinephrine in shock","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907118","expansion":"Sepsis Occurrence in Acutely Ill Patients II","citation":"De Backer D, et al. \"Comparison of dopamine and norepinephrine in the treatment of shock\". The New England Journal of Medicine. 2010. 362(9):779-89.","pageid":113,"briefResultsDescription":"Norepinephrine reduces mortality","diseases":"Sepsis;Shock","pageName":"SOAP II","trainingLevel":"Intern"},{"statusUsableDate":"2016-10-01","pmid":"27160892","title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","timestamp":"2017-12-03T22:39:15Z","published":"2016-07-07","abbreviation":"SOCRATES","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1603060","briefDesignDescription":"Ticagrelor vs. aspirin in acute stroke or TIA","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603060","expansion":"Ticagrelor versus aspirin in stroke/TIA","citation":"Johnston SC, et al. \"Ticagrelor versus aspirin in acute stroke or transient ischemic attack\". New Engl J Med. 2016. 365(1):35-43.","pageid":2809,"briefResultsDescription":"Ticagrelor not superior to aspirin in acute stroke or TIA","diseases":"Stroke","pageName":"SOCRATES","trainingLevel":"Resident"},{"pageid":394,"citation":"Yusuf S, et al. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". The New England Journal of Medicine. 1991. 325(5):293-302.","expansion":"Studies of Left Ventricular Dysfunction","trainingLevel":"Resident","diseases":"Heart Failure","briefResultsDescription":"Enalapril reduces mortality and HF hospitalizations in HFrEF","pageName":"SOLVD","published":"1991-08-01","timestamp":"2017-12-03T22:39:16Z","abbreviation":"SOLVD","statusUsableDate":"2012-04-01","pmid":"2057034","title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199108013250501","subspecialties":"Cardiology","briefDesignDescription":"Enalapril in moderate-severe HFrEF"},{"briefResultsDescription":"No benefit over age-appropriate screening","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","pageName":"SOME","trainingLevel":"Intern","expansion":"","citation":"Carrier M, et al. \"Screening for Occult Cancer in Unprovoked Venous Thromboembolism\". The New England Journal of Medicine. 2015. 373(8):697-704.","pageid":2498,"subspecialties":"Oncology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1506623","briefDesignDescription":"Occult cancer screening in unprovoked VTE","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506623","statusUsableDate":"2018-08-30","pmid":"26095467","title":"Screening for Occult Cancer in Unprovoked Venous Thromboembolism","timestamp":"2018-08-30T18:21:05Z","published":"2015-08-20","abbreviation":"SOME"},{"subspecialties":"Gastroenterology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904492","briefDesignDescription":"Infliximab ± azathioprine induction in Crohn disease","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904492","statusUsableDate":"2014-07-01","pmid":"20393175","title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","timestamp":"2017-12-03T22:39:17Z","published":"2010-04-15","abbreviation":"SONIC","briefResultsDescription":"Combination therapy better than infliximab or azathioprine for Crohn disease induction therapy","diseases":"Inflammatory Bowel Disease;Crohn Disease","pageName":"SONIC","trainingLevel":"Intern","expansion":"Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease","citation":"Colombel JF, et al. \"Infliximab, azathioprine, or combination therapy for Crohn's disease\". The New England Journal of Medicine. 2010. 362(15):1383-1395.","pageid":1863},{"briefResultsDescription":"Opioids without benefit over non-opioid management for chronic MSK pain","diseases":"Chronic Pain","pageName":"SPACE","trainingLevel":"student","expansion":"Strategies for Prescribing Analgesics Comparative Effectiveness","citation":"Krebs EE, et al. \"Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain\". JAMA. 2018. 319(9):872-882.","pageid":3620,"subspecialties":"Emergency Medicine;Pain Medicine","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2018.0899","briefDesignDescription":"Opioids vs. non-opioids in chronic MSK pain","pdfurl":"","pmid":"29509867","statusUsableDate":"2019-06-27","title":"Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain","timestamp":"2019-06-28T16:43:02Z","published":"2018-06-03","abbreviation":"SPACE"},{"pdfurl":"http://circ.ahajournals.org/content/84/2/527.full.pdf","briefDesignDescription":"Aspirin and warfarin in AF","fulltexturl":"http://circ.ahajournals.org/content/84/2/527.long","subspecialties":"Cardiology;Neurology","abbreviation":"SPAF","published":"1991-08-01","timestamp":"2017-12-03T22:39:18Z","title":"Stroke Prevention in Atrial Fibrillation Study. Final results","pmid":"1860198","statusUsableDate":"2016-08-01","trainingLevel":"Resident","pageName":"SPAF","diseases":"Atrial Fibrillation;Stroke","briefResultsDescription":"Aspirin and warfarin reduce stroke incidence in AF","pageid":2340,"citation":"SPAF Investigators. \"Stroke Prevention in Atrial Fibrillation Study. Final results\". Circulation. 1991. 84(2):527-39.","expansion":"Stroke Prevention in Atrial Fibrillation"},{"trainingLevel":"intern","pageName":"SPARCL","briefResultsDescription":"Atorvastatin ↓stroke risk in general but slightly ↑hemorrhagic strokes","diseases":"Stroke;Hyperlipidemia;Transient Ischemic Attack","citation":"Amarenco P, et al. \"High-dose atorvastatin after stroke or transient ischemic attack\". The New England Journal of Medicine. 2006. 355(6):549-559.","pageid":461,"expansion":"Stroke Prevention by Aggressive Reduction in Cholesterol Levels","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061894","briefDesignDescription":"Atorvastatin after stroke","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061894","abbreviation":"SPARCL","timestamp":"2017-12-03T22:39:20Z","published":"2006-08-10","title":"High-dose atorvastatin after stroke or transient ischemic attack","statusUsableDate":"2012-06-01","pmid":"16899775"},{"expansion":"Sedation Practice in Intensive Care Evaluation","citation":"Shehabi Y, et al. \"Early Sedation with Dexmedetomidine in Critically Ill Patients\". The New England Journal of Medicine. 2019. 380(26):2506-2517.","pageid":4073,"briefResultsDescription":"Dexmedetomidine with more adverse events vs. usual care","diseases":"Sedation;Delirium","pageName":"SPICE III","trainingLevel":"Fellow","pmid":"31112380","statusUsableDate":"2020-05-14","title":"Early Sedation with Dexmedetomidine in Critically Ill Patients","timestamp":"2021-10-26T13:55:55Z","published":"2019-05-19","abbreviation":"SPICE III","subspecialties":"Critical Care","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1904710","briefDesignDescription":"Dexmedetomidine in ICU sedation","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1904710?articleTools"},{"pmid":"26551272","statusUsableDate":"2015-11-01","title":"A randomized trial of intensive versus standard blood-pressure control","published":"2015-11-09","timestamp":"2024-12-12T20:30:17Z","abbreviation":"SPRINT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1511939","subspecialties":"Cardiology;Preventive Medicine","briefDesignDescription":"BP targets in high-risk patients","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1511939","expansion":"Systolic Blood Pressure Intervention Trial","pageid":2487,"citation":"The SPRINT Research Group. \"A randomized trial of intensive versus standard blood-pressure control\". The New England Journal of Medicine. 2015. 373(22):2103-2116.","diseases":"Hypertension","briefResultsDescription":"SBP <120 improves CV outcomes with increased risks","pageName":"SPRINT","trainingLevel":"Student"},{"abbreviation":"SPS3-Clopidogrel+ASA","timestamp":"2017-12-03T22:39:22Z","published":"2012-08-30","title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","pmid":"22931315","statusUsableDate":"2016-06-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1204133","briefDesignDescription":"Clopidogrel+ASA for lacunar strokes","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1204133","citation":"SPS3 Study Group writers. \"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke\". New England Journal of Medicine. 2012. 367(9):817-825.","pageid":2678,"expansion":"Secondary Prevention of Small Subcortical Strokes clopidogrel+ASA","trainingLevel":"Intern","pageName":"SPS3 Clopidogrel-ASA","briefResultsDescription":"Clopidogrel+ASA increased all cause mortality compared to ASA alone","diseases":"Stroke;Transient Ischemic Attack"},{"published":"2013-05-29","timestamp":"2017-12-03T22:39:24Z","abbreviation":"SPS3-BP","statusUsableDate":"2016-01-01","pmid":"23726159","title":"Blood-pressure targets in patients with recent lacunar stroke","pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)60852-1.pdf","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60852-1/abstract","subspecialties":"Neurology","briefDesignDescription":"SBP <130 vs. SBP 130-150 after lacunar strokes","pageid":2671,"citation":"SPS3 Study Group. \"Blood-pressure targets in patients with recent lacunar stroke\". The Lancet. 2013. 382(9891):507-515.","expansion":"Secondary Prevention of Small Subcortical Strokes-Blood Pressure","trainingLevel":"Intern","diseases":"Stroke","briefResultsDescription":"No significant difference in all stroke types between two groups","pageName":"SPS3-BP"},{"briefResultsDescription":"Renal denervation+meds is superior to medical therapy alone in resistant hypertension","diseases":"Hypertension","pageName":"SPYRAL HTN-ON MED","trainingLevel":"Resident","expansion":"Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy","citation":"Kandazi DE, et al. \"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs\". The Lancet. 2018. 391:2346-55.","pageid":3642,"subspecialties":"Cardiology","fulltexturl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30951-6/fulltext","briefDesignDescription":"Renal denervation in resistant hypertension","pdfurl":"https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(18)30951-6.pdf","statusUsableDate":"2018-06-12","pmid":"29803589","title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs","timestamp":"2018-06-29T18:11:38Z","published":"2018-06-09","abbreviation":"SPYRAL HTN-ON MED"},{"pageName":"STAMPEDE","diseases":"Diabetes Mellitus;Obesity","briefResultsDescription":"Bypass plus medical therapy is superior to medical therapy alone","trainingLevel":"Resident","expansion":"Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently","pageid":2266,"citation":"Schauer PR, et al. \"Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes\". The New England Journal of Medicine. 2012. 366(17):1567-76.","briefDesignDescription":"Gastric bypass vs. medical therapy for T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200225","subspecialties":"Endocrinology;Surgery","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200225","title":"Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes","statusUsableDate":"2015-01-01","pmid":"22449319","abbreviation":"STAMPEDE","published":"2012-04-26","timestamp":"2017-12-03T22:39:25Z"},{"expansion":"Study of Tamoxifen and Raloxifene (NSABP P-2)","pageid":963,"citation":"Vogel VG, et al. \"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes\". Journal of the American Medical Association. 2006. 295(23):2727-2741.","diseases":"Breast Cancer","briefResultsDescription":"Similar reduction in breast cancer risk but fewer adverse effects with raloxifene","pageName":"STAR","trainingLevel":"Fellow","statusUsableDate":"2012-08-01","pmid":"16754727","title":"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes","published":"2006-06-21","timestamp":"2017-12-03T22:39:26Z","abbreviation":"STAR","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","subspecialties":"Oncology","briefDesignDescription":"Tamoxifen vs. raloxifene in breast cancer prevention","pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5028/JOC60074.pdf"},{"expansion":"Sequenced Treatment Alternatives to Relieve Depression","citation":"Rush AJ et al. \"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report\". The American Journal of Psychiatry. 2006. 163(11):1905-1917.","pageid":1564,"briefResultsDescription":"Most patients achieved remission in first two steps","diseases":"Depression","pageName":"STAR-D","trainingLevel":"Resident","statusUsableDate":"2013-09-01","pmid":"17074942","title":"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report","timestamp":"2017-12-03T22:39:27Z","published":"2006-11-01","abbreviation":"STAR-D","subspecialties":"Psychiatry","fulltexturl":"","briefDesignDescription":"Tiered approach for depression","pdfurl":"http://ajp.psychiatryonline.org/data/Journals/AJP/3782/06aj1905.PDF"},{"expansion":"Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients","citation":"Zhang W, et al. \"Trial of intensive blood-pressure control in older patients with hypertension\". The New England Journal of Medicine. 2021. 385(14):1268-1279.","pageid":4446,"pageName":"STEP","briefResultsDescription":"Intensive BP control lowers CVD events","diseases":"Hypertension","trainingLevel":"student","title":"Trial of intensive blood-pressure control in older patients with hypertension","statusUsableDate":"2021-11-30","pmid":"34491661","abbreviation":"STEP","timestamp":"2023-02-04T04:10:40Z","published":"2021-09-30","briefDesignDescription":"Intensive BP control hypertension","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2111437","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2111437"},{"title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","statusUsableDate":"2021-04-22","pmid":"33567185","abbreviation":"STEP 1","timestamp":"2023-11-11T23:27:35Z","published":"2021-03-18","briefDesignDescription":"Semaglutide in obesity without diabetes","subspecialties":"Endocrinology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2032183","expansion":"Semaglutide Treatment Effect in People with Obesity 1","citation":"Wilding JPH, et al. \"Once-Weekly Semaglutide in Adults with Overweight or Obesity\". The New England Journal of Medicine. 2021. 384(11):989-1002.","pageid":4407,"pageName":"STEP 1","briefResultsDescription":"Semaglutide led to significant weight loss vs. placebo","diseases":"Obesity;Overweight","trainingLevel":"Resident"},{"diseases":"HFpEF;Obesity","briefResultsDescription":"Semaglutide better than placebo for HF events in HFpEF+obesity","pageName":"STEP-HFpEF","trainingLevel":"student","expansion":"Semaglutide Treatment Effect in People with Heart Failure with Preserved Ejection Fraction","pageid":5605,"citation":"Kosiborod MN, et al. \"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity\". The New England Journal of Medicine. 2023. 389(12):1069-1084.","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2306963","subspecialties":"Cardiology","briefDesignDescription":"Semaglutide in HFpEF+obesity but no DM","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2306963","pmid":"37622681","statusUsableDate":"2025-06-19","title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","published":"2023-08-25","timestamp":"2025-06-19T18:47:05Z","abbreviation":"STEP-HFpEF"},{"pmid":"21463150","statusUsableDate":"2012-12-01","title":"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction","timestamp":"2017-12-03T22:39:28Z","published":"2011-04-28","abbreviation":"STICH","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1100356","briefDesignDescription":"CABG in ischemic HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356","expansion":"Surgical Treatment for Ischemic Heart Failure","citation":"Velazquez EJ, et al. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". The New England Journal of Medicine. 2011. 354(17):1607-1616.","pageid":471,"briefResultsDescription":"No mortality benefit with CABG vs. OMT though improved CV outcomes","diseases":"Heart Failure;Coronary Artery Disease","pageName":"STICH","trainingLevel":"Resident"},{"pageid":1664,"citation":"Rummel MJ, et al. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". The Lancet. 2013. 381(9873):1203-10.","expansion":"Study Group Indolent Lymphomas","trainingLevel":"fellow","pageName":"StiL","diseases":"Lymphoma","briefResultsDescription":"BR superior to R-CHOP in PFS, similar in OS, less toxic","abbreviation":"StiL","published":"2013-04-03","timestamp":"2017-12-03T22:39:35Z","title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","statusUsableDate":"2014-06-01","pmid":"23433739","pdfurl":"http://bit.ly/1owpykX","briefDesignDescription":"BR vs. R-CHOP for indolent lymphomas","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2","subspecialties":"Oncology;Hematology"},{"title":"Trial of short-course antimicrobial therapy for intraabdominal infection","statusUsableDate":"2020-01-25","pmid":"25992746","abbreviation":"STOP-IT","timestamp":"2020-01-25T15:49:52Z","published":"2015-05-21","briefDesignDescription":"Duration of abx in intraabdominal infection","subspecialties":"Infectious Disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1411162","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411162","expansion":"Study to Optimize Peritoneal Infection Therapy","citation":"Sawyer RG, et al. \"Trial of short-course antimicrobial therapy for intraabdominal infection\". The New England Journal of Medicine. 2015. 372(21):1996-2005.","pageid":2424,"pageName":"STOP-IT","briefResultsDescription":"Short duration non-inferior to longer duration in intraabdominal infection","diseases":"Intraabdominal Infection","trainingLevel":"Intern"},{"pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(02)08905-5.pdf","briefDesignDescription":"Acarbose to prevent diabetes in high-risk patients","fulltexturl":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08905-5/fulltext","subspecialties":"Endocrinology","abbreviation":"STOP-NIDDM","published":"2002-06-15","timestamp":"2023-08-03T18:09:18Z","title":"Acarbose for prevention of type 2 diabetes mellitus","pmid":"12086760","statusUsableDate":"2023-08-03","trainingLevel":"Resident","pageName":"STOP-NIDDM","diseases":"Diabetes Mellitus","briefResultsDescription":"Acarbose reduced the risk of diabetes","pageid":2754,"citation":"Chiasson JL, et al. \"Acarbose for prevention of type 2 diabetes mellitus\". The Lancet. 2005. 359(9323):2072-2077.","expansion":"Study to Prevent NIDDM"},{"subspecialties":"Gastroenterology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1412278","briefDesignDescription":"Prednisolone vs. pentoxifylline in alcoholic hepatitis","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412278","statusUsableDate":"2016-03-01","pmid":"25901427","title":"Prednisolone or pentoxifylline for alcoholic hepatitis","timestamp":"2023-11-13T16:15:41Z","published":"2015-04-23","abbreviation":"STOPAH","briefResultsDescription":"No difference between groups","diseases":"Alcoholic Hepatitis","pageName":"STOPAH","trainingLevel":"Intern","expansion":"Steroids or Pentoxifylline for Alcoholic Hepatitis","citation":"Thursz MR, et al. \"Prednisolone or pentoxifylline for alcoholic hepatitis\". The New England Journal of Medicine. 2015. 372(17):1619-1628.","pageid":2365},{"pageid":2432,"citation":"Kutner JS, et al. \"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial\". JAMA Internal Medicine. 2015. 175(5):691-700.","expansion":"","trainingLevel":"Resident","diseases":"Hyperlipidemia","briefResultsDescription":"Discontinuing statin doesn't change 60 day all-cause mortality","pageName":"Stopping Statins at the End of Life","published":"2015-05-01","timestamp":"2017-12-03T22:39:36Z","abbreviation":"","statusUsableDate":"2015-09-01","pmid":"25798575","title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","pdfurl":"","fulltexturl":"http://bit.ly/1LOZfB6","subspecialties":"Palliative Care;Cardiology","briefDesignDescription":"Palliative statin discontinuation"},{"abbreviation":"SUP-ICU","published":"2018-10-24","timestamp":"2025-06-19T18:34:51Z","title":"Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU","statusUsableDate":"2018-11-01","pmid":"30354950","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1714919","briefDesignDescription":"Routine PPI use in the ICU","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1714919","subspecialties":"Critical Care","pageid":3725,"citation":"Krag M, et al. \"Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU\". The New England Journal of Medicine. 2018. 379:2199-2208.","expansion":"Stress Ulcer Prophylaxis in the Intensive Care Unit","trainingLevel":"Resident","pageName":"SUP-ICU","diseases":"Stress Ulcer","briefResultsDescription":"PPI doesn't reduce mortality, it reduces bleeding"},{"timestamp":"2017-12-03T22:39:31Z","published":"2017-03-17","abbreviation":"SURTAVI","pmid":"28304219","statusUsableDate":"2017-04-01","title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700456","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1700456","briefDesignDescription":"TAVI for AS in intermediate-risk surgical candidates","citation":"Reardon MJ, et al. \"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients\". The New England Journal of Medicine. 2017. epub 2017-03-17:1-11.","pageid":2895,"expansion":"Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement","trainingLevel":"Resident","briefResultsDescription":"TAVI noninferior to surgical AVR in intermediate-risk surgical candidates","diseases":"Aortic Stenosis","pageName":"SURTAVI"},{"briefDesignDescription":"Crizanlizumab vs. placebo in SCD","subspecialties":"Hematology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1611770","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770","title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","statusUsableDate":"2020-12-31","pmid":"27959701","abbreviation":"SUSTAIN","timestamp":"2021-01-05T21:10:45Z","published":"2017-02-02","pageName":"SUSTAIN","briefResultsDescription":"Crizanlizumab reduces painful crises","diseases":"Sickle Cell Disease","trainingLevel":"Fellow","expansion":"","citation":"Ataga KI, et al. \"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease\". The New England Journal of Medicine. 2017. 376(5):429-439.","pageid":4387},{"expansion":"","citation":"Tabar L, et al. \"Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades\". Radiology. 2011. 260(3):658-663.","pageid":2435,"briefResultsDescription":"Breast cancer screening with mammogram lowers cancer mortality","diseases":"Breast Cancer","pageName":"Swedish Two-County Trial","trainingLevel":"Student","statusUsableDate":"2023-02-16","pmid":"21712474","title":"Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades","timestamp":"2023-02-16T20:42:11Z","published":"2011-09-01","abbreviation":"Swedish Two-County Trial","subspecialties":"Oncology;Preventive Medicine","fulltexturl":"http://pubs.rsna.org/doi/10.1148/radiol.11110469","briefDesignDescription":"Mammogram screening 29y follow-up","pdfurl":"http://pubs.rsna.org/doi/pdf/10.1148/radiol.11110469"},{"citation":"Flanigan RC, et al. \"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer\". The New England Journal of Medicine. 2001. 345(23):1655-9.","pageid":1845,"expansion":"","trainingLevel":"Fellow","briefResultsDescription":"Cytoreductive nephrectomy improves survival in mRCC","diseases":"Renal Cell Carcinoma","pageName":"SWOG 8949","timestamp":"2024-10-03T23:36:53Z","published":"2001-12-06","abbreviation":"SWOG 8949","pmid":"11759643","statusUsableDate":"2014-06-01","title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa003013","subspecialties":"Oncology;Surgery;Urology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa003013","briefDesignDescription":"Cytoreductive nephrectomy in metastatic RCC"},{"trainingLevel":"Intern","pageName":"Symptom-Triggered Benzodiazepines in Alcohol Withdrawal","briefResultsDescription":"Symptom-triggered therapy reduces length of hospitalization without increasing adverse event risk","diseases":"Alcohol Withdrawal","citation":"Daeppen JB, et al. \"Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial\". Archives of Internal Medicine. 2002. 162(10):1117-21.","pageid":116,"expansion":"","pdfurl":"http://archinte.ama-assn.org/cgi/reprint/162/10/1117.pdf","briefDesignDescription":"Symptom-triggered therapy in alcohol withdrawal","subspecialties":"Psychiatry","fulltexturl":"http://archinte.ama-assn.org/cgi/content/full/162/10/1117","abbreviation":"","timestamp":"2013-03-05T21:40:49Z","published":"2002-05-27","title":"Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial","pmid":"12020181","statusUsableDate":"2012-03-01"},{"title":"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease","pmid":"19228612","statusUsableDate":"2012-06-01","abbreviation":"SYNTAX","timestamp":"2017-12-03T22:39:33Z","published":"2009-03-05","briefDesignDescription":"PCI vs. CABG in severe CAD","subspecialties":"Cardiology;Surgery","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804626","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804626","expansion":"Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery","citation":"Serruys PW, et al. \"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease\". The New England Journal of Medicine. 2009. 360(10):961-972.","pageid":525,"pageName":"SYNTAX","briefResultsDescription":"CABG reduces major CV events with 3VD or LM disease","diseases":"Coronary Artery Disease","trainingLevel":"Resident"},{"expansion":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban","citation":"Cannon CP, et al. \"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban\". New England Journal of Medicine. 2001. 344(25):1879-1887.","pageid":2656,"pageName":"TACTICS-TIMI 18","briefResultsDescription":"Early PCI improves outcomes in high-risk patients","diseases":"Coronary Artery Disease","trainingLevel":"Resident","title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban","pmid":"11419424","statusUsableDate":"2016-05-01","abbreviation":"TACTICS-TIMI 18","timestamp":"2020-04-01T00:34:11Z","published":"2001-06-21","briefDesignDescription":"Early vs. Delayed PCI for UA-NSTEMI","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200106213442501","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200106213442501"},{"statusUsableDate":"2015-01-01","pmid":"20979471","title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma","timestamp":"2017-12-03T22:39:38Z","published":"2010-10-28","abbreviation":"TALC","subspecialties":"Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1008770","briefDesignDescription":"Tiotropium vs. others in asthma","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008770","expansion":"Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid","citation":"Peters SP, et al. \"Tiotropium bromide step-up therapy for adults with uncontrolled asthma\". The New England Journal of Medicine. 2010. 363(18):1715-1726.","pageid":2267,"briefResultsDescription":"Adding tiotropium improves peak expiratory flow better than doubling the ICS dose","diseases":"Asthma","pageName":"TALC","trainingLevel":"Fellow"},{"pdfurl":"","briefDesignDescription":"Intensive vs. standard treatment in early RA","fulltexturl":"https://doi.org/10.1016/s0140-6736(04)16676-2","subspecialties":"Rheumatology","abbreviation":"TICORA","published":"2004-07-17","timestamp":"2022-08-25T20:01:42Z","title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","statusUsableDate":"2022-08-25","pmid":"15262104","trainingLevel":"resident","pageName":"TICORA","diseases":"Rheumatoid Arthritis","briefResultsDescription":"Intensive treatment with better disease control than late RA","pageid":2722,"citation":"Grigor C, et al. \"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial\". The Lancet. 2004. 364(9430):263-269.","expansion":"Tight Control of Rheumatoid Arthritis"},{"pmid":"19458363","statusUsableDate":"2018-05-31","title":"Early versus Delayed Invasive Intervention in Acute Coronary Syndromes","published":"2009-05-21","timestamp":"2023-09-21T17:41:32Z","abbreviation":"TIMACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807986","subspecialties":"Cardiology","briefDesignDescription":"Early vs. delayed PCI in NSTEMI and UA","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807986","expansion":"The Timing of Intervention in Acute Coronary Syndromes","pageid":2867,"citation":"Mehta SR, et al. \"Early versus Delayed Invasive Intervention in Acute Coronary Syndromes\". The New England Journal of Medicine. 2009. 360:2165-2175.","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","briefResultsDescription":"Early PCI doesn't provide additional benefit over delayed PCI in NSTEMI and UA","pageName":"TIMACS","trainingLevel":"Resident"},{"trainingLevel":"Fellow","pageName":"TIPPS","briefResultsDescription":"Dalteparin did not reduce rate of pregnancy complications","diseases":"Thrombophilia;Pregnancy;Venous Thromboembolism","citation":"Rodger MA, et al. \"Antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia\". Lancet. 2014. 384(9955):1673-1683.","pageid":3718,"expansion":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia","pdfurl":"https://reader.elsevier.com/reader/sd/pii/S0140673614607935","briefDesignDescription":"Dalteparin in pregnant woman with thrombophilias","subspecialties":"Hematology;Obstetrics","fulltexturl":"https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60793-5","abbreviation":"TIPPS","timestamp":"2019-06-20T18:30:08Z","published":"2014-11-08","title":"Antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia","pmid":"25066248","statusUsableDate":"2019-06-20"},{"pageName":"TNT","briefResultsDescription":"Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD","diseases":"Coronary Artery Disease;Hyperlipidemia","trainingLevel":"Student","expansion":"Treating to New Targets","citation":"LaRosa JC, et al. \"Intensive lipid lowering with atorvastatin in patients with stable coronary disease\". The New England Journal of Medicine. 2005. 352(14):1425-1435.","pageid":1762,"briefDesignDescription":"Atorvastatin in stable CAD","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa050461","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa050461","title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","pmid":"15755765","statusUsableDate":"2013-12-01","abbreviation":"TNT","timestamp":"2017-12-14T19:37:07Z","published":"2005-04-07"},{"diseases":"Hypertension","briefResultsDescription":"Na reduction and weight loss are effective means for hypertension control in the elderly","pageName":"TONE","trainingLevel":"Student","expansion":"Trial of Nonpharmacologic Interventions in the Elderly","pageid":2990,"citation":"Whelton PK, et al. \"Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group\". JAMA. 1998. 279(11):839-846.","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/vol/279/pg/839","subspecialties":"Cardiology","briefDesignDescription":"Na reduction and weight loss for HTN control in elderly","pdfurl":"","statusUsableDate":"2017-12-14","pmid":"9515998","title":"Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group","published":"1998-03-18","timestamp":"2017-12-14T19:36:29Z","abbreviation":"TONE"},{"expansion":"Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist","citation":"Pitt B, et al. \"Spironolactone for heart failure with preserved ejection fraction\". The New England Journal of Medicine. 2014. 370(15):1383-1392.","pageid":1797,"pageName":"TOPCAT","briefResultsDescription":"Spironolactone doesn't reduce CV mortality, aborted cardiac arrest or HF hospitalizations in HFpEF","diseases":"Heart Failure","trainingLevel":"Resident","title":"Spironolactone for heart failure with preserved ejection fraction","pmid":"24716680","statusUsableDate":"2014-05-01","abbreviation":"TOPCAT","timestamp":"2024-10-23T14:44:07Z","published":"2014-04-20","briefDesignDescription":"Spironolactone for HFpEF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313731","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313731"},{"expansion":"Trial of Prophylactic Platelets","citation":"Stanworth S, et al. \"A no-prophylaxis platelet-transfusion strategy for hematologic cancers\". The New England Journal of Medicine. 2013. 368(19):1771-1780.","pageid":2794,"briefResultsDescription":"Prophylactic platelet transfusions lower bleeding events","diseases":"Thrombocytopenia","pageName":"TOPPS","trainingLevel":"Resident","statusUsableDate":"2023-09-22","pmid":"23656642","title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","timestamp":"2023-09-21T18:44:50Z","published":"2013-05-09","abbreviation":"TOPPS","subspecialties":"Oncology;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1212772","briefDesignDescription":"Platelet transfusions in blood cancers","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212772"},{"subspecialties":"Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa063070","briefDesignDescription":"Salmeterol/fluticasone in COPD","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa063070","pmid":"17314337","statusUsableDate":"2012-03-01","title":"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease","timestamp":"2015-05-29T16:40:40Z","published":"2007-02-22","abbreviation":"TORCH","briefResultsDescription":"Trend towards mortality benefit","diseases":"Chronic Obstructive Pulmonary Disease","pageName":"TORCH","trainingLevel":"Student","expansion":"Towards a Revolution in COPD Health","citation":"Calverley PM, et al. \"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease\". The New England Journal of Medicine. 2007. 356(8):775-789.","pageid":124},{"subspecialties":"Neurology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2402980","briefDesignDescription":"tPA 4.5-24h post-stroke if ideal MRI/CT","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2402980","statusUsableDate":"2024-07-28","pmid":"38884324","title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy","timestamp":"2024-08-08T20:44:43Z","published":"2024-07-18","abbreviation":"TRACE-III","briefResultsDescription":"tPA improves recovery after stroke","diseases":"Stroke","pageName":"TRACE-III","trainingLevel":"resident","expansion":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III","citation":"Xiong Y, et al. \"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy\". The New England Journal of Medicine. 2024. 391(3):203-212.","pageid":5557},{"trainingLevel":"Intern","pageName":"Transfusion Strategies for Acute Upper Gastrointestinal Bleeding","diseases":"Gastrointestinal Hemorrhage;Hemorrhage","briefResultsDescription":"Restrictive transfusions lower mortality in UGIB","pageid":1191,"citation":"Villanueva C et al. \"Transfusion strategies for acute upper gastrointestinal bleeding\". The New England Journal of Medicine. 2013. 368(1):11-21.","expansion":"","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211801","briefDesignDescription":"Transfusion thresholds in UGIB","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1211801","subspecialties":"Gastroenterology","abbreviation":"","published":"2013-01-03","timestamp":"2017-12-03T22:39:47Z","title":"Transfusion strategies for acute upper gastrointestinal bleeding","statusUsableDate":"2013-02-01","pmid":"23281973"},{"citation":"Pengo V, et al. \"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome\". Blood. 2018. 132(13):1365-1371.","pageid":3700,"expansion":"Trial on Rivaroxaban in AntiPhospholipid Syndrome","trainingLevel":"Fellow","briefResultsDescription":"Rivaroxaban inferior to warfarin in high-risk APLS","diseases":"Antiphospholipid Syndrome","pageName":"TRAPS","timestamp":"2021-05-26T13:37:31Z","published":"2018-09-27","abbreviation":"TRAPS","pmid":"30002145","statusUsableDate":"2018-10-19","title":"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome","pdfurl":null,"subspecialties":"Hematology;Rheumatology","fulltexturl":"https://doi.org/10.1182/blood-2018-04-848333","briefDesignDescription":"Rivaroxaban in high-risk APLS"},{"pmid":"19880844","statusUsableDate":"2012-03-01","title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","timestamp":"2015-03-09T17:49:43Z","published":"2009-11-19","abbreviation":"TREAT","subspecialties":"Nephrology;Hematology;Endocrinology","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907845","briefDesignDescription":"Darbepoetin in CKD and T2DM","pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907845","expansion":"Trial to Reduce Cardiovascular Events With Aranesp Therapy","citation":"Pfeffer MA, et al. \"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease\". The New England Journal of Medicine. 2009. 361(21):2019-32.","pageid":5,"briefResultsDescription":"No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM","diseases":"Chronic Kidney Disease;Anemia;Diabetes Mellitus","pageName":"TREAT","trainingLevel":"Resident"},{"statusUsableDate":"2019-06-20","pmid":"30429050","title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","published":"2018-11-09","timestamp":"2019-06-27T20:30:21Z","abbreviation":"TRED-HF","fulltexturl":"https://doi.org/10.1016/S0140-6736(18)32484-X","subspecialties":"Cardiology","briefDesignDescription":"Withdrawal of medications in dilated cardiomyopathy","pdfurl":"https://pdf.sciencedirectassets.com/271074/1-s2.0-S0140673618X00567/1-s2.0-S014067361832484X/main.pdf","expansion":"Treatment for heart failure in patients with recovered dilated cardiomyopathy","pageid":3747,"citation":"Halliday BP, et al. \"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial\". The Lancet. 2019. 393(10166):61-73.","diseases":"Heart Failure;Dilated Cardiomyopathy","briefResultsDescription":"Withdrawal of medications increases relapse of heart failure","pageName":"TRED-HF","trainingLevel":"Resident"},{"expansion":"Transfusion Requirements in Critical Care","pageid":104,"citation":"Hebert PC, et al. \"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care\". The New England Journal of Medicine. 1999. 340(6):409-417.","diseases":"Anemia","briefResultsDescription":"Restrictive hemoglobin goals improved mortality","pageName":"TRICC","trainingLevel":"Intern","pmid":"9971864","statusUsableDate":"2012-03-01","title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care","published":"1999-02-11","timestamp":"2021-08-05T17:53:04Z","abbreviation":"TRICC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199902113400601","subspecialties":"Critical Care;Hematology;Transfusion Medicine","briefDesignDescription":"Transfusion thresholds in ICU","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199902113400601"},{"pageName":"TRICS III","diseases":"Anemia","briefResultsDescription":"Restrictive noninferior to liberal RBC transfusions","trainingLevel":"Resident","expansion":"Transfusion Requirements in Cardiac Surgery","pageid":3536,"citation":"Mazer CD, et al. \"Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery\". The New England Journal of Medicine. 2017. 377(22):2133-44.","briefDesignDescription":"Transfusion thresholds for cardiac surgery","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1711818","subspecialties":"Surgery;Hematology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711818","title":"Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery","statusUsableDate":"2018-04-26","pmid":"29130845","abbreviation":"TRICS III","published":"2017-11-30","timestamp":"2018-04-26T17:40:38Z"},{"pageName":"TRISS","briefResultsDescription":"Similar mortality; Fewer transfusions with restrictive","diseases":"Sepsis;Shock;Anemia","trainingLevel":"Intern","expansion":"Transfusion Requirements in Septic Shock","citation":"Holst L, et al. \"Transfusion thresholds in Septic Shock\". The New England Journal of Medicine. 2014. 371(15):1381-1391.","pageid":2268,"briefDesignDescription":"Transfusion thresholds in sepsis","subspecialties":"Critical Care;Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1406617","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406617","title":"Transfusion thresholds in Septic Shock","statusUsableDate":"2014-12-01","pmid":"25270275","abbreviation":"TRISS","timestamp":"2022-12-01T19:01:46Z","published":"2014-10-09"},{"title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","statusUsableDate":"2013-04-01","pmid":"17982182","abbreviation":"TRITON-TIMI 38","published":"2007-11-15","timestamp":"2017-12-03T22:39:43Z","briefDesignDescription":"Prasugrel vs. clopidogrel in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706482","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706482","expansion":"Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38","pageid":1398,"citation":"Wiviott ST, et al. \"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes\". The New England Journal of Medicine. 2007. 357(20):2001-2015.","pageName":"TRITON-TIMI 38","diseases":"Acute Coronary Syndrome","briefResultsDescription":"Prasugrel decreases CV mortality/morbidity, increases bleeding","trainingLevel":"Resident"},{"diseases":"Paroxysmal Nocturnal Hemoglobinuria","briefResultsDescription":"Eculizumab decreases transfusion requirements in PNH","pageName":"TRIUMPH","trainingLevel":"Intern","expansion":"Transfusion Reduction Efficacy and Safety Clinical Investigation, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","pageid":2810,"citation":"Hillmen P, et al. \"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria\". The New England Journal of Medicine. 2006. 355(12):1233-1243.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061648","subspecialties":"Hematology","briefDesignDescription":"Eculizumab in PNH","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061648","statusUsableDate":"2017-08-01","pmid":"16990386","title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","published":"2006-09-21","timestamp":"2017-12-03T22:39:45Z","abbreviation":"TRIUMPH"},{"expansion":"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","pageid":1783,"citation":"Nielsen N, et al. \"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest\". The New England Journal of Medicine. 2013. 369(23):2197-2206.","pageName":"TTM","diseases":"Cardiac Arrest","briefResultsDescription":"33°C cooling provides no survival benefit over 36°C","trainingLevel":"Resident","title":"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","pmid":"24237006","statusUsableDate":"2014-03-01","abbreviation":"TTM","published":"2014-03-19","timestamp":"2017-12-03T22:39:46Z","briefDesignDescription":"33 vs. 36°C body temperature after cardiac arrest","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1310519","subspecialties":"Cardiology;Neurology;Critical Care","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310519"},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100591","briefDesignDescription":"33°C vs. normothermia after cardiac arrest","subspecialties":"Emergency Medicine;Critical Care;Cardiology","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa2100591","abbreviation":"TTM2","timestamp":"2023-04-13T17:09:26Z","published":"2021-06-17","title":"Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest","pmid":"34133859","statusUsableDate":"2021-07-30","trainingLevel":"resident","pageName":"TTM2","briefResultsDescription":"No difference in survival or functional outcomes","diseases":"Cardiac Arrest","citation":"Dankiewicz J, et al. \"Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest\". The New England Journal of Medicine. 2021. 384(24):2283-2294.","pageid":4433,"expansion":"Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest 2"},{"briefResultsDescription":"Twice-daily RT with better response, PFS, survival than once-daily RT for limited SCLC","diseases":"Lung Cancer","pageName":"Twice-daily RT for SCLC","trainingLevel":"Resident","expansion":"","citation":"Turrisi AT, et al. \"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide\". The New England Journal of Medicine. 1999. 340(4):265-271.","pageid":1773,"subspecialties":"Oncology;Pulmonology;Radiation Oncology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199901283400403","briefDesignDescription":"Twice-daily RT in limited SCLC","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199901283400403","statusUsableDate":"2013-12-01","pmid":"9920950","title":"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide","timestamp":"2017-12-03T22:39:48Z","published":"1999-01-28","abbreviation":""},{"expansion":"","citation":"Zahed R. \"Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial\". Academic Emergency Medicine. 2018. 25(3):261-266.","pageid":3564,"pageName":"TXA for Epistaxis Associated with Antiplatelet Agents","briefResultsDescription":"TXA improved bleeding cessation time, rebleeding risk, and patient satisfaction","diseases":"Epistaxis","trainingLevel":"Student","title":"Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial","pmid":"29125679","statusUsableDate":"2023-09-21","abbreviation":"","timestamp":"2023-09-22T22:59:11Z","published":"2018-03-01","briefDesignDescription":"TXA vs. packing for antiplatelet agent-related epistaxis","subspecialties":"Emergency Medicine","fulltexturl":"https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.13345","pdfurl":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acem.13345"},{"diseases":"Diabetes Mellitus","briefResultsDescription":"Reduction in microvascular complications","pageName":"UKPDS 33","trainingLevel":"Intern","expansion":"United Kingdom Prospective Diabetes Study","pageid":253,"citation":"Turner R, et al. \"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\". The Lancet. 1998. 352(9131):837-53.","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673698070196","subspecialties":"Endocrinology","briefDesignDescription":"Intensive glycemic therapy in T2DM","pdfurl":"","statusUsableDate":"2012-03-01","pmid":"9742976","title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes","published":"1998-09-12","timestamp":"2022-08-27T02:08:15Z","abbreviation":"UKPDS"},{"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673698070378.pdf","briefDesignDescription":"Metformin in T2DM","subspecialties":"Endocrinology","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext","abbreviation":"UKPDS 34","timestamp":"2017-12-03T22:39:50Z","published":"1998-11-07","title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.","statusUsableDate":"2014-01-01","pmid":"9742977","trainingLevel":"Intern","pageName":"UKPDS 34","briefResultsDescription":"Metformin better than diet alone in T2DM","diseases":"Diabetes Mellitus","citation":"UKPDS Study Group. \"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.\". The Lancet. 1998. 352(9131):854-865.","pageid":1747,"expansion":"UK Prospective Diabetes Study 34"},{"pageName":"UPLIFT","briefResultsDescription":"Decreased exacerbations and mortality","diseases":"Chronic Obstructive Pulmonary Disease","trainingLevel":"Resident","expansion":"Understanding Potential Long-Term Impacts on Function with Tiotropium","citation":"Tashkin DP, et al. \"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease\". The New England Journal of Medicine. 2008. 395(15):1543-1554.","pageid":123,"briefDesignDescription":"Tiotropium in COPD","subspecialties":"Pulmonology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805800","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805800","title":"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease","statusUsableDate":"2012-03-01","pmid":"18836213","abbreviation":"UPLIFT","timestamp":"2012-10-29T23:28:48Z","published":"2008-10-09"},{"trainingLevel":"student","pageName":"V-HeFT","diseases":"Heart Failure","briefResultsDescription":"Trend towards mortality benefit in ISDN/hydralazine","pageid":155,"citation":"Cohn JN, et al. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". The New England Journal of Medicine. 1986. 314(24):1547-52.","expansion":"Vasodilator Heart Failure Trial","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404","briefDesignDescription":"ISDN/hydralazine in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198606123142404","subspecialties":"Cardiology","abbreviation":"V-HeFT","published":"1986-06-12","timestamp":"2017-12-03T22:39:51Z","title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","pmid":"3520315","statusUsableDate":"2012-12-01"},{"citation":"Cohn JN, et al. \"A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure\". The New England Journal of Medicine. 1991. 325(5):303-310.","pageid":2943,"expansion":"Vasodilator Heart Failure Trial II","trainingLevel":"Student","pageName":"V-HeFT II","briefResultsDescription":"Enalapril improves survival in HFrEF","diseases":"Heart Failure","abbreviation":"V-HeFT II","timestamp":"2018-04-13T13:08:04Z","published":"1991-08-01","title":"A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure","statusUsableDate":"2017-11-01","pmid":"2057035","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250502","briefDesignDescription":"Enalapril vs. ISDN/hydralazine in HFrEF","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199108013250502"},{"pageid":261,"citation":"Lewis HD, et al. \"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study\". The New England Journal of Medicine. 1983. 309(7):396-403.","expansion":null,"trainingLevel":"Resident","diseases":"Acute Coronary Syndrome","briefResultsDescription":"Aspirin decreases mortality","pageName":"VA Cooperative Study","published":"1983-08-18","timestamp":"2014-09-24T22:23:54Z","abbreviation":null,"statusUsableDate":"2012-03-01","pmid":"6135989","title":"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198308183090703","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198308183090703","subspecialties":"Cardiology","briefDesignDescription":"Aspirin in unstable angina"},{"trainingLevel":"Resident","pageName":"VA-NEPHRON D","diseases":"Diabetes Mellitus;Diabetic Nephropathy","briefResultsDescription":"ACE+ARB no more effective than monotherapy, increases complications","pageid":1798,"citation":"Fried LF, et al. \"Combined angiotensin inhibition for the treatment of diabetic nephropathy\". The New England Journal of Medicine. 2013. 369(20):1892-1903.","expansion":"Veterans Affairs Nephropathy in Diabetes","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1303154","briefDesignDescription":"ACE+ARB in DM nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1303154","subspecialties":"Nephrology;Endocrinology","abbreviation":"VA NEPHRON-D","published":"2013-11-14","timestamp":"2018-01-11T18:14:18Z","title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","statusUsableDate":"2014-05-01","pmid":"24206457"},{"diseases":"Diabetes Mellitus","briefResultsDescription":"No effect on macrovascular or severe microvascular outcomes","pageName":"VADT","trainingLevel":"Resident","expansion":"Veterans Affairs Diabetes Trial","pageid":254,"citation":"Duckworth W, et al. \"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes\". The New England Journal of Medicine. 2009. 360(2):129-39.","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0808431","subspecialties":"Endocrinology","briefDesignDescription":"Intensive glycemic therapy in T2DM","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808431","pmid":"19092145","statusUsableDate":"2012-03-01","title":"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes","published":"2009-01-08","timestamp":"2018-08-12T16:18:00Z","abbreviation":"VADT"},{"expansion":"Valsartan Heart Failure Trial","citation":"Cohn JN, et al. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". New England Journal of Medicine. 2001. 345(23):1667-75.","pageid":20,"briefResultsDescription":"No mortality benefit of valsartan in NYHA II-IV HF","diseases":"Heart Failure","pageName":"Val-HeFT","trainingLevel":"Resident","statusUsableDate":"2012-03-01","pmid":"11759645","title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","timestamp":"2014-08-24T17:55:57Z","published":"2001-12-06","abbreviation":"Val-HeFT","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010713","briefDesignDescription":"Valsartan in HFrEF","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713"},{"abbreviation":"VALENCE","timestamp":"2017-12-03T22:39:54Z","published":"2014-05-22","title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","statusUsableDate":"2014-12-01","pmid":"24795201","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316145","briefDesignDescription":"Sofosbuvir+ribavirin for HCV genotypes 2 or 3","subspecialties":"Infectious Disease;Gastroenterology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1316145","citation":"Zeuzem S, et al. \"Sofosbuvir and ribavirin in HCV genotypes 2 and 3\". The New England Journal of Medicine. 2014. 370(21):1993-2001.","pageid":2261,"expansion":"","trainingLevel":"Student","pageName":"VALENCE","briefResultsDescription":"Sofosbuvir+ribavirin effective without IFN","diseases":"Hepatitis C"},{"trainingLevel":"Resident","pageName":"VALIANT","briefResultsDescription":"Valsartan as effective as captopril","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","citation":"Pfeffer MA, et al. \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both\". The New England Journal of Medicine. 2003. 349(20):1893-1903.","pageid":462,"expansion":"Valsartan in Acute Myocardial Infarction Trial","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa032292","briefDesignDescription":"Valsartan vs. captopril in MI with LV dysfunction","subspecialties":"Cardiology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa032292","abbreviation":"VALIANT","timestamp":"2019-04-11T17:06:09Z","published":"2003-11-13","title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","pmid":"12921816","statusUsableDate":"2012-03-01"},{"abbreviation":null,"timestamp":"2025-07-26T15:24:13Z","published":"2007-08-01","title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","statusUsableDate":"2012-03-01","pmid":"17599306","pdfurl":"http://cid.oxfordjournals.org/content/45/3/302.full.pdf","briefDesignDescription":"Vancomycin vs. metronidazole in C. difficile","subspecialties":"Infectious Disease;Gastroenterology","fulltexturl":"http://cid.oxfordjournals.org/content/45/3/302.long","citation":"Zar FA, et al. \"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity\". Clinical Infectious Diseases. 2007. 45(3):302-7.","pageid":6,"expansion":null,"trainingLevel":"Intern","pageName":"Vancomycin vs. Metronidazole in C. difficile Diarrhea","briefResultsDescription":"Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea","diseases":"Clostridium difficile"},{"title":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","statusUsableDate":"2016-06-01","pmid":"27149033","abbreviation":"VANISH","published":"2016-05-05","timestamp":"2017-12-03T22:39:56Z","briefDesignDescription":"Ablation vs. antiarrhythmic drugs in VT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1513614","subspecialties":"Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1513614","expansion":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","pageid":2783,"citation":"Sapp JL, et al. \"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs\". The New England Journal of Medicine. 2016. 375(2):111-121.","pageName":"VANISH","diseases":"Ventricular Tachycardia","briefResultsDescription":"VT ablation superior to escalation of antiarrhythmic drugs","trainingLevel":"Resident"},{"trainingLevel":"Resident","diseases":"Sepsis;Shock","briefResultsDescription":"Vasopressin doesn't reduce mortality in shock","pageName":"VASST","pageid":1910,"citation":"Russel JA, et al. \"Vasopressin versus norepinephrine infusion in patients with septic shock\". The New England Journal of Medicine. 2008. 358(9):877-887.","expansion":"Vasopressin and Septic Shock Trial","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa067373","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa067373","subspecialties":"Critical Care","briefDesignDescription":"Vasopressin in septic shock","published":"2008-02-28","timestamp":"2020-11-22T18:00:12Z","abbreviation":"VASST","pmid":"18305265","statusUsableDate":"2014-08-01","title":"Vasopressin versus norepinephrine infusion in patients with septic shock"},{"pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800781","briefDesignDescription":"Wearable cardioverter-defibrillator post-MI","fulltexturl":"https://www.nejm.org/doi/full/10.1056/NEJMoa1800781","subspecialties":"Cardiology","abbreviation":"VEST","published":"2018-09-27","timestamp":"2019-10-17T17:47:55Z","title":"Wearable cardioverter-defibrillator after myocardial infarction","pmid":"30280654","statusUsableDate":"2018-10-11","trainingLevel":"Resident","pageName":"VEST","diseases":"Sudden Cardiac Death","briefResultsDescription":"Wearable cardioverter-defibrillator doesn't reduce arrhythmic death","pageid":3716,"citation":"Olgin JE, et al. \"Wearable cardioverter-defibrillator after myocardial infarction\". The New England Journal of Medicine. 2018. 379(13):1205-1215.","expansion":"Vest Prevention of Early Sudden Death"},{"briefDesignDescription":"Antiepileptics in status epilepticus","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199809173391202","subspecialties":"Neurology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJM199809173391202","title":"A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus","pmid":"9738086","statusUsableDate":"2022-12-20","abbreviation":"Veterans Affairs Status Epilepticus Study","published":"1998-09-17","timestamp":"2022-12-21T16:29:52Z","pageName":"Veterans Affairs Status Epilepticus Cooperative Study Group","diseases":"Epilepsy","briefResultsDescription":"No difference between four antiepileptics","trainingLevel":"Intern","expansion":"","pageid":2461,"citation":"Veterans Affairs Status Epilepticus Cooperative Study Group. \"A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus\". New England Journal of Medicine. 1998. 339(12):792-798."},{"pageid":4192,"citation":"Fujii T, et al. \"Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial\". JAMA. 2020. 323(5):423-431.","expansion":"The VitamIn C, HydrocorTisone and ThiAMINe in Patients With Septic Shock Trial","trainingLevel":"Resident","pageName":"VITAMINS","diseases":"Sepsis;Shock","briefResultsDescription":"No difference with triple-therapy in septic shock","abbreviation":"VITAMINS","published":"2020-02-04","timestamp":"2025-06-19T18:34:21Z","title":"Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial","statusUsableDate":"2020-09-03","pmid":"31950979","pdfurl":"","briefDesignDescription":"Vitamin C, hydrocortisone, & thiamine in septic shock","fulltexturl":"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.22176","subspecialties":"Critical Care"},{"pageName":"VOYAGER-PAD","briefResultsDescription":"Low-dose rivaroxaban lowers PAD events","diseases":"Peripheral Artery Disease","trainingLevel":"resident","expansion":null,"citation":"Bonaca M, et al. \"Rivaroxaban in Peripheral Artery Disease after Revascularization\". The New England Journal of Medicine. 2020. 382(21):1994-2004.","pageid":5305,"briefDesignDescription":"Rivaroxaban 2.5mg BID in PAD","subspecialties":"Cardiology","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa2000052","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2000052","title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","pmid":"32222135","statusUsableDate":"2023-04-20","abbreviation":"VOYAGER","timestamp":"2024-08-28T14:43:50Z","published":"2020-05-21"},{"briefDesignDescription":"tPA if stroke >4.5h and ideal MRI","fulltexturl":"https://www.nejm.org/doi/10.1056/NEJMoa1804355","subspecialties":"Neurology","pdfurl":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1804355","title":"MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset","statusUsableDate":"2024-07-15","pmid":"29766770","abbreviation":"WAKE-UP","published":"2018-08-16","timestamp":"2024-08-09T09:57:23Z","pageName":"WAKE-UP","diseases":"Stroke","briefResultsDescription":"tPA >4.5 with improved outcomes post-stroke if ideal MRI","trainingLevel":"Student","expansion":"","pageid":3723,"citation":"Thomalla G, et al. \"MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset\". New England Journal of Medicine. 2018. 379(7):611-622."},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1114238","subspecialties":"Hematology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1114238","briefDesignDescription":"Aspirin after VTE treatment","timestamp":"2017-12-03T22:39:59Z","published":"2012-05-24","abbreviation":"WARFASA","pmid":"22621626","statusUsableDate":"2013-03-01","title":"Aspirin for preventing the recurrence of venous thromboembolism","trainingLevel":"resident","briefResultsDescription":"Aspirin reduces recurrent VTE","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","pageName":"WARFASA","citation":"Becattini C, et al. \"Aspirin for preventing the recurrence of venous thromboembolism\". The New England Journal of Medicine. 2012. 366(21):1959-1967.","pageid":1244,"expansion":"Warfarin and Aspirin"},{"statusUsableDate":"2022-03-10","pmid":"11794192","title":"A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke","timestamp":"2022-03-10T20:02:17Z","published":"2001-11-15","abbreviation":"WARSS","subspecialties":"Neurology","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011258","briefDesignDescription":"Aspirin vs. warfarin in ischemic stroke","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011258","expansion":"Warfarin–Aspirin Recurrent Stroke Study","citation":"Mohr J, et al. \"A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke\". The New England Journal of Medicine. 2001. 345(20):1444-1451.","pageid":2784,"briefResultsDescription":"Warfarin did not reduce rates of death/stroke, caused more bleeding","diseases":"Stroke","pageName":"WARSS","trainingLevel":"Intern"},{"pageName":"WASID","diseases":"Stroke","briefResultsDescription":"Warfarin had higher adverse events","trainingLevel":"Intern","expansion":"Warfarin-Aspirin Symptomatic Intracranial Disease","pageid":2427,"citation":"Chimowitz MI, et al. \"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis\". The New England Journal of Medicine. 2005. 352(13):1305-1306.","briefDesignDescription":"Warfarin vs. aspirin for intracranial atherosclerosis","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033","subspecialties":"Neurology;Cardiology","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033","title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","pmid":"15800226","statusUsableDate":"2019-06-27","abbreviation":"WASID","published":"2005-03-31","timestamp":"2019-06-27T17:24:44Z"},{"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4840/JOC21036.pdf","briefDesignDescription":"Postmenopausal estrogen/progesterone","fulltexturl":null,"subspecialties":"Gynecology;Endocrinology","abbreviation":"WHI E+P","published":"2002-07-17","timestamp":"2017-12-03T22:40:01Z","title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial","statusUsableDate":"2013-07-01","pmid":"12117397","trainingLevel":"Student","pageName":"WHI","diseases":"Coronary Artery Disease;Menopause","briefResultsDescription":"Postmenopausal estrogen/progesterone HRT increases rates of MI and breast cancer","pageid":1507,"citation":"Rossouw JE, et al. \"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial\". The Journal of the American Medical Association. 2002. 288(3):321-333.","expansion":"Women's Health Initiative Estrogen and Progestin Trial"},{"abbreviation":"WISDOM","published":"2014-10-02","timestamp":"2017-12-03T22:40:03Z","title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","pmid":"25196117","statusUsableDate":"2015-05-01","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407154","briefDesignDescription":"ICS withdrawal in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1407154","subspecialties":"Pulmonology","pageid":2318,"citation":"Magnussen H, et al. \"Withdrawal of inhaled glucocorticoids and exacerbations of COPD\". The New England Journal of Medicine. 2014. 371(14):1285-1295.","expansion":"Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management","trainingLevel":"Resident","pageName":"WISDOM","diseases":"Chronic Obstructive Pulmonary Disease","briefResultsDescription":"ICS withdrawal may reduce FEV1, no change in COPD flares"},{"pageName":"WOEST","diseases":"Coronary Artery Disease","briefResultsDescription":"ASA increases bleeding when added to clopidogrel if chronic OAC","trainingLevel":"Resident","expansion":"What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing","pageid":1792,"citation":"Dewilde WJM, et al. \"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial\". The Lancet. 2013. 381(9872):1107-1115.","briefDesignDescription":"Clopidogrel ± ASA after PCI if on OAC","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0140673612621771","subspecialties":"Cardiology;Hematology","pdfurl":"","title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","statusUsableDate":"2015-06-01","pmid":"23415013","abbreviation":"WOEST","published":"2013-03-30","timestamp":"2017-12-03T22:40:05Z"},{"abbreviation":"WOSCOPS","published":"1995-11-16","timestamp":"2014-12-12T19:39:51Z","title":"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia","statusUsableDate":"2012-03-01","pmid":"7566020","pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199511163332001","briefDesignDescription":"Pravastatin in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199511163332001","subspecialties":"Cardiology","pageid":172,"citation":"Shepherd J, et al. \"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia\". The New England Journal of Medicine. 1995. 333(20):1301-1308.","expansion":"West of Scotland Coronary Prevention Study","trainingLevel":"Resident","pageName":"WOSCOPS","diseases":"Hyperlipidemia;Coronary Artery Disease","briefResultsDescription":"Pravastatin reduces MIs and CV mortality"},{"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199105233242101","briefDesignDescription":"RSBI for predicting weaning","subspecialties":"Pulmonology;Critical Care","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199105233242101","abbreviation":"","timestamp":"2017-12-03T22:40:06Z","published":"1991-05-23","title":"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation","statusUsableDate":"2013-01-01","pmid":"2023603","trainingLevel":"Resident","pageName":"Yang-Tobin Study","briefResultsDescription":"RSBI predicts success and failure of weaning from mechanical ventilation","diseases":"Critical Illness","citation":"Yang KL, Tobin MJ. \"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation\". The New England Journal of Medicine. 1991. 324(21):1445-1450.","pageid":75,"expansion":""}],"topic":"all"}}